ID   NOD2_HUMAN              Reviewed;        1040 AA.
AC   Q9HC29; E2JEQ6; Q96RH5; Q96RH6; Q96RH8;
DT   31-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   04-MAR-2015, entry version 150.
DE   RecName: Full=Nucleotide-binding oligomerization domain-containing protein 2;
DE   AltName: Full=Caspase recruitment domain-containing protein 15;
DE   AltName: Full=Inflammatory bowel disease protein 1;
GN   Name=NOD2; Synonyms=CARD15, IBD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), MUTAGENESIS OF LYS-305,
RP   AND VARIANT ARG-908.
RC   TISSUE=Mammary gland;
RX   PubMed=11087742; DOI=10.1074/jbc.M008072200;
RA   Ogura Y., Inohara N., Benito A., Chen F.F., Yamaoka S., Nunez G.;
RT   "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and
RT   activates NF-kappaB.";
RL   J. Biol. Chem. 276:4812-4818(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2), VARIANTS
RP   THR-140; ARG-157; MET-189; CYS-235; ARG-248; SER-268; SER-289;
RP   ASN-291; VAL-301; TRP-311; VAL-348; ARG-352; CYS-373; SER-414;
RP   LEU-431; VAL-432; LYS-441; VAL-612; THR-612; TRP-684; TRP-702;
RP   CYS-703; CYS-713; GLY-725; VAL-755; VAL-758; LYS-778; MET-793;
RP   LYS-843; SER-853; VAL-863; THR-885; ARG-908; ASP-918; ASP-924 AND
RP   ILE-955, AND INVOLVEMENT IN IBD1.
RC   TISSUE=Leukocyte;
RX   PubMed=11385576; DOI=10.1038/35079107;
RA   Hugot J.-P., Chamaillard M., Zouali H., Lesage S., Cezard J.-P.,
RA   Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., Binder V.,
RA   Finkel Y., Cortot A., Modigliani R., Laurent-Puig P.,
RA   Gower-Rousseau C., Macry J., Colombel J.-F., Sahbatou M., Thomas G.;
RT   "Association of NOD2 leucine-rich repeat variants with susceptibility
RT   to Crohn's disease.";
RL   Nature 411:599-603(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=20698950; DOI=10.1186/1756-0500-3-224;
RA   Kramer M., Boeck J., Reichenbach D., Kaether C., Schreiber S.,
RA   Platzer M., Rosenstiel P., Huse K.;
RT   "NOD2-C2 - a novel NOD2 isoform activating NF-kappaB in a muramyl
RT   dipeptide-independent manner.";
RL   BMC Res. Notes 3:224-224(2010).
RN   [4]
RP   INTERACTION WITH ERBBI2P, AND SUBCELLULAR LOCATION.
RX   PubMed=16203728; DOI=10.1074/jbc.M508538200;
RA   McDonald C., Chen F.F., Ollendorff V., Ogura Y., Marchetto S.,
RA   Lecine P., Borg J.P., Nunez G.;
RT   "A role for Erbin in the regulation of Nod2-dependent NF-kappaB
RT   signaling.";
RL   J. Biol. Chem. 280:40301-40309(2005).
RN   [5]
RP   INTERACTION WITH RIPK2.
RX   PubMed=19592251; DOI=10.1016/j.cub.2009.06.038;
RA   Tao M., Scacheri P.C., Marinis J.M., Harhaj E.W., Matesic L.E.,
RA   Abbott D.W.;
RT   "ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence
RT   inflammatory signaling pathways.";
RL   Curr. Biol. 19:1255-1263(2009).
RN   [6]
RP   IDENTIFICATION IN A COMPLEX WITH ARHGEF2 AND RIPK2, AND INTERACTION
RP   WITH RIPK2.
RX   PubMed=21887730; DOI=10.1002/ibd.21851;
RA   Zhao Y., Alonso C., Ballester I., Song J.H., Chang S.Y., Guleng B.,
RA   Arihiro S., Murray P.J., Xavier R., Kobayashi K.S., Reinecker H.C.;
RT   "Control of NOD2 and Rip2-dependent innate immune activation by GEF-
RT   H1.";
RL   Inflamm. Bowel Dis. 18:603-612(2012).
RN   [7]
RP   INTERACTION WITH HSP90 AND SOCS3, AND POLYUBIQUITINATION.
RX   PubMed=23019338; DOI=10.1074/jbc.M112.410027;
RA   Lee K.H., Biswas A., Liu Y.J., Kobayashi K.S.;
RT   "Proteasomal degradation of Nod2 protein mediates tolerance to
RT   bacterial cell wall components.";
RL   J. Biol. Chem. 287:39800-39811(2012).
RN   [8]
RP   INTERACTION WITH ATG16L1.
RX   PubMed=23376921; DOI=10.1038/emboj.2013.8;
RA   Boada-Romero E., Letek M., Fleischer A., Pallauf K., Ramon-Barros C.,
RA   Pimentel-Muinos F.X.;
RT   "TMEM59 defines a novel ATG16L1-binding motif that promotes local
RT   activation of LC3.";
RL   EMBO J. 32:566-582(2013).
RN   [9]
RP   INTERACTION WITH ANKRD17.
RX   PubMed=23711367; DOI=10.1016/j.febslet.2013.05.037;
RA   Menning M., Kufer T.A.;
RT   "A role for the Ankyrin repeat containing protein Ankrd17 in Nod1- and
RT   Nod2-mediated inflammatory responses.";
RL   FEBS Lett. 587:2137-2142(2013).
RN   [10]
RP   FUNCTION.
RX   PubMed=23806334; DOI=10.1016/j.molcel.2013.06.004;
RA   Fiil B.K., Damgaard R.B., Wagner S.A., Keusekotten K., Fritsch M.,
RA   Bekker-Jensen S., Mailand N., Choudhary C., Komander D.,
RA   Gyrd-Hansen M.;
RT   "OTULIN restricts Met1-linked ubiquitination to control innate immune
RT   signaling.";
RL   Mol. Cell 50:818-830(2013).
RN   [11]
RP   INTERACTION WITH CARD9, VARIANTS ALA-357; PHE-363; ALA-463 AND
RP   VAL-550, CHARACTERIZATION OF VARIANTS ARG-248; TRP-334; ALA-357;
RP   PHE-363; LEU-431; LYS-441; ALA-463; VAL-550; VAL-612 AND TRP-702, AND
RP   MUTAGENESIS OF ASP-379.
RX   PubMed=24960071; DOI=10.1016/j.febslet.2014.06.035;
RA   Parkhouse R., Boyle J.P., Mayle S., Sawmynaden K., Rittinger K.,
RA   Monie T.P.;
RT   "Interaction between NOD2 and CARD9 involves the NOD2 NACHT and the
RT   linker region between the NOD2 CARDs and NACHT domain.";
RL   FEBS Lett. 588:2830-2836(2014).
RN   [12]
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS GLN-334;
RP   TRP-334; GLY-383; LYS-383; PHE-469; CYS-471; ASP-481; LEU-490;
RP   TYR-495; LEU-496; THR-513; CYS-587; ASN-605; PRO-605 AND LYS-670.
RX   PubMed=25093298; DOI=10.1016/j.febslet.2014.07.029;
RA   Parkhouse R., Boyle J.P., Monie T.P.;
RT   "Blau syndrome polymorphisms in NOD2 identify nucleotide hydrolysis
RT   and helical domain 1 as signalling regulators.";
RL   FEBS Lett. 588:3382-3389(2014).
RN   [13]
RP   INTERACTION WITH HSPA1A, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF
RP   VARIANTS TRP-702 AND ARG-908.
RX   PubMed=24790089; DOI=10.1074/jbc.M114.557686;
RA   Mohanan V., Grimes C.L.;
RT   "The molecular chaperone HSP70 binds to and stabilizes NOD2, an
RT   important protein involved in Crohn disease.";
RL   J. Biol. Chem. 289:18987-18998(2014).
RN   [14]
RP   VARIANTS BS GLN-334; TRP-334 AND PHE-469.
RX   PubMed=11528384; DOI=10.1038/ng720;
RA   Miceli-Richard C., Lesage S., Rybojad M., Prieur A.M.,
RA   Manouvrier-Hanu S., Hafner R., Chamaillard M., Zouali H., Thomas G.,
RA   Hugot J.-P.;
RT   "CARD15 mutations in Blau syndrome.";
RL   Nat. Genet. 29:19-20(2001).
RN   [15]
RP   VARIANTS ASN-113; ALA-357; PHE-363; VAL-550 AND SER-852.
RX   PubMed=15024686; DOI=10.1086/382226;
RA   Tukel T., Shalata A., Present D., Rachmilewitz D., Mayer L., Grant D.,
RA   Risch N., Desnick R.J.;
RT   "Crohn disease: frequency and nature of CARD15 mutations in Ashkenazi
RT   and Sephardi/Oriental Jewish families.";
RL   Am. J. Hum. Genet. 74:623-636(2004).
RN   [16]
RP   VARIANTS EOS TRP-334; GLU-382; LEU-496; THR-513; PRO-605; THR-612 AND
RP   LYS-670, AND CHARACTERIZATION OF VARIANTS GLU-382; LEU-496; THR-513;
RP   PRO-605 AND LYS-670.
RX   PubMed=15459013; DOI=10.1182/blood-2004-07-2972;
RA   Kanazawa N., Okafuji I., Kambe N., Nishikomori R., Nakata-Hizume M.,
RA   Nagai S., Fuji A., Yuasa T., Manki A., Sakurai Y., Nakajima M.,
RA   Kobayashi H., Fujiwara I., Tsutsumi H., Utani A., Nishigori C.,
RA   Heike T., Nakahata T., Miyachi Y.;
RT   "Early-onset sarcoidosis and CARD15 mutations with constitutive
RT   nuclear factor-kappaB activation: common genetic etiology with Blau
RT   syndrome.";
RL   Blood 105:1195-1197(2005).
RN   [17]
RP   VARIANT BS LYS-383.
RX   PubMed=15812565; DOI=10.1038/sj.ejhg.5201404;
RA   van Duist M.M., Albrecht M., Podswiadek M., Giachino D., Lengauer T.,
RA   Punzi L., De Marchi M.;
RT   "A new CARD15 mutation in Blau syndrome.";
RL   Eur. J. Hum. Genet. 13:742-747(2005).
RN   [18]
RP   VARIANTS SER-268; SER-289; TRP-311; CYS-391; ALA-463; CYS-703;
RP   HIS-713; CYS-760; TRP-790; TRP-791; LYS-825 AND VAL-849.
RX   PubMed=16485124; DOI=10.1007/s00251-005-0073-2;
RA   Schnitzler F., Brand S., Staudinger T., Pfennig S., Hofbauer K.,
RA   Seiderer J., Tillack C., Goke B., Ochsenkuhn T., Lohse P.;
RT   "Eight novel CARD15 variants detected by DNA sequence analysis of the
RT   CARD15 gene in 111 patients with inflammatory bowel disease.";
RL   Immunogenetics 58:99-106(2006).
RN   [19]
RP   VARIANTS GLN-334; TRP-334; LYS-383; LEU-490; TYR-495 AND CYS-587.
RX   PubMed=19479837; DOI=10.1002/art.24533;
RA   Rose C.D., Arostegui J.I., Martin T.M., Espada G., Scalzi L.,
RA   Yague J., Rosenbaum J.T., Modesto C., Cristina Arnal M., Merino R.,
RA   Garcia-Consuegra J., Carballo Silva M.A., Wouters C.H.;
RT   "NOD2-associated pediatric granulomatous arthritis, an expanding
RT   phenotype: study of an international registry and a national cohort in
RT   Spain.";
RL   Arthritis Rheum. 60:1797-1803(2009).
RN   [20]
RP   VARIANTS GLN-334; TRP-334; GLU-382; GLY-383; TYR-495; 496-LEU;
RP   THR-513; PRO-605 AND LYS-670.
RX   PubMed=19116920; DOI=10.1002/art.24134;
RA   Okafuji I., Nishikomori R., Kanazawa N., Kambe N., Fujisawa A.,
RA   Yamazaki S., Saito M., Yoshioka T., Kawai T., Sakai H., Tanizaki H.,
RA   Heike T., Miyachi Y., Nakahata T.;
RT   "Role of the NOD2 genotype in the clinical phenotype of Blau syndrome
RT   and early-onset sarcoidosis.";
RL   Arthritis Rheum. 60:242-250(2009).
RN   [21]
RP   VARIANT EOS ASP-481.
RX   PubMed=19359344; DOI=10.1093/rheumatology/kep061;
RA   Okada S., Konishi N., Tsumura M., Shirao K., Yasunaga S., Sakai H.,
RA   Nishikomori R., Takihara Y., Kobayashi M.;
RT   "Cardiac infiltration in early-onset sarcoidosis associated with a
RT   novel heterozygous mutation, G481D, in CARD15.";
RL   Rheumatology 48:706-707(2009).
RN   [22]
RP   VARIANT BS ASN-605.
RX   PubMed=19169908; DOI=10.1080/03009740802464194;
RA   Milman N., Ursin K., Rodevand E., Nielsen F.C., Hansen T.V.;
RT   "A novel mutation in the NOD2 gene associated with Blau syndrome: a
RT   Norwegian family with four affected members.";
RL   Scand. J. Rheumatol. 38:190-197(2009).
RN   [23]
RP   VARIANT BS TRP-334.
RX   PubMed=20199415; DOI=10.1111/j.1525-1470.2009.01060.x;
RA   Stoevesandt J., Morbach H., Martin T.M., Zierhut M., Girschick H.,
RA   Hamm H.;
RT   "Sporadic Blau syndrome with onset of widespread granulomatous
RT   dermatitis in the newborn period.";
RL   Pediatr. Dermatol. 27:69-73(2010).
CC   -!- FUNCTION: Recognizes muramyl dipeptide (MDP) constituents of
CC       bacterial peptidoglycans and plays a key role in gastrointestinal
CC       immunity: upon stimulation, binds the proximal adapter receptor-
CC       interacting RIPK2, which recruits ubiquitin ligases as XIAP,
CC       BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP
CC       kinases and activation of NF-kappa-B signaling, leading to
CC       activate the transcription of hundreds of genes involved in immune
CC       response. {ECO:0000269|PubMed:23806334}.
CC   -!- SUBUNIT: Found in a signaling complex consisting of ARHGEF2, NOD2
CC       and RIPK2 (PubMed:21887730). Interacts (via CARD domain) with
CC       RIPK2 (via CARD domain) (PubMed:19592251, PubMed:21887730).
CC       Interacts with ATG16L1 (PubMed:23376921). Interacts (via NACHT
CC       domain) with CARD9 (PubMed:24960071). Interacts with ANKRD17 (via
CC       N-terminus) (PubMed:23711367). Interacts with HSPA1A; the
CC       interaction enhances NOD2 stability (PubMed:24790089). Interacts
CC       (via both CARD domains) with HSP90; the interaction enhances NOD2
CC       stability (PubMed:23019338). Interacts (via CARD domain) with
CC       SOCS3; the interaction promotes NOD2 degradation
CC       (PubMed:23019338). Interacts (via CARD domain) with ERBBI2P; the
CC       interaction inhibits activation of NOD2 (PubMed:16203728).
CC       {ECO:0000269|PubMed:16203728, ECO:0000269|PubMed:19592251,
CC       ECO:0000269|PubMed:21887730, ECO:0000269|PubMed:23019338,
CC       ECO:0000269|PubMed:23376921, ECO:0000269|PubMed:23711367,
CC       ECO:0000269|PubMed:24790089, ECO:0000269|PubMed:24960071}.
CC   -!- INTERACTION:
CC       O43353:RIPK2; NbExp=2; IntAct=EBI-7445625, EBI-358522;
CC       P14373:TRIM27; NbExp=10; IntAct=EBI-7445625, EBI-719493;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:24960071,
CC       ECO:0000269|PubMed:25093298}. Membrane
CC       {ECO:0000269|PubMed:25093298}. Basolateral cell membrane
CC       {ECO:0000269|PubMed:16203728}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=3;
CC       Name=1; Synonyms=Nod2;
CC         IsoId=Q9HC29-1; Sequence=Displayed;
CC         Note=Can activate NF-kappa-B. More abundant.;
CC       Name=2; Synonyms=Nod2b;
CC         IsoId=Q9HC29-2; Sequence=VSP_018689;
CC         Note=Can activate NF-kappa-B.;
CC       Name=3; Synonyms=NOD2-C2;
CC         IsoId=Q9HC29-3; Sequence=VSP_018689, VSP_046567, VSP_046568;
CC         Note=Can activate NF-kappa-B.;
CC   -!- TISSUE SPECIFICITY: Monocytes-specific.
CC   -!- DOMAIN: The ATG16L1-binding motif mediates interaction with
CC       ATG16L1. {ECO:0000269|PubMed:23376921}.
CC   -!- PTM: Polyubiquitinated following MDP stimulation, leading to
CC       proteasome-madiated degradation (PubMed:23019338).
CC       {ECO:0000269|PubMed:23019338}.
CC   -!- DISEASE: Blau syndrome (BS) [MIM:186580]: Rare autosomal dominant
CC       disorder characterized by early-onset granulomatous arthritis,
CC       uveitis and skin rash. {ECO:0000269|PubMed:11528384,
CC       ECO:0000269|PubMed:15812565, ECO:0000269|PubMed:19169908,
CC       ECO:0000269|PubMed:20199415}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Inflammatory bowel disease 1 (IBD1) [MIM:266600]: A
CC       chronic, relapsing inflammation of the gastrointestinal tract with
CC       a complex etiology. It is subdivided into Crohn disease and
CC       ulcerative colitis phenotypes. Crohn disease may affect any part
CC       of the gastrointestinal tract from the mouth to the anus, but most
CC       frequently it involves the terminal ileum and colon. Bowel
CC       inflammation is transmural and discontinuous; it may contain
CC       granulomas or be associated with intestinal or perianal fistulas.
CC       In contrast, in ulcerative colitis, the inflammation is continuous
CC       and limited to rectal and colonic mucosal layers; fistulas and
CC       granulomas are not observed. Both diseases include extraintestinal
CC       inflammation of the skin, eyes, or joints.
CC       {ECO:0000269|PubMed:11385576}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Sarcoidosis early-onset (EOS) [MIM:609464]: A form of
CC       sarcoidosis manifesting in children younger than 4 years of age.
CC       Sarcoidosis is an idiopathic, systemic, inflammatory disease
CC       characterized by the formation of immune granulomas in involved
CC       organs. Granulomas predominantly invade the lungs and the
CC       lymphatic system, but also skin, liver, spleen, eyes and other
CC       organs may be involved. Early-onset sarcoidosis is quite rare and
CC       has a distinct triad of skin, joint and eye disorders, without
CC       apparent pulmonary involvement. Compared with an asymptomatic and
CC       sometimes naturally disappearing course of the disease in older
CC       children, early-onset sarcoidosis is progressive and in many cases
CC       causes severe complications, such as blindness, joint destruction
CC       and visceral involvement. {ECO:0000269|PubMed:15459013}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Contains 2 CARD domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00046}.
CC   -!- SIMILARITY: Contains 9 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 NACHT domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00136}.
CC   -!- WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditary
CC       autoinflammatory disorders mutations;
CC       URL="http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=6";
DR   EMBL; AF178930; AAG33677.1; -; mRNA.
DR   EMBL; AF385089; AAK70867.1; -; Genomic_DNA.
DR   EMBL; AF385090; AAK70868.1; -; Genomic_DNA.
DR   EMBL; AJ303140; CAC42117.1; -; Genomic_DNA.
DR   EMBL; HQ204571; ADN95581.1; -; mRNA.
DR   CCDS; CCDS10746.1; -. [Q9HC29-1]
DR   RefSeq; NP_001280486.1; NM_001293557.1. [Q9HC29-2]
DR   RefSeq; NP_071445.1; NM_022162.2. [Q9HC29-1]
DR   RefSeq; XP_005256141.1; XM_005256084.1. [Q9HC29-2]
DR   UniGene; Hs.592072; -.
DR   ProteinModelPortal; Q9HC29; -.
DR   SMR; Q9HC29; 291-316, 747-1029.
DR   BioGrid; 122077; 30.
DR   DIP; DIP-41998N; -.
DR   IntAct; Q9HC29; 7.
DR   MINT; MINT-151071; -.
DR   STRING; 9606.ENSP00000300589; -.
DR   BindingDB; Q9HC29; -.
DR   ChEMBL; CHEMBL1293266; -.
DR   GuidetoPHARMACOLOGY; 1763; -.
DR   PhosphoSite; Q9HC29; -.
DR   DMDM; 20137973; -.
DR   PaxDb; Q9HC29; -.
DR   PRIDE; Q9HC29; -.
DR   DNASU; 64127; -.
DR   Ensembl; ENST00000300589; ENSP00000300589; ENSG00000167207. [Q9HC29-1]
DR   GeneID; 64127; -.
DR   KEGG; hsa:64127; -.
DR   UCSC; uc002egl.1; human. [Q9HC29-1]
DR   CTD; 64127; -.
DR   GeneCards; GC16P050729; -.
DR   HGNC; HGNC:5331; NOD2.
DR   HPA; HPA041985; -.
DR   MIM; 186580; phenotype.
DR   MIM; 266600; phenotype.
DR   MIM; 605956; gene.
DR   MIM; 609464; phenotype.
DR   neXtProt; NX_Q9HC29; -.
DR   Orphanet; 117; Behcet disease.
DR   Orphanet; 90340; Blau syndrome.
DR   Orphanet; 206; Crohn disease.
DR   Orphanet; 771; Ulcerative colitis.
DR   PharmGKB; PA26074; -.
DR   eggNOG; NOG248107; -.
DR   GeneTree; ENSGT00780000121843; -.
DR   HOGENOM; HOG000113814; -.
DR   HOVERGEN; HBG050792; -.
DR   InParanoid; Q9HC29; -.
DR   KO; K10165; -.
DR   OMA; NVGHLKL; -.
DR   OrthoDB; EOG7P5T07; -.
DR   PhylomeDB; Q9HC29; -.
DR   TreeFam; TF352118; -.
DR   Reactome; REACT_21281; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; REACT_21368; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; REACT_21399; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; REACT_22442; Interleukin-1 signaling.
DR   Reactome; REACT_75776; NOD1/2 Signaling Pathway.
DR   SignaLink; Q9HC29; -.
DR   GeneWiki; NOD2; -.
DR   GenomeRNAi; 64127; -.
DR   NextBio; 35496989; -.
DR   PRO; PR:Q9HC29; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; Q9HC29; -.
DR   CleanEx; HS_NOD2; -.
DR   ExpressionAtlas; Q9HC29; baseline and differential.
DR   Genevestigator; Q9HC29; -.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HGNC.
DR   GO; GO:0005886; C:plasma membrane; IDA:HGNC.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0050700; F:CARD domain binding; IPI:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0032500; F:muramyl dipeptide binding; IDA:HGNC.
DR   GO; GO:0042834; F:peptidoglycan binding; IDA:HGNC.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:Reactome.
DR   GO; GO:0035419; P:activation of MAPK activity involved in innate immune response; ISS:BHF-UCL.
DR   GO; GO:0071225; P:cellular response to muramyl dipeptide; IDA:UniProtKB.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0071224; P:cellular response to peptidoglycan; IEA:Ensembl.
DR   GO; GO:0002367; P:cytokine production involved in immune response; IMP:UniProtKB.
DR   GO; GO:0006952; P:defense response; TAS:HGNC.
DR   GO; GO:0042742; P:defense response to bacterium; IDA:HGNC.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0016045; P:detection of bacterium; IDA:HGNC.
DR   GO; GO:0009595; P:detection of biotic stimulus; TAS:HGNC.
DR   GO; GO:0032498; P:detection of muramyl dipeptide; IDA:HGNC.
DR   GO; GO:0002381; P:immunoglobulin production involved in immunoglobulin mediated immune response; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0002227; P:innate immune response in mucosa; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:HGNC.
DR   GO; GO:0007254; P:JNK cascade; TAS:Reactome.
DR   GO; GO:0071608; P:macrophage inflammatory protein-1 alpha production; IEA:Ensembl.
DR   GO; GO:0030277; P:maintenance of gastrointestinal epithelium; IMP:UniProtKB.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002756; P:MyD88-independent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0044130; P:negative regulation of growth of symbiont in host; IEA:Ensembl.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IEA:Ensembl.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; IEA:Ensembl.
DR   GO; GO:0032701; P:negative regulation of interleukin-18 production; IEA:Ensembl.
DR   GO; GO:0032703; P:negative regulation of interleukin-2 production; IEA:Ensembl.
DR   GO; GO:2000110; P:negative regulation of macrophage apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IEA:Ensembl.
DR   GO; GO:0002710; P:negative regulation of T cell mediated immunity; IEA:Ensembl.
DR   GO; GO:0034136; P:negative regulation of toll-like receptor 2 signaling pathway; IEA:Ensembl.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0035872; P:nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0070431; P:nucleotide-binding oligomerization domain containing 2 signaling pathway; IDA:UniProtKB.
DR   GO; GO:0070423; P:nucleotide-binding oligomerization domain containing signaling pathway; TAS:Reactome.
DR   GO; GO:0050871; P:positive regulation of B cell activation; IDA:BHF-UCL.
DR   GO; GO:0006965; P:positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteria; IEA:Ensembl.
DR   GO; GO:0002606; P:positive regulation of dendritic cell antigen processing and presentation; ISS:BHF-UCL.
DR   GO; GO:0002732; P:positive regulation of dendritic cell cytokine production; IEA:Ensembl.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:BHF-UCL.
DR   GO; GO:0046645; P:positive regulation of gamma-delta T cell activation; ISS:BHF-UCL.
DR   GO; GO:0002925; P:positive regulation of humoral immune response mediated by circulating immunoglobulin; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; IMP:BHF-UCL.
DR   GO; GO:0050718; P:positive regulation of interleukin-1 beta secretion; IDA:HGNC.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; ISS:BHF-UCL.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IEA:Ensembl.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; IMP:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:MGI.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0051353; P:positive regulation of oxidoreductase activity; ISS:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:BHF-UCL.
DR   GO; GO:2000363; P:positive regulation of prostaglandin-E synthase activity; ISS:BHF-UCL.
DR   GO; GO:0060585; P:positive regulation of prostaglandin-endoperoxide synthase activity; ISS:BHF-UCL.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; IDA:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IMP:BHF-UCL.
DR   GO; GO:0002830; P:positive regulation of type 2 immune response; IMP:BHF-UCL.
DR   GO; GO:0051259; P:protein oligomerization; TAS:HGNC.
DR   GO; GO:0050727; P:regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0090022; P:regulation of neutrophil chemotaxis; IEA:Ensembl.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IDA:HGNC.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; TAS:Reactome.
DR   GO; GO:0034166; P:toll-like receptor 10 signaling pathway; TAS:Reactome.
DR   GO; GO:0034134; P:toll-like receptor 2 signaling pathway; TAS:Reactome.
DR   GO; GO:0034138; P:toll-like receptor 3 signaling pathway; TAS:Reactome.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; TAS:Reactome.
DR   GO; GO:0034146; P:toll-like receptor 5 signaling pathway; TAS:Reactome.
DR   GO; GO:0034162; P:toll-like receptor 9 signaling pathway; TAS:Reactome.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038123; P:toll-like receptor TLR1:TLR2 signaling pathway; TAS:Reactome.
DR   GO; GO:0038124; P:toll-like receptor TLR6:TLR2 signaling pathway; TAS:Reactome.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 1.10.533.10; -; 2.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR007111; NACHT_NTPase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00619; CARD; 2.
DR   SMART; SM00114; CARD; 1.
DR   SUPFAM; SSF47986; SSF47986; 2.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS50209; CARD; 2.
DR   PROSITE; PS51450; LRR; 4.
DR   PROSITE; PS50837; NACHT; 1.
PE   1: Evidence at protein level;
KW   Alternative initiation; ATP-binding; Cell membrane; Complete proteome;
KW   Cytoplasm; Disease mutation; Immunity; Innate immunity;
KW   Leucine-rich repeat; Membrane; Nucleotide-binding; Polymorphism;
KW   Reference proteome; Repeat; Ubl conjugation.
FT   CHAIN         1   1040       Nucleotide-binding oligomerization
FT                                domain-containing protein 2.
FT                                /FTId=PRO_0000004418.
FT   DOMAIN       26    122       CARD 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   DOMAIN      126    218       CARD 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   DOMAIN      293    618       NACHT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00136}.
FT   REPEAT      791    812       LRR 1.
FT   REPEAT      816    839       LRR 2.
FT   REPEAT      844    865       LRR 3.
FT   REPEAT      872    884       LRR 4.
FT   REPEAT      900    920       LRR 5.
FT   REPEAT      928    949       LRR 6.
FT   REPEAT      956    976       LRR 7.
FT   REPEAT      984   1005       LRR 8.
FT   REPEAT     1012   1032       LRR 9.
FT   NP_BIND     299    306       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00136}.
FT   REGION      241    274       Required for CARD9 binding.
FT                                {ECO:0000269|PubMed:24960071}.
FT   MOTIF        63     77       ATG16L1-binding motif.
FT   VAR_SEQ       1     27       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:11087742,
FT                                ECO:0000303|PubMed:20698950}.
FT                                /FTId=VSP_018689.
FT   VAR_SEQ     216    224       AATCKKYMA -> DERTEAQKG (in isoform 3).
FT                                {ECO:0000303|PubMed:20698950}.
FT                                /FTId=VSP_046567.
FT   VAR_SEQ     225   1040       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:20698950}.
FT                                /FTId=VSP_046568.
FT   VARIANT      81     81       L -> V (in dbSNP:rs34936594).
FT                                /FTId=VAR_036871.
FT   VARIANT     113    113       D -> N (found in a patient with Crohn
FT                                disease; unknown pathological
FT                                significance; dbSNP:rs104895468).
FT                                {ECO:0000269|PubMed:15024686}.
FT   VARIANT     140    140       A -> T (associated with Crohn disease and
FT                                ulcerative colitis; dbSNP:rs34684955).
FT                                {ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:16485124}.
FT                                /FTId=VAR_012665.
FT   VARIANT     157    157       W -> R (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:16485124}.
FT                                /FTId=VAR_012666.
FT   VARIANT     189    189       T -> M (in dbSNP:rs61755182).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012667.
FT   VARIANT     235    235       R -> C (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012668.
FT   VARIANT     248    248       L -> R (associated with Crohn disease; no
FT                                disruption of NOD2-CARD9 interaction;
FT                                dbSNP:rs104895423).
FT                                {ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:24960071}.
FT                                /FTId=VAR_012669.
FT   VARIANT     268    268       P -> S (in dbSNP:rs2066842).
FT                                {ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:16485124}.
FT                                /FTId=VAR_012670.
FT   VARIANT     289    289       N -> S (associated with Crohn disease and
FT                                ulcerative colitis; dbSNP:rs5743271).
FT                                {ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:16485124}.
FT                                /FTId=VAR_012671.
FT   VARIANT     291    291       D -> N (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012672.
FT   VARIANT     294    294       T -> S (associated with Crohn disease).
FT                                /FTId=VAR_012673.
FT   VARIANT     301    301       A -> V (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012674.
FT   VARIANT     311    311       R -> W (associated with Crohn disease and
FT                                ulcerative colitis).
FT                                {ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:16485124}.
FT                                /FTId=VAR_012675.
FT   VARIANT     334    334       R -> Q (in BS; hyperactive;
FT                                dbSNP:rs104895461).
FT                                {ECO:0000269|PubMed:11528384,
FT                                ECO:0000269|PubMed:19116920,
FT                                ECO:0000269|PubMed:19479837,
FT                                ECO:0000269|PubMed:25093298}.
FT                                /FTId=VAR_012676.
FT   VARIANT     334    334       R -> W (in BS and EOS; no disruption of
FT                                NOD2-CARD9 interaction; hyperactive;
FT                                dbSNP:rs104895462).
FT                                {ECO:0000269|PubMed:11528384,
FT                                ECO:0000269|PubMed:15459013,
FT                                ECO:0000269|PubMed:19116920,
FT                                ECO:0000269|PubMed:19479837,
FT                                ECO:0000269|PubMed:20199415,
FT                                ECO:0000269|PubMed:24960071,
FT                                ECO:0000269|PubMed:25093298}.
FT                                /FTId=VAR_012677.
FT   VARIANT     348    348       L -> V (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012678.
FT   VARIANT     352    352       H -> R (associated with Crohn disease;
FT                                dbSNP:rs5743272).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012679.
FT   VARIANT     357    357       D -> A (found in a patient with Crohn
FT                                disease; unknown pathological
FT                                significance; no disruption of NOD2-CARD9
FT                                interaction; dbSNP:rs104895469).
FT                                {ECO:0000269|PubMed:15024686,
FT                                ECO:0000269|PubMed:24960071}.
FT   VARIANT     363    363       I -> F (found in a patient with Crohn
FT                                disease; unknown pathological
FT                                significance; no disruption of NOD2-CARD9
FT                                interaction; dbSNP:rs104895470).
FT                                {ECO:0000269|PubMed:15024686,
FT                                ECO:0000269|PubMed:24960071}.
FT   VARIANT     373    373       R -> C (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012680.
FT   VARIANT     382    382       D -> E (in EOS; hyperactive).
FT                                {ECO:0000269|PubMed:15459013,
FT                                ECO:0000269|PubMed:19116920}.
FT                                /FTId=VAR_023822.
FT   VARIANT     383    383       E -> G (found in a patient with BS/EOS
FT                                symptoms; unknown pathological
FT                                significance; hyperactive;
FT                                dbSNP:rs104895493).
FT                                {ECO:0000269|PubMed:19116920,
FT                                ECO:0000269|PubMed:25093298}.
FT   VARIANT     383    383       E -> K (in BS; hyperactive;
FT                                dbSNP:rs104895477).
FT                                {ECO:0000269|PubMed:15812565,
FT                                ECO:0000269|PubMed:19479837,
FT                                ECO:0000269|PubMed:25093298}.
FT                                /FTId=VAR_023823.
FT   VARIANT     391    391       R -> C (in dbSNP:rs104895481).
FT                                {ECO:0000269|PubMed:16485124}.
FT   VARIANT     414    414       N -> S (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012681.
FT   VARIANT     431    431       S -> L (associated with Crohn disease; no
FT                                disruption of NOD2-CARD9 interaction;
FT                                dbSNP:rs104895431).
FT                                {ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:24960071}.
FT                                /FTId=VAR_012682.
FT   VARIANT     432    432       A -> V (associated with Crohn disease;
FT                                dbSNP:rs2076754).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012683.
FT   VARIANT     441    441       E -> K (associated with Crohn disease; no
FT                                disruption of NOD2-CARD9 interaction;
FT                                dbSNP:rs104895432).
FT                                {ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:24960071}.
FT                                /FTId=VAR_012684.
FT   VARIANT     463    463       P -> A (polymorphism; no disruption of
FT                                NOD2-CARD9 interaction;
FT                                dbSNP:rs104895482).
FT                                {ECO:0000269|PubMed:16485124,
FT                                ECO:0000269|PubMed:24960071}.
FT   VARIANT     464    464       G -> W (polymorphism; hyperactive;
FT                                dbSNP:rs104895492).
FT                                {ECO:0000269|PubMed:25093298}.
FT   VARIANT     469    469       L -> F (in BS; hyperactive;
FT                                dbSNP:rs104895460).
FT                                {ECO:0000269|PubMed:11528384,
FT                                ECO:0000269|PubMed:25093298}.
FT                                /FTId=VAR_012685.
FT   VARIANT     471    471       R -> C (polymorphism; not hyperactive;
FT                                dbSNP:rs1078327).
FT                                {ECO:0000269|PubMed:25093298}.
FT                                /FTId=VAR_036872.
FT   VARIANT     481    481       G -> D (in EOS; atypical form of EOS with
FT                                cardiac infiltration; sporadic case;
FT                                unknown pathological significance;
FT                                hyperactive; dbSNP:rs104895494).
FT                                {ECO:0000269|PubMed:19359344,
FT                                ECO:0000269|PubMed:25093298}.
FT   VARIANT     490    490       W -> L (found in a patient with BS/EOS
FT                                symptoms; unknown pathological
FT                                significance; hyperactive;
FT                                dbSNP:rs104895480).
FT                                {ECO:0000269|PubMed:19479837,
FT                                ECO:0000269|PubMed:25093298}.
FT   VARIANT     495    495       C -> Y (found in a patient with BS/EOS
FT                                symptoms; unknown pathological
FT                                significance; hyperactive;
FT                                dbSNP:rs104895478).
FT                                {ECO:0000269|PubMed:19116920,
FT                                ECO:0000269|PubMed:19479837,
FT                                ECO:0000269|PubMed:25093298}.
FT   VARIANT     496    496       H -> L (in EOS; hyperactive;
FT                                dbSNP:rs104895472).
FT                                {ECO:0000269|PubMed:15459013,
FT                                ECO:0000269|PubMed:19116920,
FT                                ECO:0000269|PubMed:25093298}.
FT                                /FTId=VAR_023824.
FT   VARIANT     513    513       M -> T (in EOS; hyperactive;
FT                                dbSNP:rs104895473).
FT                                {ECO:0000269|PubMed:15459013,
FT                                ECO:0000269|PubMed:19116920,
FT                                ECO:0000269|PubMed:25093298}.
FT   VARIANT     550    550       L -> V (found in a patient with Crohn
FT                                disease; unknown pathological
FT                                significance; no disruption of NOD2-CARD9
FT                                interaction; dbSNP:rs104895471).
FT                                {ECO:0000269|PubMed:15024686,
FT                                ECO:0000269|PubMed:24960071}.
FT   VARIANT     587    587       R -> C (found in a patient with BS/EOS
FT                                symptoms; unknown pathological
FT                                significance; not hyperactive;
FT                                dbSNP:rs104895479).
FT                                {ECO:0000269|PubMed:19479837,
FT                                ECO:0000269|PubMed:25093298}.
FT   VARIANT     605    605       T -> N (in BS; hyperactive).
FT                                {ECO:0000269|PubMed:19169908,
FT                                ECO:0000269|PubMed:25093298}.
FT                                /FTId=VAR_065228.
FT   VARIANT     605    605       T -> P (in EOS; hyperactive;
FT                                dbSNP:rs104895474).
FT                                {ECO:0000269|PubMed:15459013,
FT                                ECO:0000269|PubMed:19116920,
FT                                ECO:0000269|PubMed:25093298}.
FT   VARIANT     612    612       A -> T (in EOS; associated with Crohn
FT                                disease). {ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:15459013}.
FT                                /FTId=VAR_012686.
FT   VARIANT     612    612       A -> V (associated with Crohn disease; no
FT                                disruption of NOD2-CARD9 interaction;
FT                                dbSNP:rs104895439).
FT                                {ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:24960071}.
FT                                /FTId=VAR_012687.
FT   VARIANT     670    670       N -> K (in EOS; hyperactive;
FT                                dbSNP:rs104895475).
FT                                {ECO:0000269|PubMed:15459013,
FT                                ECO:0000269|PubMed:19116920,
FT                                ECO:0000269|PubMed:25093298}.
FT   VARIANT     684    684       R -> W (associated with Crohn disease;
FT                                dbSNP:rs5743276).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012688.
FT   VARIANT     702    702       R -> W (associated with Crohn disease; no
FT                                disruption of NOD2-CARD9 interaction;
FT                                decreases half-life of protein;
FT                                dbSNP:rs2066844).
FT                                {ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:24790089,
FT                                ECO:0000269|PubMed:24960071}.
FT                                /FTId=VAR_012689.
FT   VARIANT     703    703       R -> C (associated with Crohn disease and
FT                                ulcerative colitis; dbSNP:rs5743277).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012690.
FT   VARIANT     713    713       R -> C (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012691.
FT   VARIANT     713    713       R -> H (found in a patient with Crohn
FT                                disease; unknown pathological
FT                                significance; dbSNP:rs104895483).
FT                                {ECO:0000269|PubMed:16485124}.
FT   VARIANT     725    725       A -> G (associated with Crohn disease;
FT                                dbSNP:rs5743278).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012692.
FT   VARIANT     755    755       A -> V (associated with Crohn disease and
FT                                ulcerative colitis; dbSNP:rs61747625).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012693.
FT   VARIANT     758    758       A -> V (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012694.
FT   VARIANT     760    760       R -> C (found in a patient with Crohn
FT                                disease; unknown pathological
FT                                significance; dbSNP:rs3813758).
FT                                {ECO:0000269|PubMed:16485124}.
FT   VARIANT     778    778       E -> K (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012695.
FT   VARIANT     790    790       R -> Q (in dbSNP:rs5743279).
FT                                /FTId=VAR_024402.
FT   VARIANT     790    790       R -> W (found in a patient with Crohn
FT                                disease; unknown pathological
FT                                significance; dbSNP:rs62029861).
FT                                {ECO:0000269|PubMed:16485124}.
FT   VARIANT     791    791       R -> W (in dbSNP:rs104895484).
FT                                {ECO:0000269|PubMed:16485124}.
FT   VARIANT     793    793       V -> M (associated with Crohn disease;
FT                                dbSNP:rs104895444).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012696.
FT   VARIANT     825    825       N -> K (in dbSNP:rs104895485).
FT                                {ECO:0000269|PubMed:16485124}.
FT   VARIANT     843    843       E -> K (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012697.
FT   VARIANT     849    849       A -> V (in dbSNP:rs104895486).
FT                                {ECO:0000269|PubMed:16485124}.
FT   VARIANT     852    852       N -> S (found in a patient with Crohn
FT                                disease; unknown pathological
FT                                significance; dbSNP:rs104895467).
FT                                {ECO:0000269|PubMed:15024686}.
FT   VARIANT     853    853       N -> S (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012698.
FT   VARIANT     863    863       M -> V (associated with Crohn disease;
FT                                dbSNP:rs104895447).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012699.
FT   VARIANT     885    885       A -> T (associated with ulcerative
FT                                colitis). {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012700.
FT   VARIANT     908    908       G -> R (associated with Crohn disease;
FT                                decreases half-life of protein;
FT                                dbSNP:rs2066845).
FT                                {ECO:0000269|PubMed:11087742,
FT                                ECO:0000269|PubMed:11385576,
FT                                ECO:0000269|PubMed:24790089}.
FT                                /FTId=VAR_012701.
FT   VARIANT     918    918       A -> D (associated with Crohn disease;
FT                                dbSNP:rs104895452).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012702.
FT   VARIANT     924    924       G -> D (associated with Crohn disease).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012703.
FT   VARIANT     955    955       V -> I (in dbSNP:rs5743291).
FT                                {ECO:0000269|PubMed:11385576}.
FT                                /FTId=VAR_012704.
FT   MUTAGEN     305    305       K->R: No activation.
FT                                {ECO:0000269|PubMed:11087742}.
FT   MUTAGEN     379    379       D->A: No disruption in NOD2-CARD9
FT                                interaction.
FT                                {ECO:0000269|PubMed:24960071}.
**
**   #################    INTERNAL SECTION    ##################
**CL 16q12;
**EV ECO:0000255; PROSITE-ProRule:PRU00046; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00136; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:11087742; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:11385576; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:11528384; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:15024686; BAP; 09-FEB-2015.
**EV ECO:0000269; PubMed:15459013; BAP; 06-FEB-2015.
**EV ECO:0000269; PubMed:15812565; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:16203728; BAP; 04-FEB-2015.
**EV ECO:0000269; PubMed:16485124; BAP; 19-FEB-2015.
**EV ECO:0000269; PubMed:19116920; BAP; 06-FEB-2015.
**EV ECO:0000269; PubMed:19169908; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:19359344; BAP; 06-FEB-2015.
**EV ECO:0000269; PubMed:19479837; BAP; 06-FEB-2015.
**EV ECO:0000269; PubMed:19592251; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:20199415; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:21887730; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:23019338; BAP; 02-FEB-2015.
**EV ECO:0000269; PubMed:23376921; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:23711367; NAG; 20-NOV-2014.
**EV ECO:0000269; PubMed:23806334; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:24790089; BAP; 03-FEB-2015.
**EV ECO:0000269; PubMed:24960071; BAP; 09-FEB-2015.
**EV ECO:0000269; PubMed:25093298; BAP; 19-FEB-2015.
**EV ECO:0000303; PubMed:11087742; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:20698950; XXX; 01-JAN-1900.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**IS Q9HC29-4
**ZA UHI/SIB, 28-NOV-2001;
**ZB SEF, 06-JAN-2006; MCB, 12-MAY-2006; MIM, 26-MAR-2007; ARG, 03-SEP-2007;
**ZB LIF, 09-JUN-2010; LIF, 11-JUN-2010; LIF, 13-AUG-2010; LIF, 15-APR-2011;
**ZB SYP, 21-FEB-2013; ALG, 02-MAY-2013; SYP, 21-AUG-2013; ANS, 25-NOV-2013;
**ZB SYP, 06-MAR-2014; SED, 07-APR-2014; BAP, 27-FEB-2015;
SQ   SEQUENCE   1040 AA;  115283 MW;  0037592D96D7DDFF CRC64;
     MGEEGGSASH DEEERASVLL GHSPGCEMCS QEAFQAQRSQ LVELLVSGSL EGFESVLDWL
     LSWEVLSWED YEGFHLLGQP LSHLARRLLD TVWNKGTWAC QKLIAAAQEA QADSQSPKLH
     GCWDPHSLHP ARDLQSHRPA IVRRLHSHVE NMLDLAWERG FVSQYECDEI RLPIFTPSQR
     ARRLLDLATV KANGLAAFLL QHVQELPVPL ALPLEAATCK KYMAKLRTTV SAQSRFLSTY
     DGAETLCLED IYTENVLEVW ADVGMAGPPQ KSPATLGLEE LFSTPGHLND DADTVLVVGE
     AGSGKSTLLQ RLHLLWAAGQ DFQEFLFVFP FSCRQLQCMA KPLSVRTLLF EHCCWPDVGQ
     EDIFQLLLDH PDRVLLTFDG FDEFKFRFTD RERHCSPTDP TSVQTLLFNL LQGNLLKNAR
     KVVTSRPAAV SAFLRKYIRT EFNLKGFSEQ GIELYLRKRH HEPGVADRLI RLLQETSALH
     GLCHLPVFSW MVSKCHQELL LQEGGSPKTT TDMYLLILQH FLLHATPPDS ASQGLGPSLL
     RGRLPTLLHL GRLALWGLGM CCYVFSAQQL QAAQVSPDDI SLGFLVRAKG VVPGSTAPLE
     FLHITFQCFF AAFYLALSAD VPPALLRHLF NCGRPGNSPM ARLLPTMCIQ ASEGKDSSVA
     ALLQKAEPHN LQITAAFLAG LLSREHWGLL AECQTSEKAL LRRQACARWC LARSLRKHFH
     SIPPAAPGEA KSVHAMPGFI WLIRSLYEMQ EERLARKAAR GLNVGHLKLT FCSVGPTECA
     ALAFVLQHLR RPVALQLDYN SVGDIGVEQL LPCLGVCKAL YLRDNNISDR GICKLIECAL
     HCEQLQKLAL FNNKLTDGCA HSMAKLLACR QNFLALRLGN NYITAAGAQV LAEGLRGNTS
     LQFLGFWGNR VGDEGAQALA EALGDHQSLR WLSLVGNNIG SVGAQALALM LAKNVMLEEL
     CLEENHLQDE GVCSLAEGLK KNSSLKILKL SNNCITYLGA EALLQALERN DTILEVWLRG
     NTFSLEEVDK LGCRDTRLLL
//
ID   NOD2_HYLLA              Reviewed;        1040 AA.
AC   Q53B88;
DT   05-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   24-MAY-2005, sequence version 1.
DT   01-OCT-2014, entry version 53.
DE   RecName: Full=Nucleotide-binding oligomerization domain-containing protein 2;
DE   AltName: Full=Caspase recruitment domain-containing protein 15;
GN   Name=NOD2; Synonyms=CARD15;
OS   Hylobates lar (Common gibbon) (White-handed gibbon).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hylobatidae; Hylobates.
OX   NCBI_TaxID=9580;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   King K., Sheikh M., Cuthbert A.P., Fisher S.A., Mirza M.M.,
RA   Sanderson J., Forbes A., Mansfield J., Roberts R.G., Mathew C.G.;
RT   "Mutation, selection and evolution of the Crohn's disease
RT   susceptibility gene, CARD15.";
RL   Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Recognizes muramyl dipeptide (MDP) constituents of
CC       bacterial peptidoglycans and plays a key role in gastrointestinal
CC       immunity: upon stimulation, binds the proximal adapter receptor-
CC       interacting RIPK2, which recruits ubiquitin ligases as XIAP,
CC       BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP
CC       kinases and activation of NF-kappa-B signaling, leading to
CC       activate the transcription of hundreds of genes involved in immune
CC       response. {ECO:0000250}.
CC   -!- SUBUNIT: Found in a signaling complex consisting of ARHGEF2, NOD2
CC       and RIPK2. Interacts (via CARD domain) with RIPK2 (via CARD
CC       domain). Interacts with ATG16L1. Interacts (via NACHT domain) with
CC       CARD9. Interacts with ANKRD17 (via N-terminus). Interacts with
CC       HSPA1A; the interaction enhances NOD2 stability. Interacts (via
CC       both CARD domains) with HSP90; the interaction enhances NOD2
CC       stability. Interacts (via CARD domain) with SOCS3; the interaction
CC       promotes NOD2 degradation. Interacts (via CARD domain) with
CC       ERBBI2P; the interaction inhibits activation of NOD2.
CC       {ECO:0000250|UniProtKB:Q9HC29}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9HC29}.
CC       Membrane {ECO:0000250|UniProtKB:Q9HC29}. Basolateral cell membrane
CC       {ECO:0000250|UniProtKB:Q9HC29}.
CC   -!- DOMAIN: The ATG16L1-binding motif mediates interaction with
CC       ATG16L1. {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated following MDP stimulation, leading to
CC       proteasome-madiated degradation. {ECO:0000250|UniProtKB:Q9HC29}.
CC   -!- SIMILARITY: Contains 2 CARD domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00046}.
CC   -!- SIMILARITY: Contains 9 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 NACHT domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00136}.
DR   EMBL; AY594161; AAS89990.1; -; Genomic_DNA.
DR   EMBL; AY594150; AAS89990.1; JOINED; Genomic_DNA.
DR   EMBL; AY594151; AAS89990.1; JOINED; Genomic_DNA.
DR   EMBL; AY594152; AAS89990.1; JOINED; Genomic_DNA.
DR   EMBL; AY594153; AAS89990.1; JOINED; Genomic_DNA.
DR   EMBL; AY594154; AAS89990.1; JOINED; Genomic_DNA.
DR   EMBL; AY594155; AAS89990.1; JOINED; Genomic_DNA.
DR   EMBL; AY594156; AAS89990.1; JOINED; Genomic_DNA.
DR   EMBL; AY594157; AAS89990.1; JOINED; Genomic_DNA.
DR   EMBL; AY594158; AAS89990.1; JOINED; Genomic_DNA.
DR   EMBL; AY594159; AAS89990.1; JOINED; Genomic_DNA.
DR   EMBL; AY594160; AAS89990.1; JOINED; Genomic_DNA.
DR   ProteinModelPortal; Q53B88; -.
DR   HOVERGEN; HBG050792; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043234; C:protein complex; ISS:UniProtKB.
DR   GO; GO:0031982; C:vesicle; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0050700; F:CARD domain binding; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISS:UniProtKB.
DR   GO; GO:0032500; F:muramyl dipeptide binding; ISS:UniProtKB.
DR   GO; GO:0042834; F:peptidoglycan binding; ISS:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISS:UniProtKB.
DR   GO; GO:0071225; P:cellular response to muramyl dipeptide; ISS:UniProtKB.
DR   GO; GO:0002367; P:cytokine production involved in immune response; ISS:UniProtKB.
DR   GO; GO:0042742; P:defense response to bacterium; ISS:UniProtKB.
DR   GO; GO:0016045; P:detection of bacterium; ISS:UniProtKB.
DR   GO; GO:0032498; P:detection of muramyl dipeptide; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:UniProtKB.
DR   GO; GO:0070431; P:nucleotide-binding oligomerization domain containing 2 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0050718; P:positive regulation of interleukin-1 beta secretion; ISS:UniProtKB.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:InterPro.
DR   GO; GO:0032495; P:response to muramyl dipeptide; ISS:UniProtKB.
DR   Gene3D; 1.10.533.10; -; 2.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR007111; NACHT_NTPase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00619; CARD; 2.
DR   SMART; SM00114; CARD; 1.
DR   SUPFAM; SSF47986; SSF47986; 2.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS50209; CARD; 2.
DR   PROSITE; PS51450; LRR; 4.
DR   PROSITE; PS50837; NACHT; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cell membrane; Cytoplasm; Immunity; Innate immunity;
KW   Leucine-rich repeat; Membrane; Nucleotide-binding; Repeat;
KW   Ubl conjugation.
FT   CHAIN         1   1040       Nucleotide-binding oligomerization
FT                                domain-containing protein 2.
FT                                /FTId=PRO_0000144090.
FT   DOMAIN       26    122       CARD 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   DOMAIN      126    218       CARD 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   DOMAIN      293    618       NACHT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00136}.
FT   REPEAT      791    812       LRR 1.
FT   REPEAT      816    839       LRR 2.
FT   REPEAT      844    865       LRR 3.
FT   REPEAT      872    884       LRR 4.
FT   REPEAT      900    920       LRR 5.
FT   REPEAT      928    949       LRR 6.
FT   REPEAT      956    976       LRR 7.
FT   REPEAT      984   1005       LRR 8.
FT   REPEAT     1012   1032       LRR 9.
FT   NP_BIND     299    306       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00136}.
FT   REGION      241    274       Required for CARD9 binding.
FT                                {ECO:0000250|UniProtKB:Q9HC29}.
FT   MOTIF        63     77       ATG16L1-binding motif.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:Q9HC29; BAP; 19-FEB-2015.
**EV ECO:0000255; PROSITE-ProRule:PRU00046; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00136; XXX; 01-JAN-1900.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**ZB SEF, 06-JAN-2006; MIM, 26-MAR-2007; LIF, 09-JUN-2010; SYP, 21-FEB-2013;
**ZB SYP, 21-AUG-2013; ANS, 25-NOV-2013; SYP, 06-MAR-2014; BAP, 27-FEB-2015;
SQ   SEQUENCE   1040 AA;  115262 MW;  2BE59A6C96AAC0D1 CRC64;
     MGEEGGSVSH DEEERASVLL GQYLGCEMCS QEAFQAQRSQ LVELLVSGSL EGFESVLDWL
     LSWEVLSWED YEGFHLLGQP LSHLARRLLD TVWNKGTWAC QKLIAAAQEA QADSQSPKLH
     GCWDPHSLHP ARDLQSHRPA IVRRLHSHVE GVLDLAWERG FVSQYECDEI RLPIFTPSQR
     ARRLLDLATV KANGLAAFLL QHVQELPVPL ALPLEAATCR KYMAKLRTTV SAQSRFLSTY
     DGAETLCLED IYTENVLEVW ADVGTAGPPP KSPATLGLEE LFSTPGHLND DADTVLVVGE
     AGSGKSTLLQ RLHLLWAAGR DFQEFLFVFP FSCRQLQCMA KPLSVRTLLF EHCCWPDVGQ
     EDIFQLLLDH PDRVLLTFDG FDEFKFRFTD RERHCSPTDP TSVQTLLFNL LQGNLLKNAR
     KVVTSRPAAV SAFLRKYIRT EFNLKGFSEQ GIELYLRKRH REPGVADRLI RLLQATSALH
     GLCHLPVFSW MVSKCHQELL LQEGGSPKTT TDMYLLILQH FLLHAIPPDS ASQGLGPSLL
     RGRLPTLLHL GRLALWGLGM CCYVFSAQQL QAAQVSPDDI SLGFLVRAKG VVPGSTAPLE
     FLHITFQCFF AAFYLALSAD VPPALLRHLF NCGRPGNSPV ARLLPTLCIQ GSEGKDSSVA
     ALLQKAEPHN LQITAAFLAG LLSREHWGLL AECQTSEKAL LRRQACARWC LARSLRKHFH
     SIPPAAPGEA KSMHAMPGFI WLIRSLYEMQ EERLARKAAR GLNVGHLKLT FCSVGPAECA
     ALAFVLQHLR RPVALQLDYN SVGDIGVEQL LPCLGVCKAL YLRDNNISDR GICKLIECAL
     HCEQLQKLVL FNNKLTDGCA HSMAKLLACR QNFLALRLGN NHITPAGAQV LAEGLRGNTS
     LQFLGFWGNR VGDEGAQALA EALGDHQSLR WLSLVGNNIG SVGAQALALM LAKNVMLEEL
     CLEENHIQDE GVCSLAEGLK KNSSLKILKL SNNCITYLGA KALLQALERN DTILEVWLRG
     NIFSLEEVDK LGCRDIRLLL
//
ID   NOD2_MOUSE              Reviewed;        1020 AA.
AC   Q8K3Z0;
DT   28-MAR-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   04-MAR-2015, entry version 118.
DE   RecName: Full=Nucleotide-binding oligomerization domain-containing protein 2;
DE   AltName: Full=Caspase recruitment domain-containing protein 15;
GN   Name=Nod2; Synonyms=Card15;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=BALB/c; TISSUE=Monocyte;
RX   PubMed=12835899; DOI=10.1007/s00011-003-1170-z;
RA   Iwanaga Y., Davey M.P., Martin T.M., Planck S.R., DePriest M.L.,
RA   Baugh M.M., Suing C.M., Rosenbaum J.T.;
RT   "Cloning, sequencing and expression analysis of the mouse Nod2/Card15
RT   gene.";
RL   Inflamm. Res. 52:272-276(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS
RP   ALA-212; ARG-240; CYS-422; VAL-485; ALA-603; ILE-675 AND GLN-925.
RC   STRAIN=NMRI; TISSUE=Mammary cancer;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   INTERACTION WITH CARD9.
RX   PubMed=17187069; DOI=10.1038/ni1426;
RA   Hsu Y.M., Zhang Y., You Y., Wang D., Li H., Duramad O., Qin X.F.,
RA   Dong C., Lin X.;
RT   "The adaptor protein CARD9 is required for innate immune responses to
RT   intracellular pathogens.";
RL   Nat. Immunol. 8:198-205(2007).
RN   [4]
RP   INTERACTION WITH HSP90 AND SOCS3.
RX   PubMed=23019338; DOI=10.1074/jbc.M112.410027;
RA   Lee K.H., Biswas A., Liu Y.J., Kobayashi K.S.;
RT   "Proteasomal degradation of Nod2 protein mediates tolerance to
RT   bacterial cell wall components.";
RL   J. Biol. Chem. 287:39800-39811(2012).
RN   [5]
RP   FUNCTION.
RX   PubMed=22607974; DOI=10.1016/j.molcel.2012.04.014;
RA   Damgaard R.B., Nachbur U., Yabal M., Wong W.W., Fiil B.K., Kastirr M.,
RA   Rieser E., Rickard J.A., Bankovacki A., Peschel C., Ruland J.,
RA   Bekker-Jensen S., Mailand N., Kaufmann T., Strasser A., Walczak H.,
RA   Silke J., Jost P.J., Gyrd-Hansen M.;
RT   "The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in
RT   inflammation and innate immunity.";
RL   Mol. Cell 46:746-758(2012).
CC   -!- FUNCTION: Recognizes muramyl dipeptide (MDP) constituents of
CC       bacterial peptidoglycans and plays a key role in gastrointestinal
CC       immunity: upon stimulation, binds the proximal adapter receptor-
CC       interacting RIPK2, which recruits ubiquitin ligases as XIAP,
CC       BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP
CC       kinases and activation of NF-kappa-B signaling, leading to
CC       activate the transcription of hundreds of genes involved in immune
CC       response. {ECO:0000269|PubMed:22607974}.
CC   -!- SUBUNIT: Found in a signaling complex consisting of ARHGEF2, NOD2
CC       and RIPK2 (By similarity). Interacts (via CARD domain) with RIPK2
CC       (via CARD domain) (By similarity). Interacts with ATG16L1 (By
CC       similarity). Interacts (via NACHT domain) with CARD9
CC       (PubMed:17187069). Interacts with ANKRD17 (via N-terminus) (By
CC       similarity). Interacts with HSPA1A; the interaction enhances NOD2
CC       stability (By similarity). Interacts (via both CARD domains) with
CC       HSP90; the interaction enhances NOD2 stability (PubMed:23019338).
CC       Interacts (via CARD domain) with SOCS3; the interaction promotes
CC       NOD2 degradation (PubMed:23019338). Interacts (via CARD domain)
CC       with ERBBI2P; the interaction inhibits activation of NOD2 (By
CC       similarity). {ECO:0000250|UniProtKB:Q9HC29,
CC       ECO:0000269|PubMed:17187069, ECO:0000269|PubMed:23019338}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9HC29}.
CC       Membrane {ECO:0000250|UniProtKB:Q9HC29}. Basolateral cell membrane
CC       {ECO:0000250|UniProtKB:Q9HC29}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8K3Z0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8K3Z0-2; Sequence=VSP_007069, VSP_007070;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The ATG16L1-binding motif mediates interaction with
CC       ATG16L1. {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated following MDP stimulation, leading to
CC       proteasome-madiated degradation (By similarity).
CC       {ECO:0000250|UniProtKB:Q9HC29}.
CC   -!- SIMILARITY: Contains 2 CARD domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00046}.
CC   -!- SIMILARITY: Contains 10 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 NACHT domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00136}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH44774.1; Type=Erroneous initiation; Evidence={ECO:0000305};
DR   EMBL; AF520774; AAM76073.1; -; mRNA.
DR   EMBL; BC044774; AAH44774.1; ALT_INIT; mRNA.
DR   UniGene; Mm.222633; -.
DR   ProteinModelPortal; Q8K3Z0; -.
DR   SMR; Q8K3Z0; 760-1012.
DR   DIP; DIP-46115N; -.
DR   PhosphoSite; Q8K3Z0; -.
DR   PRIDE; Q8K3Z0; -.
DR   Ensembl; ENSMUST00000054324; ENSMUSP00000050538; ENSMUSG00000055994. [Q8K3Z0-2]
DR   Ensembl; ENSMUST00000109634; ENSMUSP00000105262; ENSMUSG00000055994. [Q8K3Z0-1]
DR   UCSC; uc009mrq.1; mouse. [Q8K3Z0-1]
DR   MGI; MGI:2429397; Nod2.
DR   eggNOG; NOG248107; -.
DR   GeneTree; ENSGT00780000121843; -.
DR   HOGENOM; HOG000113814; -.
DR   HOVERGEN; HBG050792; -.
DR   InParanoid; Q8K3Z0; -.
DR   OMA; NVGHLKL; -.
DR   PhylomeDB; Q8K3Z0; -.
DR   TreeFam; TF352118; -.
DR   Reactome; REACT_288310; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; REACT_301153; NOD1/2 Signaling Pathway.
DR   Reactome; REACT_305279; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; REACT_324009; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; REACT_337033; Interleukin-1 signaling.
DR   PRO; PR:Q8K3Z0; -.
DR   Proteomes; UP000000589; Chromosome 8.
DR   Bgee; Q8K3Z0; -.
DR   ExpressionAtlas; Q8K3Z0; baseline and differential.
DR   Genevestigator; Q8K3Z0; -.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:HGNC.
DR   GO; GO:0005886; C:plasma membrane; ISS:HGNC.
DR   GO; GO:0043234; C:protein complex; ISS:UniProtKB.
DR   GO; GO:0031982; C:vesicle; ISS:HGNC.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0050700; F:CARD domain binding; ISS:HGNC.
DR   GO; GO:0016888; F:endodeoxyribonuclease activity, producing 5'-phosphomonoesters; IEA:InterPro.
DR   GO; GO:0019899; F:enzyme binding; ISS:HGNC.
DR   GO; GO:0032500; F:muramyl dipeptide binding; ISS:HGNC.
DR   GO; GO:0042834; F:peptidoglycan binding; ISS:HGNC.
DR   GO; GO:0019901; F:protein kinase binding; ISS:HGNC.
DR   GO; GO:0002253; P:activation of immune response; IMP:MGI.
DR   GO; GO:0035419; P:activation of MAPK activity involved in innate immune response; IDA:BHF-UCL.
DR   GO; GO:0071225; P:cellular response to muramyl dipeptide; ISS:UniProtKB.
DR   GO; GO:0071224; P:cellular response to peptidoglycan; IMP:MGI.
DR   GO; GO:0002367; P:cytokine production involved in immune response; ISS:UniProtKB.
DR   GO; GO:0006952; P:defense response; TAS:HGNC.
DR   GO; GO:0042742; P:defense response to bacterium; ISS:HGNC.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IMP:MGI.
DR   GO; GO:0016045; P:detection of bacterium; ISS:HGNC.
DR   GO; GO:0009595; P:detection of biotic stimulus; TAS:HGNC.
DR   GO; GO:0032498; P:detection of muramyl dipeptide; ISS:HGNC.
DR   GO; GO:0002381; P:immunoglobulin production involved in immunoglobulin mediated immune response; IMP:MGI.
DR   GO; GO:0006954; P:inflammatory response; TAS:HGNC.
DR   GO; GO:0045087; P:innate immune response; ISS:UniProtKB.
DR   GO; GO:0002227; P:innate immune response in mucosa; IMP:MGI.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:UniProtKB.
DR   GO; GO:0071608; P:macrophage inflammatory protein-1 alpha production; IMP:MGI.
DR   GO; GO:0030277; P:maintenance of gastrointestinal epithelium; ISO:MGI.
DR   GO; GO:0044130; P:negative regulation of growth of symbiont in host; IMP:MGI.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; IMP:MGI.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IMP:MGI.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; IDA:MGI.
DR   GO; GO:0032701; P:negative regulation of interleukin-18 production; IMP:MGI.
DR   GO; GO:0032703; P:negative regulation of interleukin-2 production; IMP:MGI.
DR   GO; GO:2000110; P:negative regulation of macrophage apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IMP:MGI.
DR   GO; GO:0002710; P:negative regulation of T cell mediated immunity; IMP:MGI.
DR   GO; GO:0034136; P:negative regulation of toll-like receptor 2 signaling pathway; IMP:MGI.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IMP:MGI.
DR   GO; GO:0070431; P:nucleotide-binding oligomerization domain containing 2 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0006963; P:positive regulation of antibacterial peptide biosynthetic process; IDA:MGI.
DR   GO; GO:0050871; P:positive regulation of B cell activation; ISO:MGI.
DR   GO; GO:0006965; P:positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteria; IMP:MGI.
DR   GO; GO:0002606; P:positive regulation of dendritic cell antigen processing and presentation; IMP:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0002925; P:positive regulation of humoral immune response mediated by circulating immunoglobulin; IMP:MGI.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; ISS:HGNC.
DR   GO; GO:0045089; P:positive regulation of innate immune response; IMP:MGI.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; ISO:MGI.
DR   GO; GO:0050718; P:positive regulation of interleukin-1 beta secretion; ISS:UniProtKB.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; IMP:BHF-UCL.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IDA:MGI.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; ISS:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:MGI.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:MGI.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:HGNC.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0051353; P:positive regulation of oxidoreductase activity; IDA:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:MGI.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IMP:MGI.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:BHF-UCL.
DR   GO; GO:2000363; P:positive regulation of prostaglandin-E synthase activity; IDA:BHF-UCL.
DR   GO; GO:0060585; P:positive regulation of prostaglandin-endoperoxide synthase activity; IDA:BHF-UCL.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; IDA:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:MGI.
DR   GO; GO:0002830; P:positive regulation of type 2 immune response; ISS:BHF-UCL.
DR   GO; GO:0051259; P:protein oligomerization; TAS:HGNC.
DR   GO; GO:0050727; P:regulation of inflammatory response; IMP:MGI.
DR   GO; GO:0090022; P:regulation of neutrophil chemotaxis; IMP:MGI.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IMP:MGI.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IMP:MGI.
DR   GO; GO:0032495; P:response to muramyl dipeptide; ISS:HGNC.
DR   GO; GO:0032494; P:response to peptidoglycan; IDA:MGI.
DR   GO; GO:0007165; P:signal transduction; TAS:HGNC.
DR   Gene3D; 1.10.533.10; -; 2.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR018228; DNase_TatD-rel_CS.
DR   InterPro; IPR007111; NACHT_NTPase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00619; CARD; 2.
DR   SUPFAM; SSF47986; SSF47986; 2.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS50209; CARD; 2.
DR   PROSITE; PS50837; NACHT; 1.
**   PROSITE; PS01137; TATD_1; 1; FALSE_POS.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Cytoplasm; Immunity; Innate immunity; Leucine-rich repeat; Membrane;
KW   Nucleotide-binding; Reference proteome; Repeat; Ubl conjugation.
FT   CHAIN         1   1020       Nucleotide-binding oligomerization
FT                                domain-containing protein 2.
FT                                /FTId=PRO_0000144091.
FT   DOMAIN        6    104       CARD 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   DOMAIN      106    200       CARD 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   DOMAIN      273    600       NACHT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00136}.
FT   REPEAT      685    709       LRR 1.
FT   REPEAT      726    749       LRR 2.
FT   REPEAT      766    792       LRR 3.
FT   REPEAT      794    817       LRR 4.
FT   REPEAT      822    845       LRR 5.
FT   REPEAT      850    873       LRR 6.
FT   REPEAT      906    929       LRR 7.
FT   REPEAT      934    962       LRR 8.
FT   REPEAT      963    985       LRR 9.
FT   REPEAT     1005   1019       LRR 10.
FT   REGION      221    254       Required for CARD9 binding.
FT                                {ECO:0000250|UniProtKB:Q9HC29}.
FT   MOTIF        43     57       ATG16L1-binding motif.
FT   VAR_SEQ       1      7       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_007069.
FT   VAR_SEQ     195    195       E -> EGYSLCRSRCDRGFTLICLFCIL (in isoform
FT                                2). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_007070.
FT   VARIANT     212    212       T -> A (in strain: NMRI).
FT                                {ECO:0000269|PubMed:15489334}.
FT   VARIANT     240    240       Q -> R (in strain: NMRI).
FT                                {ECO:0000269|PubMed:15489334}.
FT   VARIANT     422    422       L -> C (in strain: NMRI; requires 2
FT                                nucleotide substitutions).
FT                                {ECO:0000269|PubMed:15489334}.
FT   VARIANT     485    485       G -> V (in strain: NMRI).
FT                                {ECO:0000269|PubMed:15489334}.
FT   VARIANT     603    603       V -> A (in strain: NMRI).
FT                                {ECO:0000269|PubMed:15489334}.
FT   VARIANT     675    675       V -> I (in strain: NMRI).
FT                                {ECO:0000269|PubMed:15489334}.
FT   VARIANT     925    925       E -> Q (in strain: NMRI).
FT                                {ECO:0000269|PubMed:15489334}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:Q9HC29; BAP; 19-FEB-2015.
**EV ECO:0000255; PROSITE-ProRule:PRU00046; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00136; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:15489334; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:17187069; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:22607974; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:23019338; BAP; 02-FEB-2015.
**EV ECO:0000303; PubMed:15489334; XXX; 01-JAN-1900.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**IS Q8K3Z0-3
**ZA UHI, 20-MAR-2003, Quick;
**ZB SEF, 06-JAN-2006; MIM, 26-MAR-2007; LIF, 09-JUN-2010; SYP, 21-FEB-2013;
**ZB SYP, 21-AUG-2013; ANS, 25-NOV-2013; SYP, 06-MAR-2014; BAP, 27-FEB-2015;
SQ   SEQUENCE   1020 AA;  113562 MW;  25504905ECF70FBB CRC64;
     MRSSCCDMCS QEEFQAQRSQ LVALLISGSL EGFESILDWL LSWDVLSRED YEGLSLPGQP
     LSHSARRLLD TVWNKGVWGC QKLLEAVQEA QANSHTFELY GSWDTHSLHP TRDLQSHRPA
     IVRRLYNHVE AMLELAREGG FLSQYECEEI RLPIFTSSQR ARRLLDLAAV KANGLAAFLL
     QHVRELPAPL PLPYEAAECQ KFISKLRTMV LTQSRFLSTY DGSENLCLED IYTENILELQ
     TEVGTAGALQ KSPAILGLED LFDTHGHLNR DADTILVVGE AGSGKSTLLQ RLHLLWATGR
     SFQEFLFIFP FSCRQLQCVA KPLSLRTLLF EHCCWPDVAQ DDVFQFLLDH PDRVLLTFDG
     LDEFKFRFTD RERHCSPIDP TSVQTLLFNL LQGNLLKNAC KVLTSRPDAV SALLRKFVRT
     ELQLKGFSEE GIQLYLRKHH REPGVADRLI QLIQATSALH GLCHLPVFSW MVSRCHRELL
     LQNRGFPTTS TDMYLLILQH FLLHASPPDS SPLGLGPGLL QSRLSTLLHL GHLALRGLAM
     SCYVFSAQQL QAAQVDSDDI SLGFLVRAQS SVPGSKAPLE FLHITFQCFF AAFYLAVSAD
     TSVASLKHLF SCGRLGSSLL GRLLPNLCIQ GSRVKKGSEA ALLQKAEPHN LQITAAFLAG
     LLSQQHRDLL AACQVSERVL LQRQARARSC LAHSLREHFH SIPPAVPGET KSMHAMPGFI
     WLIRSLYEMQ EEQLAQEAVR RLDIGHLKLT FCRVGPAECA ALAFVLQHLQ RPVALQLDYN
     SVGDVGVEQL RPCLGVCTAL YLRDNNISDR GARTLVECAL RCEQLQKLAL FNNKLTDACA
     CSMAKLLAHK QNFLSLRVGN NHITAAGAEV LAQGLKSNTS LKFLGFWGNS VGDKGTQALA
     EVVADHQNLK WLSLVGNNIG SMGAEALALM LEKNKSLEEL CLEENHICDE GVYSLAEGLK
     RNSTLKFLKL SNNGITYRGA EALLQALSRN SAILEVWLRG NTFSLEEIQT LSSRDARLLL
//
ID   NOD2_PANTR              Reviewed;        1040 AA.
AC   Q53B87;
DT   05-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   24-MAY-2005, sequence version 1.
DT   04-FEB-2015, entry version 64.
DE   RecName: Full=Nucleotide-binding oligomerization domain-containing protein 2;
DE   AltName: Full=Caspase recruitment domain-containing protein 15;
GN   Name=NOD2; Synonyms=CARD15;
OS   Pan troglodytes (Chimpanzee).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Pan.
OX   NCBI_TaxID=9598;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   King K., Sheikh M., Cuthbert A.P., Fisher S.A., Mirza M.M.,
RA   Sanderson J., Forbes A., Mansfield J., Roberts R.G., Mathew C.G.;
RT   "Mutation, selection and evolution of the Crohn's disease
RT   susceptibility gene, CARD15.";
RL   Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Recognizes muramyl dipeptide (MDP) constituents of
CC       bacterial peptidoglycans and plays a key role in gastrointestinal
CC       immunity: upon stimulation, binds the proximal adapter receptor-
CC       interacting RIPK2, which recruits ubiquitin ligases as XIAP,
CC       BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP
CC       kinases and activation of NF-kappa-B signaling, leading to
CC       activate the transcription of hundreds of genes involved in immune
CC       response. {ECO:0000250}.
CC   -!- SUBUNIT: Found in a signaling complex consisting of ARHGEF2, NOD2
CC       and RIPK2. Interacts (via CARD domain) with RIPK2 (via CARD
CC       domain). Interacts with ATG16L1. Interacts (via NACHT domain) with
CC       CARD9. Interacts with ANKRD17 (via N-terminus). Interacts with
CC       HSPA1A; the interaction enhances NOD2 stability. Interacts (via
CC       both CARD domains) with HSP90; the interaction enhances NOD2
CC       stability. Interacts (via CARD domain) with SOCS3; the interaction
CC       promotes NOD2 degradation. Interacts (via CARD domain) with
CC       ERBBI2P; the interaction inhibits activation of NOD2.
CC       {ECO:0000250|UniProtKB:Q9HC29}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9HC29}.
CC       Membrane {ECO:0000250|UniProtKB:Q9HC29}. Basolateral cell membrane
CC       {ECO:0000250|UniProtKB:Q9HC29}.
CC   -!- DOMAIN: The ATG16L1-binding motif mediates interaction with
CC       ATG16L1. {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated following MDP stimulation, leading to
CC       proteasome-madiated degradation. {ECO:0000250|UniProtKB:Q9HC29}.
CC   -!- SIMILARITY: Contains 2 CARD domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00046}.
CC   -!- SIMILARITY: Contains 9 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 NACHT domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00136}.
DR   EMBL; AY594173; AAS89991.1; -; Genomic_DNA.
DR   EMBL; AY594162; AAS89991.1; JOINED; Genomic_DNA.
DR   EMBL; AY594163; AAS89991.1; JOINED; Genomic_DNA.
DR   EMBL; AY594164; AAS89991.1; JOINED; Genomic_DNA.
DR   EMBL; AY594165; AAS89991.1; JOINED; Genomic_DNA.
DR   EMBL; AY594166; AAS89991.1; JOINED; Genomic_DNA.
DR   EMBL; AY594167; AAS89991.1; JOINED; Genomic_DNA.
DR   EMBL; AY594168; AAS89991.1; JOINED; Genomic_DNA.
DR   EMBL; AY594169; AAS89991.1; JOINED; Genomic_DNA.
DR   EMBL; AY594170; AAS89991.1; JOINED; Genomic_DNA.
DR   EMBL; AY594171; AAS89991.1; JOINED; Genomic_DNA.
DR   EMBL; AY594172; AAS89991.1; JOINED; Genomic_DNA.
DR   RefSeq; NP_001098710.1; NM_001105240.1.
DR   UniGene; Ptr.6327; -.
DR   ProteinModelPortal; Q53B87; -.
DR   STRING; 9598.ENSPTRP00000013836; -.
DR   GeneID; 454083; -.
DR   KEGG; ptr:454083; -.
DR   CTD; 64127; -.
DR   eggNOG; NOG248107; -.
DR   HOGENOM; HOG000113814; -.
DR   HOVERGEN; HBG050792; -.
DR   InParanoid; Q53B87; -.
DR   KO; K10165; -.
DR   NextBio; 20835837; -.
DR   Proteomes; UP000002277; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0043234; C:protein complex; ISS:UniProtKB.
DR   GO; GO:0031982; C:vesicle; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0071225; P:cellular response to muramyl dipeptide; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; ISS:UniProtKB.
DR   GO; GO:0070431; P:nucleotide-binding oligomerization domain containing 2 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:InterPro.
DR   Gene3D; 1.10.533.10; -; 2.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR007111; NACHT_NTPase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00619; CARD; 2.
DR   SMART; SM00114; CARD; 1.
DR   SUPFAM; SSF47986; SSF47986; 2.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS50209; CARD; 2.
DR   PROSITE; PS51450; LRR; 4.
DR   PROSITE; PS50837; NACHT; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cell membrane; Complete proteome; Cytoplasm; Immunity;
KW   Innate immunity; Leucine-rich repeat; Membrane; Nucleotide-binding;
KW   Reference proteome; Repeat; Ubl conjugation.
FT   CHAIN         1   1040       Nucleotide-binding oligomerization
FT                                domain-containing protein 2.
FT                                /FTId=PRO_0000144092.
FT   DOMAIN       26    122       CARD 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   DOMAIN      126    218       CARD 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   DOMAIN      293    618       NACHT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00136}.
FT   REPEAT      791    812       LRR 1.
FT   REPEAT      816    839       LRR 2.
FT   REPEAT      844    865       LRR 3.
FT   REPEAT      872    884       LRR 4.
FT   REPEAT      900    920       LRR 5.
FT   REPEAT      928    949       LRR 6.
FT   REPEAT      956    976       LRR 7.
FT   REPEAT      984   1005       LRR 8.
FT   REPEAT     1012   1032       LRR 9.
FT   NP_BIND     299    306       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00136}.
FT   REGION      241    274       Required for CARD9 binding.
FT                                {ECO:0000250|UniProtKB:Q9HC29}.
FT   MOTIF        63     77       ATG16L1-binding motif.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:Q9HC29; BAP; 19-FEB-2015.
**EV ECO:0000255; PROSITE-ProRule:PRU00046; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00136; XXX; 01-JAN-1900.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**ZB SEF, 06-JAN-2006; MIM, 26-MAR-2007; LIF, 09-JUN-2010; ELS, 13-FEB-2012;
**ZB ELS, 11-APR-2012; SYP, 21-FEB-2013; SYP, 21-AUG-2013; ANS, 25-NOV-2013;
**ZB SYP, 06-MAR-2014; BAP, 27-FEB-2015;
SQ   SEQUENCE   1040 AA;  115298 MW;  BF0496FFF39D0428 CRC64;
     MGEEGGSVSH DEEERASVLL GHSLGCEMCS QEAFQAQRSQ LVELLVSGSL EGFESVLDWL
     LSWEVLSWED YEGFHLLGQP LSHLARRLLD TVWNKGTWAC QKLIAAAQEA QADSQSPKLH
     GCWDPHSLHP ARDLQSHRPA IVRRLHNHVE NMLDLAWERG FVSQYECDEI RLPIFTPSQR
     ARRLLDLATV KANGLAAFLL QHVQELPVPL ALPLEAATCK KYMAKLRTTV SAQSRFLSTY
     DGAETLCLED IYTENVLEVW ADVGMAGPPQ KSPATLGLEE LFSTPGHLND DADTVLVVGE
     AGSGKSTLLQ RLHLLWAAGR DFQEFLFVFP FSCRQLQCMA KPLSVRTLLF EHCCWPDVGQ
     EDIFQLLLDH PDRVLLTFDG FDEFKFRFTD RERHCSPTDP TSVQTLLFNL LQGNLLKNAR
     KVVTSRPAAV SAFLRKYIRT EFNLKGFSEQ GIELYLRKRH REPGVADRLI RLLQATSALH
     GLCHLPVFSW MVSKCHQELL LQEGGSPKTT TDMYLLILQH FLLHATPPDS ASQGLGPSLL
     RGRLPTLLHL GRLALWGLGM CCYVFSAQQL QAAQVSPDDI SLGFLVRAKG VVPGSTAPLE
     FLHITFQCFF AAFYLALSAD VPPALLRHLF NCGRPGNSPM ARLLPTMCIQ GSEGKDSSVA
     ALLQKAEPHN LQITAAFLAG LLSREHWGLL AECQTSEKAL LRRQACARWC LARSLRKHFH
     SIPPAAPGEA KSVHAMPGFI WLIRSLYEMQ EERLARKAAR GLNVGHLKLT FCSVGPAECA
     ALAFVLQHLR RPVALQLDYN SVGDIGVEQL LPCLGVCKAL YLRDNNISDR GICKLIECAL
     HCEQLQKLAL FNNKLTDGCA HSMAKLLACR QNFLALRLGN NYITAAGAQV LAQGLRGNTS
     LQFLGFWGNR VGDEGAQALA EALGDHQSLR WLSLVGNNIG SVGAQALALM LAKNVMLEEL
     CLEENHLQDE GVCSLAEGLK KNSSLKILKL SNNCITYLGA EALLQALERN DTILEVWLRG
     NTFSLEEVDK LGCRDTRLLL
//
ID   SOCS3_BOVIN             Reviewed;         229 AA.
AC   Q9BEG9;
DT   16-APR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   04-MAR-2015, entry version 97.
DE   RecName: Full=Suppressor of cytokine signaling 3;
DE            Short=SOCS-3;
GN   Name=SOCS3;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Hirano A., Norimine J., Brown W.C.;
RT   "Cloning of bovine suppressor of cytokine signaling-3.";
RL   Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: SOCS family proteins form part of a classical negative
CC       feedback system that regulates cytokine signal transduction. SOCS3
CC       is involved in negative regulation of cytokines that signal
CC       through the JAK/STAT pathway. Inhibits cytokine signal
CC       transduction by binding to tyrosine kinase receptors including
CC       gp130, LIF, erythropoietin, insulin and leptin receptors. Inhibits
CC       JAK2 kinase activity. Suppresses fetal liver erythropoiesis.
CC       Regulates onset and maintenance of allergic responses mediated by
CC       T-helper type 2 cells. Regulates IL-6 signaling in vivo. Probable
CC       substrate recognition component of a SCF-like ECS (Elongin BC-
CC       CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which
CC       mediates the ubiquitination and subsequent proteasomal degradation
CC       of target proteins. Seems to recognize IL6ST (By similarity).
CC       {ECO:0000250}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with multiple activated proteins of the
CC       tyrosine kinase signaling pathway including IGF1 receptor, insulin
CC       receptor and JAK2. Binding to JAK2 is mediated through the KIR and
CC       SH2 domains to a phosphorylated tyrosine residue within the JAK2
CC       JH1 domain. Binds specific activated tyrosine residues of the
CC       leptin, EPO, IL12, GSCF and gp130 receptors. Interaction with
CC       CSNK1E stabilizes SOCS3 protein. Component of the probable
CC       ECS(SOSC3) E3 ubiquitin-protein ligase complex which contains
CC       CUL5, RNF7/RBX2, Elongin BC complex and SOCS3. Interacts with
CC       CUL5, RNF7, TCEB1 and TCEB2. Interacts with FGFR3 (By similarity).
CC       Interacts with INSR (By similarity). Interacts with BCL10; this
CC       interaction may interfere with BCL10-binding with PELI2 (By
CC       similarity). Interacts with NOD2 (via CARD domain); the
CC       interaction promotes NOD2 degradation (By similarity).
CC       {ECO:0000250}.
CC   -!- DOMAIN: The ESS and SH2 domains are required for JAK
CC       phosphotyrosine binding. Further interaction with the KIR domain
CC       is necessary for signal and kinase inhibition.
CC   -!- DOMAIN: The SOCS box domain mediates the interaction with the
CC       Elongin BC complex, an adapter module in different E3 ubiquitin
CC       ligase complexes. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on tyrosine residues after stimulation by the
CC       cytokines, IL-2, EPO or IGF1. {ECO:0000250}.
CC   -!- SIMILARITY: Contains 1 SH2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00191}.
CC   -!- SIMILARITY: Contains 1 SOCS box domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00194}.
DR   EMBL; AY026859; AAK07689.1; -; mRNA.
DR   RefSeq; NP_776891.1; NM_174466.2.
DR   RefSeq; XP_005221196.1; XM_005221139.2.
DR   UniGene; Bt.8137; -.
DR   ProteinModelPortal; Q9BEG9; -.
DR   SMR; Q9BEG9; 30-189.
DR   STRING; 9913.ENSBTAP00000011106; -.
DR   PRIDE; Q9BEG9; -.
DR   Ensembl; ENSBTAT00000011106; ENSBTAP00000011106; ENSBTAG00000008441.
DR   GeneID; 282081; -.
DR   KEGG; bta:282081; -.
DR   CTD; 9021; -.
DR   eggNOG; NOG281730; -.
DR   GeneTree; ENSGT00760000119136; -.
DR   HOGENOM; HOG000236320; -.
DR   HOVERGEN; HBG105645; -.
DR   InParanoid; Q9BEG9; -.
DR   KO; K04696; -.
DR   OMA; KRTYYIY; -.
DR   OrthoDB; EOG7TXKHR; -.
DR   TreeFam; TF321368; -.
DR   Reactome; REACT_272797; Regulation of IFNG signaling.
DR   Reactome; REACT_277376; Regulation of IFNA signaling.
DR   Reactome; REACT_289933; Interleukin-6 signaling.
DR   Reactome; REACT_318368; Growth hormone receptor signaling.
DR   Reactome; REACT_334471; Interferon alpha/beta signaling.
DR   Reactome; REACT_347693; Signaling by Leptin.
DR   Reactome; REACT_353696; Interferon gamma signaling.
DR   UniPathway; UPA00143; -.
DR   NextBio; 20805927; -.
DR   Proteomes; UP000009136; Chromosome 19.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; IBA:GO_Central.
DR   GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0007259; P:JAK-STAT cascade; IEA:InterPro.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:InterPro.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0046426; P:negative regulation of JAK-STAT cascade; IBA:GO_Central.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IBA:GO_Central.
DR   GO; GO:0060674; P:placenta blood vessel development; IEA:Ensembl.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IEA:Ensembl.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   GO; GO:0040008; P:regulation of growth; IEA:UniProtKB-KW.
DR   GO; GO:0060708; P:spongiotrophoblast differentiation; IEA:Ensembl.
DR   GO; GO:0060707; P:trophoblast giant cell differentiation; IEA:Ensembl.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR028413; SOCS.
DR   InterPro; IPR028414; SOCS3.
DR   InterPro; IPR001496; SOCS_C.
DR   PANTHER; PTHR10385; PTHR10385; 1.
DR   PANTHER; PTHR10385:SF4; PTHR10385:SF4; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF07525; SOCS_box; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00253; SOCS; 1.
DR   SMART; SM00969; SOCS_box; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50225; SOCS; 1.
PE   2: Evidence at transcript level;
KW   Complete proteome; Growth regulation; Phosphoprotein;
KW   Reference proteome; SH2 domain; Signal transduction inhibitor;
KW   Ubl conjugation pathway.
FT   CHAIN         1    229       Suppressor of cytokine signaling 3.
FT                                /FTId=PRO_0000181241.
FT   DOMAIN       46    142       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      181    228       SOCS box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00194}.
FT   REGION       22     33       Kinase inhibitory region (KIR).
FT   REGION       34     45       Extended SH2 subdomain (ESS).
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00191; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00194; XXX; 01-JAN-1900.
**ZA JAJ, 08-APR-2002;
**ZB JAJ, 21-JUL-2006; BER, 18-OCT-2007; NAG, 13-DEC-2011; ANN, 24-OCT-2012;
**ZB BAP, 27-FEB-2015;
SQ   SEQUENCE   229 AA;  25134 MW;  263969074012D7C8 CRC64;
     MVTHSKFPAA GMSRPLDTSL RLKTFSSKSE YQLVVNAVRK LQESGFYWST VTGGEANLLL
     SAEPAGTFLI RDSSDQRHFF TLSVKTQSGT KNLRIQCEGG SFSLQSDPRS TQPVPRFDCV
     LKLVHHYMPA AGAPSFSQPP AEPSSSPSSE VPEQPPAQPL SGNPPRRAYY IYSGGEKIPL
     VLSRPLSSNV ATLQHLCRKT VNGHLDSYEK VTQLPGPIRE FLDQYDAPL
//
ID   SOCS3_CANFA             Reviewed;         225 AA.
AC   Q68AM8;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2004, sequence version 1.
DT   07-JAN-2015, entry version 64.
DE   RecName: Full=Suppressor of cytokine signaling 3;
DE            Short=SOCS-3;
GN   Name=SOCS3;
OS   Canis familiaris (Dog) (Canis lupus familiaris).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Carnivora; Caniformia; Canidae;
OC   Canis.
OX   NCBI_TaxID=9615;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Tsukui T., Sakaguchi M., Maeda S., Koyanagi M., Masuda K., Ohno K.,
RA   Tsujimoto H., Iwabuchi S.;
RT   "Expression analysis of suppressor of cytokine signaling 3 (SOCS3)
RT   gene in canine atopic dermatitis.";
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: SOCS family proteins form part of a classical negative
CC       feedback system that regulates cytokine signal transduction. SOCS3
CC       is involved in negative regulation of cytokines that signal
CC       through the JAK/STAT pathway. Inhibits cytokine signal
CC       transduction by binding to tyrosine kinase receptors including
CC       gp130, LIF, erythropoietin, insulin and leptin receptors. Inhibits
CC       JAK2 kinase activity. Suppresses fetal liver erythropoiesis.
CC       Regulates onset and maintenance of allergic responses mediated by
CC       T-helper type 2 cells. Regulates IL-6 signaling in vivo. Probable
CC       substrate recognition component of a SCF-like ECS (Elongin BC-
CC       CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which
CC       mediates the ubiquitination and subsequent proteasomal degradation
CC       of target proteins. Seems to recognize IL6ST (By similarity).
CC       {ECO:0000250}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with multiple activated proteins of the
CC       tyrosine kinase signaling pathway including IGF1 receptor, insulin
CC       receptor and JAK2. Binding to JAK2 is mediated through the KIR and
CC       SH2 domains to a phosphorylated tyrosine residue within the JAK2
CC       JH1 domain. Binds specific activated tyrosine residues of the
CC       leptin, EPO, IL12, GSCF and gp130 receptors. Interaction with
CC       CSNK1E stabilizes SOCS3 protein. Component of the probable
CC       ECS(SOCS3) E3 ubiquitin-protein ligase complex which contains
CC       CUL5, RNF7/RBX2, Elongin BC complex and SOCS3. Interacts with
CC       CUL5, RNF7, TCEB1 and TCEB2. Interacts with FGFR3 (By similarity).
CC       Interacts with INSR (By similarity). Interacts with BCL10; this
CC       interaction may interfere with BCL10-binding with PELI2 (By
CC       similarity). Interacts with NOD2 (via CARD domain); the
CC       interaction promotes NOD2 degradation (By similarity).
CC       {ECO:0000250}.
CC   -!- DOMAIN: The ESS and SH2 domains are required for JAK
CC       phosphotyrosine binding. Further interaction with the KIR domain
CC       is necessary for signal and kinase inhibition.
CC   -!- DOMAIN: The SOCS box domain mediates the interaction with the
CC       Elongin BC complex, an adapter module in different E3 ubiquitin
CC       ligase complexes. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on tyrosine residues after stimulation by the
CC       cytokines, IL-2, EPO or IGF1. {ECO:0000250}.
CC   -!- SIMILARITY: Contains 1 SH2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00191}.
CC   -!- SIMILARITY: Contains 1 SOCS box domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00194}.
DR   EMBL; AB164434; BAD42435.1; -; mRNA.
DR   RefSeq; NP_001026801.1; NM_001031631.1.
DR   UniGene; Cfa.3905; -.
DR   ProteinModelPortal; Q68AM8; -.
DR   SMR; Q68AM8; 30-185.
DR   STRING; 9615.ENSCAFP00000007917; -.
DR   GeneID; 442949; -.
DR   KEGG; cfa:442949; -.
DR   CTD; 9021; -.
DR   eggNOG; NOG281730; -.
DR   HOGENOM; HOG000236320; -.
DR   HOVERGEN; HBG105645; -.
DR   InParanoid; Q68AM8; -.
DR   KO; K04696; -.
DR   UniPathway; UPA00143; -.
DR   NextBio; 20831618; -.
DR   Proteomes; UP000002254; Unplaced.
DR   GO; GO:0007259; P:JAK-STAT cascade; IEA:InterPro.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:InterPro.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IEA:UniProtKB-KW.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   GO; GO:0040008; P:regulation of growth; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR028413; SOCS.
DR   InterPro; IPR028414; SOCS3.
DR   InterPro; IPR001496; SOCS_C.
DR   PANTHER; PTHR10385; PTHR10385; 1.
DR   PANTHER; PTHR10385:SF4; PTHR10385:SF4; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF07525; SOCS_box; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00253; SOCS; 1.
DR   SMART; SM00969; SOCS_box; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50225; SOCS; 1.
PE   2: Evidence at transcript level;
KW   Complete proteome; Growth regulation; Phosphoprotein;
KW   Reference proteome; SH2 domain; Signal transduction inhibitor;
KW   Ubl conjugation pathway.
FT   CHAIN         1    225       Suppressor of cytokine signaling 3.
FT                                /FTId=PRO_0000181242.
FT   DOMAIN       46    142       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      177    224       SOCS box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00194}.
FT   REGION       22     33       Kinase inhibitory region (KIR).
FT   REGION       34     45       Extended SH2 subdomain (ESS).
FT   COMPBIAS    129    161       Pro-rich.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00191; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00194; XXX; 01-JAN-1900.
**ZB JAJ, 21-JUL-2006; BER, 18-OCT-2007; NAG, 13-DEC-2011; ANN, 24-OCT-2012;
**ZB BAP, 27-FEB-2015;
SQ   SEQUENCE   225 AA;  24718 MW;  0EF17DFF2366A699 CRC64;
     MVTHSKFPAA GMSRPLDTSL RLKTFSSKSE YQLVVNAVCK LQESGFYWSA VTGGEANLLL
     SAEPAGTFLI RDSSDQRHFF TLSVKTQSGT KNLRIQCEGG SFSLQSDPRS TQPVPRFDCV
     LKLVHHYMPP PGAPSFPAPP TEPSSEVSEQ PPSQPLPGNP PRRAYYIYSG GEKIPLVLSR
     PLSSNVATLQ HLCRKTVNGH LDSYEKVTQL PGAIREFLDQ YDAPL
//
ID   SOCS3_HUMAN             Reviewed;         225 AA.
AC   O14543; O14509;
DT   16-APR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   04-MAR-2015, entry version 134.
DE   RecName: Full=Suppressor of cytokine signaling 3;
DE            Short=SOCS-3;
DE   AltName: Full=Cytokine-inducible SH2 protein 3;
DE            Short=CIS-3;
DE   AltName: Full=STAT-induced STAT inhibitor 3;
DE            Short=SSI-3;
GN   Name=SOCS3; Synonyms=CIS3, SSI3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TYR-125.
RC   TISSUE=T-cell lymphoma;
RX   PubMed=9266833; DOI=10.1006/bbrc.1997.7080;
RA   Minamoto S., Ikegame K., Ueno K., Narazaki M., Naka T., Yamamoto H.,
RA   Matsumoto T., Saito H., Hosoe S., Kishimoto T.;
RT   "Cloning and functional analysis of new members of STAT induced STAT
RT   inhibitor (SSI) family: SSI-2 and SSI-3.";
RL   Biochem. Biophys. Res. Commun. 237:79-83(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9344848; DOI=10.1006/bbrc.1997.7484;
RA   Masuhara M., Sakamoto H., Matsumoto A., Suzuki R., Yasukawa H.,
RA   Mitsui K., Wakioka T., Tanimura S., Sasaki A., Misawa H., Yokouchi M.,
RA   Ohtsubo M., Yoshimura A.;
RT   "Cloning and characterization of novel CIS family genes.";
RL   Biochem. Biophys. Res. Commun. 239:439-446(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skeletal muscle;
RX   PubMed=11071852; DOI=10.1006/bbrc.2000.3762;
RA   Dey B.R., Furlanetto R.W., Nissley P.;
RT   "Suppressor of cytokine signaling (SOCS)-3 protein interacts with the
RT   insulin-like growth factor-I receptor.";
RL   Biochem. Biophys. Res. Commun. 278:38-43(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH JAK2, AND MUTAGENESIS OF LEU-22; PHE-25; GLU-30;
RP   TYR-31; VAL-34; LEU-41; GLY-45 AND ARG-71.
RX   PubMed=10421843; DOI=10.1046/j.1365-2443.1999.00263.x;
RA   Sasaki A., Yasukawa H., Suzuki A., Kamizono S., Syoda T., Kinjyo I.,
RA   Sasaki M., Johnston J.A., Yoshimura A.;
RT   "Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine
RT   kinase by binding through the N-terminal kinase inhibitory region as
RT   well as SH2 domain.";
RL   Genes Cells 4:339-351(1999).
RN   [6]
RP   INTERACTION WITH EPOR, AND MUTAGENESIS OF GLY-53; LEU-58; LEU-93 AND
RP   ARG-94.
RX   PubMed=12027890; DOI=10.1046/j.1432-1033.2002.02916.x;
RA   Hoertner M., Nielsch U., Mayr L.M., Heinrich P.C., Haan S.;
RT   "A new high affinity binding site for suppressor of cytokine
RT   signaling-3 on the erythropoietin receptor.";
RL   Eur. J. Biochem. 269:2516-2526(2002).
RN   [7]
RP   INTERACTION WITH IL12RB2, AND MUTAGENESIS OF ARG-71.
RX   PubMed=14559241; DOI=10.1016/j.bbrc.2003.09.140;
RA   Yamamoto K., Yamaguchi M., Miyasaka N., Miura O.;
RT   "SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its
RT   SH2 domain to the STAT4 docking site in the IL-12 receptor beta2
RT   subunit.";
RL   Biochem. Biophys. Res. Commun. 310:1188-1193(2003).
RN   [8]
RP   INTERACTION WITH CSNK1E, AND PROTEIN STABILIZATION.
RX   PubMed=15070676; DOI=10.1182/blood-2003-08-2768;
RA   Okamura A., Iwata N., Nagata A., Tamekane A., Shimoyama M., Gomyo H.,
RA   Yakushijin K., Urahama N., Hamaguchi M., Fukui C., Chihara K., Ito M.,
RA   Matsui T.;
RT   "Involvement of casein kinase Iepsilon in cytokine-induced
RT   granulocytic differentiation.";
RL   Blood 103:2997-3004(2004).
RN   [9]
RP   FUNCTION IN AN E3 UBIQUITIN-PROTEIN LIGASE COMPLEX, AND INTERACTION
RP   WITH CUL5; RNF7; TCEB1 AND TCEB2.
RX   PubMed=15601820; DOI=10.1101/gad.1252404;
RA   Kamura T., Maenaka K., Kotoshiba S., Matsumoto M., Kohda D.,
RA   Conaway R.C., Conaway J.W., Nakayama K.I.;
RT   "VHL-box and SOCS-box domains determine binding specificity for Cul2-
RT   Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases.";
RL   Genes Dev. 18:3055-3065(2004).
RN   [10]
RP   POSSIBLE INVOLVEMENT IN ATOPIC DERMATITIS.
RX   PubMed=16685656; DOI=10.1086/504272;
RA   Ekelund E., Saeaef A., Tengvall-Linder M., Melen E., Link J.,
RA   Barker J., Reynolds N.J., Meggitt S.J., Kere J., Wahlgren C.-F.,
RA   Pershagen G., Wickman M., Nordenskjoeld M., Kockum I., Bradley M.;
RT   "Elevated expression and genetic association links the SOCS3 gene to
RT   atopic dermatitis.";
RL   Am. J. Hum. Genet. 78:1060-1065(2006).
RN   [11]
RP   INTERACTION WITH FGFR3.
RX   PubMed=16410555; DOI=10.1242/jcs.02740;
RA   Ben-Zvi T., Yayon A., Gertler A., Monsonego-Ornan E.;
RT   "Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with
RT   and modulate fibroblast growth factor receptor signaling.";
RL   J. Cell Sci. 119:380-387(2006).
RN   [12]
RP   INTERACTION WITH NOD2.
RX   PubMed=23019338; DOI=10.1074/jbc.M112.410027;
RA   Lee K.H., Biswas A., Liu Y.J., Kobayashi K.S.;
RT   "Proteasomal degradation of Nod2 protein mediates tolerance to
RT   bacterial cell wall components.";
RL   J. Biol. Chem. 287:39800-39811(2012).
CC   -!- FUNCTION: SOCS family proteins form part of a classical negative
CC       feedback system that regulates cytokine signal transduction. SOCS3
CC       is involved in negative regulation of cytokines that signal
CC       through the JAK/STAT pathway. Inhibits cytokine signal
CC       transduction by binding to tyrosine kinase receptors including
CC       gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin
CC       receptors. Binding to JAK2 inhibits its kinase activity.
CC       Suppresses fetal liver erythropoiesis. Regulates onset and
CC       maintenance of allergic responses mediated by T-helper type 2
CC       cells. Regulates IL-6 signaling in vivo (By similarity). Probable
CC       substrate recognition component of a SCF-like ECS (Elongin BC-
CC       CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which
CC       mediates the ubiquitination and subsequent proteasomal degradation
CC       of target proteins. Seems to recognize IL6ST (By similarity).
CC       {ECO:0000250}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with multiple activated proteins of the
CC       tyrosine kinase signaling pathway including IGF1 receptor, insulin
CC       receptor and JAK2. Binding to JAK2 is mediated through the KIR and
CC       SH2 domains to a phosphorylated tyrosine residue within the JAK2
CC       JH1 domain. Binds specific activated tyrosine residues of the
CC       leptin, EPO, IL12, GSCF and gp130 receptors. Interaction with
CC       CSNK1E stabilizes SOCS3 protein. Component of the probable
CC       ECS(SOCS3) E3 ubiquitin-protein ligase complex which contains
CC       CUL5, RNF7/RBX2, Elongin BC complex and SOCS3. Interacts with
CC       CUL5, RNF7, TCEB1 and TCEB2. Interacts with CUL2. Interacts with
CC       FGFR3. Interacts with INSR (By similarity). Interacts with BCL10;
CC       this interaction may interfere with BCL10-binding with PELI2 (By
CC       similarity). Interacts with NOD2 (via CARD domain); the
CC       interaction promotes NOD2 degradation (PubMed:23019338).
CC       {ECO:0000250, ECO:0000269|PubMed:23019338}.
CC   -!- INTERACTION:
CC       Q13480:GAB1; NbExp=4; IntAct=EBI-714146, EBI-517684;
CC       P10721:KIT; NbExp=3; IntAct=EBI-714146, EBI-1379503;
CC       Q66K74:MAP1S; NbExp=6; IntAct=EBI-714146, EBI-2133734;
CC   -!- TISSUE SPECIFICITY: Widely expressed with high expression in
CC       heart, placenta, skeletal muscle, peripheral blood leukocytes,
CC       fetal and adult lung, and fetal liver and kidney. Lower levels in
CC       thymus.
CC   -!- DOMAIN: The ESS and SH2 domains are required for JAK
CC       phosphotyrosine binding. Further interaction with the KIR domain
CC       is necessary for signal and kinase inhibition.
CC   -!- DOMAIN: The SOCS box domain mediates the interaction with the
CC       Elongin BC complex, an adapter module in different E3 ubiquitin
CC       ligase complexes. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on tyrosine residues after stimulation by the
CC       cytokines, IL-2, EPO or IGF1.
CC   -!- DISEASE: Note=There is some evidence that SOCS3 may be a
CC       susceptibility gene for atopic dermatitis linked to 17q25. SOCS3
CC       messenger RNA is significantly more highly expressed in skin from
CC       patients with atopic dermatitis than in skin from healthy
CC       controls. Furthermore, a genetic association between atopic
CC       dermatitis and a haplotype in the SOCS3 gene has been found in two
CC       independent groups of patients.
CC   -!- SIMILARITY: Contains 1 SH2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00191}.
CC   -!- SIMILARITY: Contains 1 SOCS box domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00194}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SOCS3ID44124ch17q25.html";
DR   EMBL; AB004904; BAA22430.1; -; mRNA.
DR   EMBL; AB006967; BAA22537.1; -; mRNA.
DR   EMBL; AF159854; AAD42231.1; -; mRNA.
DR   EMBL; BC060858; AAH60858.1; -; mRNA.
DR   CCDS; CCDS11756.1; -.
DR   PIR; JC5627; JC5627.
DR   PIR; JC5761; JC5761.
DR   RefSeq; NP_003946.3; NM_003955.4.
DR   UniGene; Hs.527973; -.
DR   UniGene; Hs.703620; -.
DR   ProteinModelPortal; O14543; -.
DR   SMR; O14543; 30-185.
DR   BioGrid; 114488; 71.
DR   IntAct; O14543; 29.
DR   MINT; MINT-149732; -.
DR   STRING; 9606.ENSP00000330341; -.
DR   PhosphoSite; O14543; -.
DR   PaxDb; O14543; -.
DR   PRIDE; O14543; -.
DR   DNASU; 9021; -.
DR   Ensembl; ENST00000330871; ENSP00000330341; ENSG00000184557.
DR   GeneID; 9021; -.
DR   KEGG; hsa:9021; -.
DR   UCSC; uc002jvl.2; human.
DR   CTD; 9021; -.
DR   GeneCards; GC17M076352; -.
DR   HGNC; HGNC:19391; SOCS3.
DR   HPA; CAB012220; -.
DR   MIM; 604176; gene.
DR   neXtProt; NX_O14543; -.
DR   PharmGKB; PA134885765; -.
DR   eggNOG; NOG281730; -.
DR   HOGENOM; HOG000236320; -.
DR   HOVERGEN; HBG105645; -.
DR   InParanoid; O14543; -.
DR   KO; K04696; -.
DR   OMA; KRTYYIY; -.
DR   PhylomeDB; O14543; -.
DR   TreeFam; TF321368; -.
DR   Reactome; REACT_111133; Growth hormone receptor signaling.
DR   Reactome; REACT_169118; Signaling by Leptin.
DR   Reactome; REACT_24980; Regulation of IFNG signaling.
DR   Reactome; REACT_25078; Interferon gamma signaling.
DR   Reactome; REACT_25162; Interferon alpha/beta signaling.
DR   Reactome; REACT_25216; Regulation of IFNA signaling.
DR   Reactome; REACT_27307; Interleukin-6 signaling.
DR   Reactome; REACT_75842; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; O14543; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; SOCS3; human.
DR   GeneWiki; SOCS3; -.
DR   GenomeRNAi; 9021; -.
DR   NextBio; 33797; -.
DR   PRO; PR:O14543; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; O14543; -.
DR   CleanEx; HS_SOCS3; -.
DR   ExpressionAtlas; O14543; baseline and differential.
DR   Genevestigator; O14543; -.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; TAS:ProtInc.
DR   GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0007259; P:JAK-STAT cascade; TAS:ProtInc.
DR   GO; GO:0060397; P:JAK-STAT cascade involved in growth hormone signaling pathway; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0046426; P:negative regulation of JAK-STAT cascade; IBA:GO_Central.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; TAS:GOC.
DR   GO; GO:0060674; P:placenta blood vessel development; IEA:Ensembl.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IEA:Ensembl.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   GO; GO:0040008; P:regulation of growth; IEA:UniProtKB-KW.
DR   GO; GO:0060334; P:regulation of interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060338; P:regulation of type I interferon-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060708; P:spongiotrophoblast differentiation; IEA:Ensembl.
DR   GO; GO:0060707; P:trophoblast giant cell differentiation; IEA:Ensembl.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR028413; SOCS.
DR   InterPro; IPR028414; SOCS3.
DR   InterPro; IPR001496; SOCS_C.
DR   PANTHER; PTHR10385; PTHR10385; 1.
DR   PANTHER; PTHR10385:SF4; PTHR10385:SF4; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF07525; SOCS_box; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00253; SOCS; 1.
DR   SMART; SM00969; SOCS_box; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50225; SOCS; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Growth regulation; Pharmaceutical; Phosphoprotein;
KW   Polymorphism; Reference proteome; SH2 domain;
KW   Signal transduction inhibitor; Ubl conjugation pathway.
FT   CHAIN         1    225       Suppressor of cytokine signaling 3.
FT                                /FTId=PRO_0000181243.
FT   DOMAIN       46    142       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      177    224       SOCS box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00194}.
FT   REGION       22     33       Kinase inhibitory region (KIR).
FT   REGION       34     45       Extended SH2 subdomain (ESS).
FT   VARIANT     125    125       H -> Y (in dbSNP:rs1061489).
FT                                {ECO:0000269|PubMed:9266833}.
FT                                /FTId=VAR_030033.
FT   MUTAGEN      22     22       L->A,F: Little effect on EPO-induced
FT                                STAT5 signaling suppression.
FT                                {ECO:0000269|PubMed:10421843}.
FT   MUTAGEN      22     22       L->D: Complete loss of EPO-induced STAT5
FT                                signaling suppression. No suppression of
FT                                JAK2 phosphorylation.
FT                                {ECO:0000269|PubMed:10421843}.
FT   MUTAGEN      25     25       F->A: Complete loss of EPO-induced STAT5
FT                                signaling suppression. Abolishes binding
FT                                to JH1. {ECO:0000269|PubMed:10421843}.
FT   MUTAGEN      30     30       E->R: Partial loss of EPO-induced STAT5
FT                                signaling suppression. No effect on LIF-
FT                                induced signaling suppression. Abolishes
FT                                binding to JH1. Inhibits JAK2
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:10421843}.
FT   MUTAGEN      31     31       Y->A: Complete loss of EPO-induced STAT5
FT                                signaling suppression. No effect on LIF-
FT                                induced STAT3 signaling. Abolishes
FT                                binding to JH1.
FT                                {ECO:0000269|PubMed:10421843}.
FT   MUTAGEN      31     31       Y->F: Little effect on EPO-induced
FT                                signaling suppression.
FT                                {ECO:0000269|PubMed:10421843}.
FT   MUTAGEN      34     34       V->E: Complete loss of EPO/LIF-induced
FT                                signaling suppression.
FT                                {ECO:0000269|PubMed:10421843}.
FT   MUTAGEN      41     41       L->R: Complete loss of EPO/LIF-induced
FT                                signaling inhibition. Abolishes binding
FT                                to JH1. {ECO:0000269|PubMed:10421843}.
FT   MUTAGEN      45     45       G->A: Little effect on EPO/LIF signaling.
FT                                {ECO:0000269|PubMed:10421843}.
FT   MUTAGEN      53     53       G->V: No effect on binding to Y429/Y431
FT                                phosphorylated EPOR.
FT                                {ECO:0000269|PubMed:12027890}.
FT   MUTAGEN      58     58       L->A: Impaired binding to Y429/Y431
FT                                phosphorylated EPOR.
FT                                {ECO:0000269|PubMed:12027890}.
FT   MUTAGEN      71     71       R->E: Complete loss of EPO/LIF-induced
FT                                signaling suppression. No inhibition of
FT                                JAK2 phosphorylation.
FT                                {ECO:0000269|PubMed:10421843,
FT                                ECO:0000269|PubMed:14559241}.
FT   MUTAGEN      71     71       R->K: No effect on EPO/LIF-induced
FT                                signaling suppression. Partial
FT                                suppression of JAK2 phosphorylation. No
FT                                effect on binding to JH1. Loss of binding
FT                                to IL12RB2. {ECO:0000269|PubMed:10421843,
FT                                ECO:0000269|PubMed:14559241}.
FT   MUTAGEN      93     93       L->A: Impaired binding to Y429/Y431
FT                                phosphorylated EPOR.
FT                                {ECO:0000269|PubMed:12027890}.
FT   MUTAGEN      94     94       R->E: Greatly impaired binding to
FT                                Y429/Y431 phosphorylated EPOR.
FT                                {ECO:0000269|PubMed:12027890}.
FT   CONFLICT     81     81       T -> A (in Ref. 1; BAA22430).
FT                                {ECO:0000305}.
**
**   #################    INTERNAL SECTION    ##################
**CL 17q25.3;
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00191; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00194; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:10421843; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:12027890; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:14559241; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:23019338; BAP; 02-FEB-2015.
**EV ECO:0000269; PubMed:9266833; XXX; 01-JAN-1900.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**ZA JAJ, 08-APR-2002;
**ZB JAJ, 15-OCT-2003; JAJ, 10-MAY-2004; JAJ, 21-JUL-2006; PDR, 06-DEC-2006;
**ZB LIF, 16-SEP-2010; UHI, 23-AUG-2011; NAG, 13-DEC-2011; ANN, 24-OCT-2012;
**ZB BAP, 27-FEB-2015;
SQ   SEQUENCE   225 AA;  24770 MW;  08581DC411EFFF19 CRC64;
     MVTHSKFPAA GMSRPLDTSL RLKTFSSKSE YQLVVNAVRK LQESGFYWSA VTGGEANLLL
     SAEPAGTFLI RDSSDQRHFF TLSVKTQSGT KNLRIQCEGG SFSLQSDPRS TQPVPRFDCV
     LKLVHHYMPP PGAPSFPSPP TEPSSEVPEQ PSAQPLPGSP PRRAYYIYSG GEKIPLVLSR
     PLSSNVATLQ HLCRKTVNGH LDSYEKVTQL PGPIREFLDQ YDAPL
//
ID   SOCS3_MOUSE             Reviewed;         225 AA.
AC   O35718; P97803; Q3U7X5;
DT   16-APR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   04-FEB-2015, entry version 137.
DE   RecName: Full=Suppressor of cytokine signaling 3;
DE            Short=SOCS-3;
DE   AltName: Full=Cytokine-inducible SH2 protein 3;
DE            Short=CIS-3;
DE   AltName: Full=Protein EF-10;
GN   Name=Socs3; Synonyms=Cis3, Cish3;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung, and Thymus;
RX   PubMed=9202125; DOI=10.1038/43206;
RA   Starr R., Willson T.A., Viney E.M., Murray L.J.L., Rayner J.R.,
RA   Jenkins B.J., Gonda T.J., Alexander W.S., Metcalf D., Nicola N.A.,
RA   Hilton D.J.;
RT   "A family of cytokine-inducible inhibitors of signaling.";
RL   Nature 387:917-921(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Le Provost F., Henninghausen L.;
RT   "Murine SOCS3 gene structure.";
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and NOD; TISSUE=Bone marrow, Cerebellum, and Spleen;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-30.
RC   STRAIN=ICR X Swiss Webster;
RX   PubMed=10359822; DOI=10.1073/pnas.96.12.6964;
RA   Auernhammer C.J., Bousquet C., Melmed S.;
RT   "Autoregulation of pituitary corticotroph SOCS-3 expression:
RT   characterization of the murine SOCS-3 promoter.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:6964-6969(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 221-225.
RC   STRAIN=BALB/c;
RX   PubMed=9032278;
RA   Fu X., Kamps M.P.;
RT   "E2a-Pbx1 induces aberrant expression of tissue-specific and
RT   developmentally regulated genes when expressed in NIH 3T3
RT   fibroblasts.";
RL   Mol. Cell. Biol. 17:1503-1512(1997).
RN   [7]
RP   FUNCTION IN LIF AND IL6 SIGNALING.
RX   PubMed=9889194; DOI=10.1093/emboj/18.2.375;
RA   Nicholson S.E., Willson T.A., Farley A., Starr R., Zhang J.-G.,
RA   Baca M., Alexander W.S., Metcalf D., Hilton D.J., Nicola N.A.;
RT   "Mutational analyses of the SOCS proteins suggest a dual domain
RT   requirement but distinct mechanisms for inhibition of LIF and IL-6
RT   signal transduction.";
RL   EMBO J. 18:375-385(1999).
RN   [8]
RP   FUNCTION IN INHIBITION OF INSR KINASE ACTIVITY, AND INTERACTION WITH
RP   INSR.
RX   PubMed=10821852; DOI=10.1074/jbc.275.21.15985;
RA   Emanuelli B., Peraldi P., Filloux C., Sawka-Verhelle D., Hilton D.,
RA   Van Obberghen E.;
RT   "SOCS-3 is an insulin-induced negative regulator of insulin
RT   signaling.";
RL   J. Biol. Chem. 275:15985-15991(2000).
RN   [9]
RP   INTERACTION WITH EPOR AND JAK2, AND MUTAGENESIS OF LEU-22; PHE-25;
RP   GLY-45 AND ARG-71.
RX   PubMed=10882725; DOI=10.1074/jbc.M003456200;
RA   Sasaki A., Yasukawa H., Shouda T., Kitamura T., Dikic I.,
RA   Yoshimura A.;
RT   "CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the
RT   EPO receptor and JAK2.";
RL   J. Biol. Chem. 275:29338-29347(2000).
RN   [10]
RP   TISSUE SPECIFICITY.
RX   PubMed=12242343; DOI=10.1073/pnas.202477099;
RA   Seki Y., Hayashi K., Matsumoto A., Seki N., Tsukada J., Ransom J.,
RA   Naka T., Kishimoto T., Yoshimura A., Kubo M.;
RT   "Expression of the suppressor of cytokine signaling-5 (SOCS5)
RT   negatively regulates IL-4-dependent STAT6 activation and Th2
RT   differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:13003-13008(2002).
RN   [11]
RP   FUNCTION IN ERYTHROPOIESIS.
RX   PubMed=10490101; DOI=10.1016/S0092-8674(00)80049-5;
RA   Marine J.-C., McKay C., Wang D., Topham D.J., Parganas E.,
RA   Nakajima H., Pendeville H., Yasukawa H., Sasaki A., Yoshimura A.,
RA   Ihle J.N.;
RT   "SOCS3 is essential in the regulation of fetal liver erythropoiesis.";
RL   Cell 98:617-627(1999).
RN   [12]
RP   ROLE IN IL-6 SIGNALING.
RX   PubMed=12754505; DOI=10.1038/ni931;
RA   Croker B.A., Krebs D.L., Zhang J.-G., Wormald S., Willson T.A.,
RA   Stanley E.G., Robb L., Greenhalgh C.J., Foerster I., Clausen B.E.,
RA   Nicola N.A., Metcalf D., Hilton D.J., Roberts A.W., Alexander W.S.;
RT   "SOCS3 negatively regulates IL-6 signaling in vivo.";
RL   Nat. Immunol. 4:540-545(2003).
RN   [13]
RP   ROLE IN ALLERGIC RESPONSE, AND INDUCTION BY IL-4.
RX   PubMed=12847520; DOI=10.1038/nm896;
RA   Seki Y., Inoue H., Nagata N., Hayashi K., Fukuyama S., Matsumoto K.,
RA   Komine O., Hamano S., Himeno K., Inagaki-Ohara K., Cacalano N.,
RA   O'Garra A., Oshida T., Saito H., Johnston J.A., Yoshimura A., Kubo M.;
RT   "SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic
RT   responses.";
RL   Nat. Med. 9:1047-1054(2003).
RN   [14]
RP   INTERACTION WITH BCL10.
RX   PubMed=15213237; DOI=10.1074/jbc.M400241200;
RA   Liu Y., Dong W., Chen L., Xiang R., Xiao H., De G., Wang Z., Qi Y.;
RT   "BCL10 mediates lipopolysaccharide/toll-like receptor-4 signaling
RT   through interaction with Pellino2.";
RL   J. Biol. Chem. 279:37436-37444(2004).
RN   [15]
RP   INTERACTION WITH NOD2.
RX   PubMed=23019338; DOI=10.1074/jbc.M112.410027;
RA   Lee K.H., Biswas A., Liu Y.J., Kobayashi K.S.;
RT   "Proteasomal degradation of Nod2 protein mediates tolerance to
RT   bacterial cell wall components.";
RL   J. Biol. Chem. 287:39800-39811(2012).
RN   [16]
RP   STRUCTURE BY NMR OF 22-185.
RX   PubMed=16630890; DOI=10.1016/j.molcel.2006.03.024;
RA   Babon J.J., McManus E.J., Yao S., DeSouza D.P., Mielke L.A.,
RA   Sprigg N.S., Willson T.A., Hilton D.J., Nicola N.A., Baca M.,
RA   Nicholson S.E., Norton R.S.;
RT   "The structure of SOCS3 reveals the basis of the extended SH2 domain
RT   function and identifies an unstructured insertion that regulates
RT   stability.";
RL   Mol. Cell 22:205-216(2006).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 15-185 IN COMPLEX WITH
RP   PHOSPHORYLATED IL6ST.
RX   PubMed=16905102; DOI=10.1016/j.str.2006.06.011;
RA   Bergamin E., Wu J., Hubbard S.R.;
RT   "Structural basis for phosphotyrosine recognition by suppressor of
RT   cytokine signaling-3.";
RL   Structure 14:1285-1292(2006).
CC   -!- FUNCTION: SOCS family proteins form part of a classical negative
CC       feedback system that regulates cytokine signal transduction. SOCS3
CC       is involved in negative regulation of cytokines that signal
CC       through the JAK/STAT pathway. Inhibits cytokine signal
CC       transduction by binding to tyrosine kinase receptors including
CC       gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin
CC       receptors. Binding to JAK2 inhibits its kinase activity.
CC       Suppresses fetal liver erythropoiesis. Regulates onset and
CC       maintenance of allergic responses mediated by T-helper type 2
CC       cells. Regulates IL-6 signaling in vivo. Probable substrate-
CC       recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-
CC       box protein) E3 ubiquitin-protein ligase complex which mediates
CC       the ubiquitination and subsequent proteasomal degradation of
CC       target proteins (By similarity). Seems to recognize IL6ST.
CC       {ECO:0000250, ECO:0000269|PubMed:10490101,
CC       ECO:0000269|PubMed:10821852, ECO:0000269|PubMed:12754505,
CC       ECO:0000269|PubMed:12847520, ECO:0000269|PubMed:9889194}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with multiple activated proteins of the
CC       tyrosine kinase signaling pathway including IGF1 receptor, insulin
CC       receptor and JAK2. Binding to JAK2 is mediated through the KIR and
CC       SH2 domains to a phosphorylated tyrosine residue within the JAK2
CC       JH1 domain. Binds specific activated tyrosine residues of the
CC       leptin, EPO, IL12, GSCF and gp130 receptors. Interaction with
CC       CSNK1E stabilizes SOCS3 protein. Component of the probable
CC       ECS(SOCS3) E3 ubiquitin-protein ligase complex which contains
CC       CUL5, RNF7/RBX2, elongin BC complex and SOCS3. Interacts with
CC       CUL5, RNF7, TCEB1 and TCEB2. Interacts with FGFR3 (By similarity).
CC       Interacts with INSR. Interacts with BCL10; this interaction may
CC       interfere with BCL10-binding with PELI2. Interacts with NOD2 (via
CC       CARD domain); the interaction promotes NOD2 degradation
CC       (PubMed:23019338). {ECO:0000250, ECO:0000269|PubMed:10821852,
CC       ECO:0000269|PubMed:10882725, ECO:0000269|PubMed:15213237,
CC       ECO:0000269|PubMed:16905102, ECO:0000269|PubMed:23019338}.
CC   -!- INTERACTION:
CC       Q00560:Il6st; NbExp=3; IntAct=EBI-2659360, EBI-3862992;
CC   -!- TISSUE SPECIFICITY: Low expression in lung, spleen and thymus.
CC       Expressed in Th2 but not TH1 cells. {ECO:0000269|PubMed:12242343}.
CC   -!- DEVELOPMENTAL STAGE: In the developing brain, expressed at low
CC       levels from E10 stages to young adulthood (P25) with peak levels
CC       from E14 to P8. In the cortex, first expressed uniformly in all
CC       cells at E14. Not expressed in the retina. Highly expressed in
CC       fetal liver progenitors at E12.5.
CC   -!- INDUCTION: By a subset of cytokines including EPO, leptin, LIF,
CC       IL-2, IL-3, IL-4, IGF1, growth hormone and prolactin.
CC       {ECO:0000269|PubMed:12847520}.
CC   -!- DOMAIN: The ESS and SH2 domains are required for JAK
CC       phosphotyrosine binding. Further interaction with the KIR domain
CC       is necessary for signal and kinase inhibition.
CC   -!- DOMAIN: The SOCS box domain mediates the interaction with the
CC       Elongin BC complex, an adapter module in different E3 ubiquitin
CC       ligase complexes. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on tyrosine residues after stimulation by the
CC       cytokines, IL-2, EPO or IGF1. {ECO:0000250}.
CC   -!- SIMILARITY: Contains 1 SH2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00191}.
CC   -!- SIMILARITY: Contains 1 SOCS box domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00194}.
DR   EMBL; U88328; AAB62403.1; -; mRNA.
DR   EMBL; AF314501; AAK60601.1; -; Genomic_DNA.
DR   EMBL; AK047165; BAC32977.1; -; mRNA.
DR   EMBL; AK139241; BAE23929.1; -; mRNA.
DR   EMBL; AK152468; BAE31244.1; -; mRNA.
DR   EMBL; AK152514; BAE31277.1; -; mRNA.
DR   EMBL; AK157708; BAE34161.1; -; mRNA.
DR   EMBL; AK159395; BAE35049.1; -; mRNA.
DR   EMBL; AK170406; BAE41773.1; -; mRNA.
DR   EMBL; AK172399; BAE42985.1; -; mRNA.
DR   EMBL; BC052031; AAH52031.1; -; mRNA.
DR   EMBL; AF117732; AAD18024.1; -; Genomic_DNA.
DR   EMBL; U72673; AAB51035.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS25697.1; -.
DR   RefSeq; NP_031733.1; NM_007707.3.
DR   UniGene; Mm.3468; -.
DR   PDB; 2BBU; NMR; -; A=22-185.
DR   PDB; 2HMH; X-ray; 2.00 A; A=15-185.
DR   PDB; 2JZ3; NMR; -; A=186-225.
DR   PDB; 4GL9; X-ray; 3.90 A; E/F/G/H=38-128, E/F/G/H=182-185.
DR   PDBsum; 2BBU; -.
DR   PDBsum; 2HMH; -.
DR   PDBsum; 2JZ3; -.
DR   PDBsum; 4GL9; -.
DR   DisProt; DP00446; -.
DR   ProteinModelPortal; O35718; -.
DR   SMR; O35718; 30-185.
DR   BioGrid; 198718; 13.
DR   DIP; DIP-29137N; -.
DR   IntAct; O35718; 9.
DR   MINT; MINT-2569503; -.
DR   STRING; 10090.ENSMUSP00000059129; -.
DR   PhosphoSite; O35718; -.
DR   PRIDE; O35718; -.
DR   DNASU; 12702; -.
DR   Ensembl; ENSMUST00000054002; ENSMUSP00000059129; ENSMUSG00000053113.
DR   GeneID; 12702; -.
DR   KEGG; mmu:12702; -.
DR   UCSC; uc007moi.2; mouse.
DR   CTD; 9021; -.
DR   MGI; MGI:1201791; Socs3.
DR   eggNOG; NOG281730; -.
DR   GeneTree; ENSGT00760000119136; -.
DR   HOGENOM; HOG000236320; -.
DR   HOVERGEN; HBG105645; -.
DR   InParanoid; O35718; -.
DR   KO; K04696; -.
DR   OMA; KRTYYIY; -.
DR   OrthoDB; EOG7TXKHR; -.
DR   PhylomeDB; O35718; -.
DR   TreeFam; TF321368; -.
DR   Reactome; REACT_169390; Signaling by Leptin.
DR   Reactome; REACT_289967; Regulation of IFNG signaling.
DR   Reactome; REACT_301070; Interleukin-6 signaling.
DR   Reactome; REACT_317434; Growth hormone receptor signaling.
DR   Reactome; REACT_323806; Signaling by Leptin.
DR   Reactome; REACT_336467; Interferon alpha/beta signaling.
DR   Reactome; REACT_343568; Antigen processing: Ubiquitination & Proteasome degradation.
DR   Reactome; REACT_349056; Interferon gamma signaling.
DR   UniPathway; UPA00143; -.
DR   EvolutionaryTrace; O35718; -.
DR   NextBio; 281958; -.
DR   PRO; PR:O35718; -.
DR   Proteomes; UP000000589; Chromosome 11.
DR   Bgee; O35718; -.
DR   CleanEx; MM_SOCS3; -.
DR   Genevestigator; O35718; -.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; IBA:GO_Central.
DR   GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; IMP:MGI.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0007259; P:JAK-STAT cascade; IEA:InterPro.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:InterPro.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IGI:MGI.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IDA:MGI.
DR   GO; GO:0046426; P:negative regulation of JAK-STAT cascade; IBA:GO_Central.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IBA:GO_Central.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IGI:MGI.
DR   GO; GO:0060674; P:placenta blood vessel development; IMP:MGI.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IDA:MGI.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   GO; GO:0045595; P:regulation of cell differentiation; IMP:MGI.
DR   GO; GO:0040008; P:regulation of growth; IEA:UniProtKB-KW.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IDA:MGI.
DR   GO; GO:0060708; P:spongiotrophoblast differentiation; IMP:MGI.
DR   GO; GO:0060707; P:trophoblast giant cell differentiation; IMP:MGI.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR028413; SOCS.
DR   InterPro; IPR028414; SOCS3.
DR   InterPro; IPR001496; SOCS_C.
DR   PANTHER; PTHR10385; PTHR10385; 1.
DR   PANTHER; PTHR10385:SF4; PTHR10385:SF4; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF07525; SOCS_box; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00253; SOCS; 1.
DR   SMART; SM00969; SOCS_box; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50225; SOCS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Growth regulation; Phosphoprotein;
KW   Reference proteome; SH2 domain; Signal transduction inhibitor;
KW   Ubl conjugation pathway.
FT   CHAIN         1    225       Suppressor of cytokine signaling 3.
FT                                /FTId=PRO_0000181244.
FT   DOMAIN       46    142       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      177    224       SOCS box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00194}.
FT   REGION       22     33       Kinase inhibitory region (KIR).
FT   REGION       34     45       Extended SH2 subdomain (ESS).
FT   MUTAGEN      22     22       L->A: No effect on LIF-induced signal
FT                                transduction suppression.
FT                                {ECO:0000269|PubMed:10882725}.
FT   MUTAGEN      22     22       L->D: Abolishes binding to JAK2. No
FT                                effect on binding to EPOR.
FT                                {ECO:0000269|PubMed:10882725}.
FT   MUTAGEN      25     25       F->A: Loss of LIF/EPO-induced signal
FT                                transduction suppression. Abolishes
FT                                binding to JAK2 and to EPOR.
FT                                {ECO:0000269|PubMed:10882725}.
FT   MUTAGEN      30     30       E->R: No effect on LIF-induced signal
FT                                transduction suppression.
FT   MUTAGEN      45     45       G->A: Abolishes binding to EPOR. No
FT                                effect on binding to JAK2.
FT                                {ECO:0000269|PubMed:10882725}.
FT   MUTAGEN      71     71       R->K: Little effect on LIF-induced signal
FT                                transduction suppression. Loss of EPO-
FT                                induced signal transduction suppression.
FT                                Abolishes binding to JAK2 and EPOR.
FT                                {ECO:0000269|PubMed:10882725}.
FT   HELIX        32     43       {ECO:0000244|PDB:2HMH}.
FT   STRAND       45     48       {ECO:0000244|PDB:2HMH}.
FT   HELIX        53     61       {ECO:0000244|PDB:2HMH}.
FT   STRAND       67     72       {ECO:0000244|PDB:2HMH}.
FT   STRAND       79     86       {ECO:0000244|PDB:2HMH}.
FT   STRAND       89     96       {ECO:0000244|PDB:2HMH}.
FT   HELIX        98    100       {ECO:0000244|PDB:2HMH}.
FT   STRAND      102    104       {ECO:0000244|PDB:2HMH}.
FT   STRAND      117    119       {ECO:0000244|PDB:2HMH}.
FT   HELIX       120    126       {ECO:0000244|PDB:2HMH}.
FT   STRAND      137    139       {ECO:0000244|PDB:2BBU}.
FT   STRAND      165    167       {ECO:0000244|PDB:2HMH}.
FT   STRAND      174    176       {ECO:0000244|PDB:2HMH}.
FT   HELIX       189    199       {ECO:0000244|PDB:2JZ3}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000244; PDB:2BBU; INT; 08-OCT-2014.
**EV ECO:0000244; PDB:2HMH; INT; 08-OCT-2014.
**EV ECO:0000244; PDB:2JZ3; INT; 08-OCT-2014.
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00191; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00194; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:10490101; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:10821852; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:10882725; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:12242343; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:12754505; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:12847520; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:15213237; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:16905102; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:23019338; BAP; 02-FEB-2015.
**EV ECO:0000269; PubMed:9889194; XXX; 01-JAN-1900.
**ZA JAJ, 08-APR-2002;
**ZB MIM, 19-NOV-2003; JAJ, 10-MAY-2004; JAJ, 21-JUL-2006; NAG, 13-DEC-2011;
**ZB ANN, 24-OCT-2012; BAP, 27-FEB-2015;
SQ   SEQUENCE   225 AA;  24776 MW;  CD3859561D4CCDED CRC64;
     MVTHSKFPAA GMSRPLDTSL RLKTFSSKSE YQLVVNAVRK LQESGFYWSA VTGGEANLLL
     SAEPAGTFLI RDSSDQRHFF TLSVKTQSGT KNLRIQCEGG SFSLQSDPRS TQPVPRFDCV
     LKLVHHYMPP PGTPSFSLPP TEPSSEVPEQ PPAQALPGST PKRAYYIYSG GEKIPLVLSR
     PLSSNVATLQ HLCRKTVNGH LDSYEKVTQL PGPIREFLDQ YDAPL
//
ID   SOCS3_RAT               Reviewed;         225 AA.
AC   O88583; Q9QYV5;
DT   16-APR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   04-FEB-2015, entry version 104.
DE   RecName: Full=Suppressor of cytokine signaling 3;
DE            Short=SOCS-3;
DE   AltName: Full=Cytokine-inducible SH2 protein 3;
GN   Name=Socs3; Synonyms=Cish3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=10579313; DOI=10.1210/en.140.12.5505;
RA   Mao Y., Ling P.R., Fitzgibbons T.P., McCowen K.C., Frick G.P.,
RA   Bistrian B.R., Smith R.J.;
RT   "Endotoxin-induced inhibition of growth hormone receptor signaling in
RT   rat liver in vivo.";
RL   Endocrinology 140:5505-5515(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Sprague-Dawley;
RA   le Cam A.;
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   INTERACTION WITH LEPTIN.
RX   PubMed=11108838; DOI=10.1016/S0014-5793(00)02205-5;
RA   Eyckerman S., Broekaert D., Verhee A., Vandekerckhove J.,
RA   Tavernier J.;
RT   "Identification of the Y985 and Y1077 motifs as SOCS3 recruitment
RT   sites in the murine leptin receptor.";
RL   FEBS Lett. 486:33-37(2000).
CC   -!- FUNCTION: SOCS family proteins form part of a classical negative
CC       feedback system that regulates cytokine signal transduction. SOCS3
CC       is involved in negative regulation of cytokines that signal
CC       through the JAK/STAT pathway. Inhibits cytokine signal
CC       transduction by binding to tyrosine kinase receptors including
CC       gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin
CC       receptors. Binding to JAK2 inhibits its kinase activity.
CC       Suppresses fetal liver erythropoiesis. Regulates onset and
CC       maintenance of allergic responses mediated by T-helper type 2
CC       cells. Regulates IL-6 signaling in vivo. Probable substrate-
CC       recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-
CC       box protein) E3 ubiquitin-protein ligase complex which mediates
CC       the ubiquitination and subsequent proteasomal degradation of
CC       target proteins. Seems to recognize IL6ST (By similarity).
CC       {ECO:0000250}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with multiple activated proteins of the
CC       tyrosine kinase signaling pathway including IGF1 receptor, insulin
CC       receptor and JAK2. Binding to JAK2 is mediated through the KIR and
CC       SH2 domains to a phosphorylated tyrosine residue within the JAK2
CC       JH1 domain. Binds specific activated tyrosine residues of the
CC       leptin, EPO, IL12, GSCF and gp130 receptors. Interaction with
CC       CSNK1E stabilize SOCS3 protein. Component of the probable
CC       ECS(SOCS3) E3 ubiquitin-protein ligase complex which contains
CC       CUL5, RNF7/RBX2, Elongin BC complex and SOCS3. Interacts with
CC       CUL5, RNF7, TCEB1 and TCEB2. Interacts with FGFR3 (By similarity).
CC       Interacts with INSR (By similarity). Interacts with BCL10; this
CC       interaction may interfere with BCL10-binding with PELI2 (By
CC       similarity). Interacts with NOD2 (via CARD domain); the
CC       interaction promotes NOD2 degradation (By similarity).
CC       {ECO:0000250}.
CC   -!- DOMAIN: The ESS and SH2 domains are required for JAK
CC       phosphotyrosine binding. Further interaction with the KIR domain
CC       is necessary for signal and kinase inhibition.
CC   -!- DOMAIN: The SOCS box domain mediates the interaction with the
CC       Elongin BC complex, an adapter module in different E3 ubiquitin
CC       ligase complexes. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on tyrosine residues after stimulation by the
CC       cytokines, IL-2, EPO or IGF1. {ECO:0000250}.
CC   -!- SIMILARITY: Contains 1 SH2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00191}.
CC   -!- SIMILARITY: Contains 1 SOCS box domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00194}.
DR   EMBL; AF075383; AAC26223.1; -; mRNA.
DR   EMBL; AJ249240; CAB56083.1; -; Genomic_DNA.
DR   RefSeq; NP_446017.1; NM_053565.1.
DR   UniGene; Rn.127801; -.
DR   ProteinModelPortal; O88583; -.
DR   SMR; O88583; 30-185.
DR   BioGrid; 250151; 1.
DR   STRING; 10116.ENSRNOP00000003940; -.
DR   PaxDb; O88583; -.
DR   GeneID; 89829; -.
DR   KEGG; rno:89829; -.
DR   UCSC; RGD:621087; rat.
DR   CTD; 9021; -.
DR   RGD; 621087; Socs3.
DR   eggNOG; NOG281730; -.
DR   HOGENOM; HOG000236320; -.
DR   HOVERGEN; HBG105645; -.
DR   InParanoid; O88583; -.
DR   KO; K04696; -.
DR   PhylomeDB; O88583; -.
DR   UniPathway; UPA00143; -.
DR   NextBio; 617752; -.
DR   PRO; PR:O88583; -.
DR   Proteomes; UP000002494; Unplaced.
DR   Genevestigator; O88583; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; IBA:GO_Central.
DR   GO; GO:0007568; P:aging; IEP:RGD.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:RGD.
DR   GO; GO:0007259; P:JAK-STAT cascade; IDA:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:InterPro.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0046426; P:negative regulation of JAK-STAT cascade; IBA:GO_Central.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IBA:GO_Central.
DR   GO; GO:0031100; P:organ regeneration; IEP:RGD.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   GO; GO:0001558; P:regulation of cell growth; TAS:RGD.
DR   GO; GO:0009617; P:response to bacterium; IEP:RGD.
DR   GO; GO:0034097; P:response to cytokine; IEP:RGD.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0032094; P:response to food; IEP:RGD.
DR   GO; GO:0010332; P:response to gamma radiation; IEP:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IEP:RGD.
DR   GO; GO:0009408; P:response to heat; IEP:RGD.
DR   GO; GO:0009725; P:response to hormone; IEP:RGD.
DR   GO; GO:0001666; P:response to hypoxia; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0043434; P:response to peptide hormone; IEP:RGD.
DR   GO; GO:0032570; P:response to progesterone; IEP:RGD.
DR   GO; GO:0007165; P:signal transduction; IDA:RGD.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR028413; SOCS.
DR   InterPro; IPR028414; SOCS3.
DR   InterPro; IPR001496; SOCS_C.
DR   PANTHER; PTHR10385; PTHR10385; 1.
DR   PANTHER; PTHR10385:SF4; PTHR10385:SF4; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF07525; SOCS_box; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00253; SOCS; 1.
DR   SMART; SM00969; SOCS_box; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50225; SOCS; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Growth regulation; Phosphoprotein;
KW   Reference proteome; SH2 domain; Signal transduction inhibitor;
KW   Ubl conjugation pathway.
FT   CHAIN         1    225       Suppressor of cytokine signaling 3.
FT                                /FTId=PRO_0000181245.
FT   DOMAIN       46    142       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      177    224       SOCS box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00194}.
FT   REGION       22     33       Kinase inhibitory region (KIR).
FT   REGION       34     45       Extended SH2 subdomain (ESS).
FT   CONFLICT     75     75       D -> G (in Ref. 2; CAB56083).
FT                                {ECO:0000305}.
FT   CONFLICT     85     85       E -> K (in Ref. 2; CAB56083).
FT                                {ECO:0000305}.
FT   CONFLICT    145    145       F -> S (in Ref. 2; CAB56083).
FT                                {ECO:0000305}.
FT   CONFLICT    164    164       A -> G (in Ref. 2; CAB56083).
FT                                {ECO:0000305}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00191; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00194; XXX; 01-JAN-1900.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**ZA JAJ, 08-APR-2002;
**ZB JAJ, 10-MAY-2004; JAJ, 21-JUL-2006; NAG, 13-DEC-2011; ANN, 24-OCT-2012;
**ZB BAP, 27-FEB-2015;
SQ   SEQUENCE   225 AA;  24808 MW;  BC95FF2074125D8F CRC64;
     MVTHSKFPAA GMSRPLDTSL RLKTFSSKSE YQLVVNAVRK LQESGFYWSA VTGGEANLLL
     SAEPAGTFLI RDSSDQRHFF TLSVETQSGT KNLRIQCEGG SFSLQSDPRS TQPVPRFDCV
     LKLVHHYMPP PGAPSFSLPP TEPSFEVQEQ PPAQALPGGT PKRAYYIYSG GEKIPLVLSR
     PLSSNVATLQ HLCRKTVNGH LDSYEKVTQL PGPIREFLDQ YDAPL
//
ID   HS71A_BOVIN             Reviewed;         641 AA.
AC   Q27975; Q27964; Q6DLW1; Q7YQF7;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   21-DEC-2004, sequence version 2.
DT   04-MAR-2015, entry version 93.
DE   RecName: Full=Heat shock 70 kDa protein 1A;
DE   AltName: Full=Heat shock 70 kDa protein 1;
DE            Short=HSP70.1;
GN   Name=HSPA1A; Synonyms=HSP70-1;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skeletal muscle;
RX   PubMed=7826329;
RA   Gutierrez J.A., Guerriero V.;
RT   "Chemical modifications of a recombinant bovine stress-inducible 70
RT   kDa heat-shock protein (Hsp70) mimics Hsp70 isoforms from tissues.";
RL   Biochem. J. 305:197-203(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Holstein-Friesian;
RX   PubMed=12755819; DOI=10.1046/j.1365-2052.2003.00990.x;
RA   Sugimoto M., Furuoka H., Sugimoto Y.;
RT   "Deletion of one of the duplicated Hsp70 genes causes hereditary
RT   myopathy of diaphragmatic muscles in Holstein-Friesian cattle.";
RL   Anim. Genet. 34:191-197(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Heart muscle;
RX   PubMed=15491140; DOI=10.1021/bi049036k;
RA   Lakshmikuttyamma A., Selvakumar P., Anderson D.H., Datla R.S.,
RA   Sharma R.K.;
RT   "Molecular cloning of bovine cardiac muscle heat-shock protein 70 kDa
RT   and its phosphorylation by cAMP-dependent protein kinase in vitro.";
RL   Biochemistry 43:13340-13347(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 212-641.
RC   STRAIN=Angus;
RX   PubMed=7943958;
RA   Grosz M.D., Skow L.C., Stone R.T.;
RT   "An AluI polymorphism at the bovine 70 kD heat-shock protein-1 (HSP70-
RT   1) locus.";
RL   Anim. Genet. 25:196-196(1994).
CC   -!- FUNCTION: In cooperation with other chaperones, Hsp70s stabilize
CC       preexistent proteins against aggregation and mediate the folding
CC       of newly translated polypeptides in the cytosol as well as within
CC       organelles. These chaperones participate in all these processes
CC       through their ability to recognize nonnative conformations of
CC       other proteins. They bind extended peptide segments with a net
CC       hydrophobic character exposed by polypeptides during translation
CC       and membrane translocation, or following stress-induced damage.
CC       Essential for STUB1-mediated ubiquitination and degradation of
CC       FOXP3 in regulatory T-cells (Treg) during inflammation.
CC       {ECO:0000250|UniProtKB:P08107}.
CC   -!- SUBUNIT: Interacts with IRAK1BP1, DNAAF2 and TSC2. Interacts with
CC       TERT; the interaction occurs in the absence of the RNA component,
CC       TERC, and dissociates once the TERT complex has formed. Interacts
CC       with TRIM5 (via B30.2/SPRY domain). Interacts with FOXP3.
CC       Interacts with NOD2; the interaction enhances NOD2 stability (By
CC       similarity). {ECO:0000250|UniProtKB:P08107}.
CC   -!- INTERACTION:
CC       P02639:S100A1; NbExp=2; IntAct=EBI-6477341, EBI-6477285;
CC   -!- INDUCTION: By heat shock.
CC   -!- SIMILARITY: Belongs to the heat shock protein 70 family.
CC       {ECO:0000305}.
DR   EMBL; U09861; AAA73914.1; -; mRNA.
DR   EMBL; AY149618; AAN78092.1; -; Genomic_DNA.
DR   EMBL; AY149619; AAN78094.1; -; Genomic_DNA.
DR   EMBL; AY662497; AAT75223.1; -; mRNA.
DR   EMBL; U02891; AAA03450.1; -; Unassigned_DNA.
DR   PIR; S53357; S53357.
DR   RefSeq; NP_776975.1; NM_174550.1.
DR   UniGene; Bt.49659; -.
DR   ProteinModelPortal; Q27975; -.
DR   SMR; Q27975; 1-619.
DR   BioGrid; 159138; 1.
DR   IntAct; Q27975; 1.
DR   PaxDb; Q27975; -.
DR   PRIDE; Q27975; -.
DR   Ensembl; ENSBTAT00000017500; ENSBTAP00000017500; ENSBTAG00000025441.
DR   GeneID; 281825; -.
DR   KEGG; bta:281825; -.
DR   CTD; 3303; -.
DR   eggNOG; COG0443; -.
DR   GeneTree; ENSGT00750000117237; -.
DR   HOGENOM; HOG000228135; -.
DR   HOVERGEN; HBG051845; -.
DR   InParanoid; Q27975; -.
DR   KO; K03283; -.
DR   OMA; MAKSTAI; -.
DR   OrthoDB; EOG7PCJGF; -.
DR   TreeFam; TF105042; -.
DR   Reactome; REACT_300103; HSF1-dependent transactivation.
DR   Reactome; REACT_329646; AUF1 (hnRNP D0) destabilizes mRNA.
DR   Reactome; REACT_338158; Regulation of HSF1-mediated heat shock response.
DR   Reactome; REACT_344297; Attenuation phase.
DR   NextBio; 20805735; -.
DR   PRO; PR:Q27975; -.
DR   Proteomes; UP000009136; Chromosome 23.
DR   ExpressionAtlas; Q27975; baseline.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.1270.10; -; 1.
DR   Gene3D; 2.60.34.10; -; 1.
DR   InterPro; IPR018181; Heat_shock_70_CS.
DR   InterPro; IPR029048; HSP70_C.
DR   InterPro; IPR029047; HSP70_peptide-bd.
DR   InterPro; IPR013126; Hsp_70_fam.
DR   Pfam; PF00012; HSP70; 1.
DR   PRINTS; PR00301; HEATSHOCK70.
DR   SUPFAM; SSF100920; SSF100920; 1.
DR   SUPFAM; SSF100934; SSF100934; 1.
DR   PROSITE; PS00297; HSP70_1; 1.
DR   PROSITE; PS00329; HSP70_2; 1.
DR   PROSITE; PS01036; HSP70_3; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ATP-binding; Chaperone; Complete proteome; Methylation;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Stress response.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P08107}.
FT   CHAIN         2    641       Heat shock 70 kDa protein 1A.
FT                                /FTId=PRO_0000078245.
FT   NP_BIND      12     15       ATP. {ECO:0000250}.
FT   NP_BIND     202    204       ATP. {ECO:0000250}.
FT   NP_BIND     268    275       ATP. {ECO:0000250}.
FT   NP_BIND     339    342       ATP. {ECO:0000250}.
FT   BINDING      71     71       ATP. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     108    108       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     246    246       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     348    348       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     561    561       N6,N6,N6-trimethyllysine; by METTL21A; in
FT                                vitro. {ECO:0000250}.
FT   MOD_RES     631    631       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     633    633       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     636    636       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   CONFLICT     57     57       N -> S (in Ref. 3; AAT75223).
FT                                {ECO:0000305}.
FT   CONFLICT     89     89       H -> E (in Ref. 1; AAA73914).
FT                                {ECO:0000305}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:P08107; SHS; 21-JAN-2015.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**ZB SYP, 04-FEB-2009; ANN, 26-MAR-2009; ANN, 08-APR-2009; JAJ, 22-DEC-2009;
**ZB ISC, 14-JUN-2011; SHS, 11-DEC-2012; ANN, 06-JUN-2013; SHS, 30-JAN-2015;
**ZB BAP, 27-FEB-2015;
SQ   SEQUENCE   641 AA;  70259 MW;  6FAC1F30540E80F9 CRC64;
     MAKNMAIGID LGTTYSCVGV FQHGKVEIIA NDQGNRTTPS YVAFTDTERL IGDAAKNQVA
     LNPQNTVFDA KRLIGRKFGD PVVQSDMKHW PFRVINDGDK PKVQVSYKGE TKAFYPEEIS
     SMVLTKMKEI AEAYLGHPVT NAVITVPAYF NDSQRQATKD AGVIAGLNVL RIINEPTAAA
     IAYGLDRTGK GERNVLIFDL GGGTFDVSIL TIDDGIFEVK ATAGDTHLGG EDFDNRLVNH
     FVEEFKRKHK KDISQNKRAV RRLRTACERA KRTLSSSTQA SLEIDSLFEG IDFYTSITRA
     RFEELCSDLF RSTLEPVEKA LRDAKLDKAQ IHDLVLVGGS TRIPKVQKLL QDFFNGRDLN
     KSINPDEAVA YGAAVQAAIL MGDKSENVQD LLLLDVAPLS LGLETAGGVM TALIKRNSTI
     PTKQTQIFTT YSDNQPGVLI QVYEGERAMT RDNNLLGRFE LSGIPPAPRG VPQIEVTFDI
     DANGILNVTA TDKSTGKANK ITITNDKGRL SKEEIERMVQ EAEKYKAEDE VQRERVSAKN
     ALESYAFNMK SAVEDEGLKG KISEADKKKV LDKCQEVISW LDANTLAEKD EFEHKRKELE
     QVCNPIISRL YQGAGGPGAG GFGAQGPKGG SGSGPTIEEV D
//
ID   HSP71_HUMAN             Reviewed;         641 AA.
AC   P08107; B4E3B6; P19790; Q5JQI4; Q5SP17; Q9UQL9; Q9UQM0;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   15-MAY-2007, sequence version 5.
DT   04-MAR-2015, entry version 189.
DE   RecName: Full=Heat shock 70 kDa protein 1A/1B;
DE   AltName: Full=Heat shock 70 kDa protein 1/2;
DE            Short=HSP70-1/HSP70-2;
DE            Short=HSP70.1/HSP70.2;
GN   Name=HSPA1A; Synonyms=HSPA1, HSX70;
GN   and
GN   Name=HSPA1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1700760; DOI=10.1007/BF00187095;
RA   Milner C.M., Campbell R.D.;
RT   "Structure and expression of the three MHC-linked HSP70 genes.";
RL   Immunogenetics 32:242-251(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3931075; DOI=10.1073/pnas.82.19.6455;
RA   Hunt C., Morimoto R.I.;
RT   "Conserved features of eukaryotic hsp70 genes revealed by comparison
RT   with the nucleotide sequence of human hsp70.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:6455-6459(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (HSPA1A AND HSPA1B), AND
RP   VARIANTS ASP-110 AND SER-499.
RX   PubMed=14656967; DOI=10.1101/gr.1736803;
RA   Xie T., Rowen L., Aguado B., Ahearn M.E., Madan A., Qin S.,
RA   Campbell R.D., Hood L.;
RT   "Analysis of the gene-dense major histocompatibility complex class III
RT   region and its comparison to mouse.";
RL   Genome Res. 13:2621-2636(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (HSPA1A AND HSPA1B).
RA   Shiina S., Tamiya G., Oka A., Inoko H.;
RT   "Homo sapiens 2,229,817bp genomic DNA of 6p21.3 HLA class I region.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-95; ASP-110;
RP   VAL-467 AND SER-499.
RG   NIEHS SNPs program;
RL   Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASP-110.
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, Muscle, Pancreas, PNS, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-36 AND 360-424.
RX   PubMed=2538825; DOI=10.1073/pnas.86.6.1968;
RA   Sargent C.A., Dunham I., Trowsdale J., Campbell R.D.;
RT   "Human major histocompatibility complex contains genes for the major
RT   heat shock protein HSP70.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:1968-1972(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22 AND 617-641.
RX   PubMed=3786141; DOI=10.1093/nar/14.22.8933;
RA   Drabent B., Genthe A., Benecke B.-J.;
RT   "In vitro transcription of a human hsp 70 heat shock gene by extracts
RT   prepared from heat-shocked and non-heat-shocked human cells.";
RL   Nucleic Acids Res. 14:8933-8948(1986).
RN   [11]
RP   PROTEIN SEQUENCE OF 4-49; 57-71; 77-155; 160-187; 221-247; 273-311;
RP   326-342; 349-357; 362-416; 424-447; 459-469; 510-517; 540-550; 574-595
RP   AND 598-641, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [12]
RP   PROTEIN SEQUENCE OF 37-49; 57-71; 78-88; 113-126; 160-187; 221-247;
RP   302-311; 329-342; 349-357; 362-384; 540-550 AND 574-589, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [13]
RP   PROTEIN SEQUENCE OF 551-567, METHYLATION AT LYS-561, MUTAGENESIS OF
RP   LYS-561, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23349634; DOI=10.1371/journal.pgen.1003210;
RA   Cloutier P., Lavallee-Adam M., Faubert D., Blanchette M., Coulombe B.;
RT   "A newly uncovered group of distantly related lysine
RT   methyltransferases preferentially interact with molecular chaperones
RT   to regulate their activity.";
RL   PLoS Genet. 9:E1003210-E1003210(2013).
RN   [14]
RP   INTERACTION WITH TERT.
RX   PubMed=11274138; DOI=10.1074/jbc.C100055200;
RA   Forsythe H.L., Jarvis J.L., Turner J.W., Elmore L.W., Holt S.E.;
RT   "Stable association of hsp90 and p23, but Not hsp70, with active human
RT   telomerase.";
RL   J. Biol. Chem. 276:15571-15574(2001).
RN   [15]
RP   INTERACTION WITH DNAJC7.
RX   PubMed=12853476; DOI=10.1093/emboj/cdg362;
RA   Brychzy A., Rein T., Winklhofer K.F., Hartl F.U., Young J.C.,
RA   Obermann W.M.;
RT   "Cofactor Tpr2 combines two TPR domains and a J domain to regulate the
RT   Hsp70/Hsp90 chaperone system.";
RL   EMBO J. 22:3613-3623(2003).
RN   [16]
RP   INTERACTION WITH TSC2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15963462; DOI=10.1016/j.bbrc.2005.05.175;
RA   Nellist M., Burgers P.C., van den Ouweland A.M.W., Halley D.J.J.,
RA   Luider T.M.;
RT   "Phosphorylation and binding partner analysis of the TSC1-TSC2
RT   complex.";
RL   Biochem. Biophys. Res. Commun. 333:818-826(2005).
RN   [17]
RP   INTERACTION WITH PPP5C, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15383005; DOI=10.1042/BJ20040690;
RA   Zeke T., Morrice N., Vazquez-Martin C., Cohen P.T.;
RT   "Human protein phosphatase 5 dissociates from heat-shock proteins and
RT   is proteolytically activated in response to arachidonic acid and the
RT   microtubule-depolymerizing drug nocodazole.";
RL   Biochem. J. 385:45-56(2005).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [19]
RP   INTERACTION WITH IRAK1BP1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17233114; DOI=10.1089/dna.2006.25.704;
RA   Haag Breese E., Uversky V.N., Georgiadis M.M., Harrington M.A.;
RT   "The disordered amino-terminus of SIMPL interacts with members of the
RT   70-kDa heat-shock protein family.";
RL   DNA Cell Biol. 25:704-714(2006).
RN   [20]
RP   FUNCTION AS A RECEPTOR FOR ROTAVIRUS A.
RX   PubMed=16537599; DOI=10.1128/JVI.80.7.3322-3331.2006;
RA   Perez-Vargas J., Romero P., Lopez S., Arias C.F.;
RT   "The peptide-binding and ATPase domains of recombinant hsc70 are
RT   required to interact with rotavirus and reduce its infectivity.";
RL   J. Virol. 80:3322-3331(2006).
RN   [21]
RP   IDENTIFICATION IN A MRNP GRANULE COMPLEX, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND SUBCELLULAR LOCATION.
RX   PubMed=17289661; DOI=10.1074/mcp.M600346-MCP200;
RA   Joeson L., Vikesaa J., Krogh A., Nielsen L.K., Hansen T., Borup R.,
RA   Johnsen A.H., Christiansen J., Nielsen F.C.;
RT   "Molecular composition of IMP1 ribonucleoprotein granules.";
RL   Mol. Cell. Proteomics 6:798-811(2007).
RN   [22]
RP   INTERACTION WITH DNAJC7.
RX   PubMed=18620420; DOI=10.1021/bi800770g;
RA   Moffatt N.S., Bruinsma E., Uhl C., Obermann W.M., Toft D.;
RT   "Role of the cochaperone Tpr2 in Hsp90 chaperoning.";
RL   Biochemistry 47:8203-8213(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [25]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-108; LYS-246 AND LYS-348,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [26]
RP   INTERACTION WITH TRIM5.
RX   PubMed=20053985; DOI=10.1074/jbc.M109.040618;
RA   Hwang C.Y., Holl J., Rajan D., Lee Y., Kim S., Um M., Kwon K.S.,
RA   Song B.;
RT   "Hsp70 interacts with the retroviral restriction factor TRIM5alpha and
RT   assists the folding of TRIM5alpha.";
RL   J. Biol. Chem. 285:7827-7837(2010).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631; SER-633 AND
RP   THR-636, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   INTERACTION WITH CHCHD3.
RX   PubMed=21081504; DOI=10.1074/jbc.M110.171975;
RA   Darshi M., Mendiola V.L., Mackey M.R., Murphy A.N., Koller A.,
RA   Perkins G.A., Ellisman M.H., Taylor S.S.;
RT   "ChChd3, an inner mitochondrial membrane protein, is essential for
RT   maintaining crista integrity and mitochondrial function.";
RL   J. Biol. Chem. 286:2918-2932(2011).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH
RP   FOXP3.
RX   PubMed=23973223; DOI=10.1016/j.immuni.2013.08.006;
RA   Chen Z., Barbi J., Bu S., Yang H.Y., Li Z., Gao Y., Jinasena D.,
RA   Fu J., Lin F., Chen C., Zhang J., Yu N., Li X., Shan Z., Nie J.,
RA   Gao Z., Tian H., Li Y., Yao Z., Zheng Y., Park B.V., Pan Z., Zhang J.,
RA   Dang E., Li Z., Wang H., Luo W., Li L., Semenza G.L., Zheng S.G.,
RA   Loser K., Tsun A., Greene M.I., Pardoll D.M., Pan F., Li B.;
RT   "The ubiquitin ligase Stub1 negatively modulates regulatory T cell
RT   suppressive activity by promoting degradation of the transcription
RT   factor Foxp3.";
RL   Immunity 39:272-285(2013).
RN   [32]
RP   METHYLATION AT LYS-561, MUTAGENESIS OF LYS-561, AND INTERACTION WITH
RP   METTL21A.
RX   PubMed=23921388; DOI=10.1074/jbc.M113.483248;
RA   Jakobsson M.E., Moen A., Bousset L., Egge-Jacobsen W., Kernstock S.,
RA   Melki R., Falnes P.O.;
RT   "Identification and characterization of a novel human
RT   methyltransferase modulating Hsp70 function through lysine
RT   methylation.";
RL   J. Biol. Chem. 288:27752-27763(2013).
RN   [33]
RP   INTERACTION WITH PARK2.
RX   PubMed=24270810; DOI=10.1038/nature12748;
RA   Hasson S.A., Kane L.A., Yamano K., Huang C.H., Sliter D.A.,
RA   Buehler E., Wang C., Heman-Ackah S.M., Hessa T., Guha R., Martin S.E.,
RA   Youle R.J.;
RT   "High-content genome-wide RNAi screens identify regulators of parkin
RT   upstream of mitophagy.";
RL   Nature 504:291-295(2013).
RN   [34]
RP   INTERACTION WITH NOD2.
RX   PubMed=24790089; DOI=10.1074/jbc.M114.557686;
RA   Mohanan V., Grimes C.L.;
RT   "The molecular chaperone HSP70 binds to and stabilizes NOD2, an
RT   important protein involved in Crohn disease.";
RL   J. Biol. Chem. 289:18987-18998(2014).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1-382 IN COMPLEX WITH ADP,
RP   AND ATP-BINDING.
RX   PubMed=10216320; DOI=10.1107/S0907444999002103;
RA   Osipiuk J., Walsh M.A., Freeman B.C., Morimoto R.I., Joachimiak A.;
RT   "Structure of a new crystal form of human hsp70 ATPase domain.";
RL   Acta Crystallogr. D 55:1105-1107(1999).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.77 ANGSTROMS) OF 389-641 IN COMPLEX WITH ATP
RP   ANALOG, AND ATP-BINDING.
RX   PubMed=20179333; DOI=10.1107/S0907444909053979;
RA   Shida M., Arakawa A., Ishii R., Kishishita S., Takagi T.,
RA   Kukimoto-Niino M., Sugano S., Tanaka A., Shirouzu M., Yokoyama S.;
RT   "Direct inter-subdomain interactions switch between the closed and
RT   open forms of the Hsp70 nucleotide-binding domain in the nucleotide-
RT   free state.";
RL   Acta Crystallogr. D 66:223-232(2010).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.14 ANGSTROMS) OF 1-387 IN COMPLEX WITH ADP,
RP   AND ATP-BINDING.
RX   PubMed=20072699; DOI=10.1371/journal.pone.0008625;
RA   Wisniewska M., Karlberg T., Lehtio L., Johansson I., Kotenyova T.,
RA   Moche M., Schuler H.;
RT   "Crystal structures of the ATPase domains of four human Hsp70
RT   isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B', and
RT   HSPA5/BiP/GRP78.";
RL   PLoS ONE 5:E8625-E8625(2010).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1-388 IN COMPLEX WITH BAG5.
RX   PubMed=20223214; DOI=10.1016/j.str.2010.01.004;
RA   Arakawa A., Handa N., Ohsawa N., Shida M., Kigawa T., Hayashi F.,
RA   Shirouzu M., Yokoyama S.;
RT   "The C-terminal BAG domain of BAG5 induces conformational changes of
RT   the Hsp70 nucleotide-binding domain for ADP-ATP exchange.";
RL   Structure 18:309-319(2010).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.58 ANGSTROMS) OF 1-388, ATP-BINDING, AND
RP   MUTAGENESIS OF ASP-10 AND ASP-199.
RX   PubMed=21608060; DOI=10.1002/pro.663;
RA   Arakawa A., Handa N., Shirouzu M., Yokoyama S.;
RT   "Biochemical and structural studies on the high affinity of Hsp70 for
RT   ADP.";
RL   Protein Sci. 20:1367-1379(2011).
CC   -!- FUNCTION: In cooperation with other chaperones, Hsp70s stabilize
CC       preexistent proteins against aggregation and mediate the folding
CC       of newly translated polypeptides in the cytosol as well as within
CC       organelles. These chaperones participate in all these processes
CC       through their ability to recognize nonnative conformations of
CC       other proteins. They bind extended peptide segments with a net
CC       hydrophobic character exposed by polypeptides during translation
CC       and membrane translocation, or following stress-induced damage. In
CC       case of rotavirus A infection, serves as a post-attachment
CC       receptor for the virus to facilitate entry into the cell.
CC       Essential for STUB1-mediated ubiquitination and degradation of
CC       FOXP3 in regulatory T-cells (Treg) during inflammation
CC       (PubMed:23973223). {ECO:0000269|PubMed:16537599,
CC       ECO:0000269|PubMed:23973223}.
CC   -!- SUBUNIT: Component of the CatSper complex. Identified in a
CC       IGF2BP1-dependent mRNP granule complex containing untranslated
CC       mRNAs (PubMed:17289661). Interacts with CHCHD3, DNAJC7, IRAK1BP1,
CC       PPP5C and TSC2 (PubMed:21081504, PubMed:12853476, PubMed:18620420,
CC       PubMed:17233114, PubMed:15383005, PubMed:15963462). Interacts with
CC       TERT; the interaction occurs in the absence of the RNA component,
CC       TERC, and dissociates once the TERT complex has formed
CC       (PubMed:11274138). Interacts with TRIM5 (via B30.2/SPRY domain)
CC       (PubMed:20053985). Interacts with METTL21A (PubMed:23921388).
CC       Interacts with PARK2 (PubMed:24270810). Interacts with FOXP3
CC       (PubMed:23973223). Interacts with NOD2; the interaction enhances
CC       NOD2 stability (PubMed:24790089). {ECO:0000269|PubMed:10216320,
CC       ECO:0000269|PubMed:11274138, ECO:0000269|PubMed:12853476,
CC       ECO:0000269|PubMed:15383005, ECO:0000269|PubMed:15963462,
CC       ECO:0000269|PubMed:17233114, ECO:0000269|PubMed:17289661,
CC       ECO:0000269|PubMed:18620420, ECO:0000269|PubMed:20053985,
CC       ECO:0000269|PubMed:20072699, ECO:0000269|PubMed:20179333,
CC       ECO:0000269|PubMed:20223214, ECO:0000269|PubMed:21081504,
CC       ECO:0000269|PubMed:23921388, ECO:0000269|PubMed:23973223,
CC       ECO:0000269|PubMed:24270810, ECO:0000269|PubMed:24790089}.
CC   -!- INTERACTION:
CC       P29846:- (xeno); NbExp=3; IntAct=EBI-629985, EBI-9303040;
CC       Q9UL15:BAG5; NbExp=6; IntAct=EBI-629985, EBI-356517;
CC       Q9HB09-2:BCL2L12; NbExp=2; IntAct=EBI-629985, EBI-6969019;
CC       Q8AZK7:EBNA-LP (xeno); NbExp=3; IntAct=EBI-629985, EBI-1185167;
CC       P00533:EGFR; NbExp=6; IntAct=EBI-629985, EBI-297353;
CC       P15976:GATA1; NbExp=5; IntAct=EBI-629985, EBI-3909284;
CC       P28301:Lox (xeno); NbExp=6; IntAct=EBI-629985, EBI-642911;
CC       P08473:MME; NbExp=3; IntAct=EBI-629985, EBI-353759;
CC       Q62392:Phlda1 (xeno); NbExp=2; IntAct=EBI-629985, EBI-309727;
CC       P53350:PLK1; NbExp=5; IntAct=EBI-629985, EBI-476768;
CC       P35467:S100a1 (xeno); NbExp=4; IntAct=EBI-629985, EBI-6477109;
CC       P37840:SNCA; NbExp=7; IntAct=EBI-629985, EBI-985879;
CC       P32589:SSE1 (xeno); NbExp=2; IntAct=EBI-629985, EBI-8648;
CC       Q9UNE7:STUB1; NbExp=5; IntAct=EBI-629985, EBI-357085;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17289661}.
CC       Note=Localized in cytoplasmic mRNP granules containing
CC       untranslated mRNAs.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P08107-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08107-2; Sequence=VSP_044427;
CC   -!- TISSUE SPECIFICITY: HSPA1B is testis-specific.
CC   -!- INDUCTION: By heat shock.
CC   -!- SIMILARITY: Belongs to the heat shock protein 70 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/hspa1a/";
DR   EMBL; M59828; AAA63226.1; -; Genomic_DNA.
DR   EMBL; M59830; AAA63227.1; -; Genomic_DNA.
DR   EMBL; M11717; AAA52697.1; -; Genomic_DNA.
DR   EMBL; AF134726; AAD21815.1; -; Genomic_DNA.
DR   EMBL; AF134726; AAD21816.1; -; Genomic_DNA.
DR   EMBL; BA000025; BAB63299.1; -; Genomic_DNA.
DR   EMBL; BA000025; BAB63300.1; -; Genomic_DNA.
DR   EMBL; AK304652; BAG65428.1; -; mRNA.
DR   EMBL; DQ388429; ABD48956.1; -; Genomic_DNA.
DR   EMBL; DQ451402; ABD96830.1; -; Genomic_DNA.
DR   EMBL; AL662834; CAI17737.1; -; Genomic_DNA.
DR   EMBL; AL662834; CAI17738.1; -; Genomic_DNA.
DR   EMBL; AL671762; CAI18216.1; -; Genomic_DNA.
DR   EMBL; AL671762; CAI18217.1; -; Genomic_DNA.
DR   EMBL; AL929592; CAI18464.1; -; Genomic_DNA.
DR   EMBL; AL929592; CAI18466.1; -; Genomic_DNA.
DR   EMBL; BC002453; AAH02453.1; -; mRNA.
DR   EMBL; BC009322; AAH09322.1; -; mRNA.
DR   EMBL; BC018740; AAH18740.1; -; mRNA.
DR   EMBL; BC057397; AAH57397.1; -; mRNA.
DR   EMBL; BC063507; AAH63507.1; -; mRNA.
DR   EMBL; M24743; AAA59844.1; -; Genomic_DNA.
DR   EMBL; M24744; AAA59845.1; -; Genomic_DNA.
DR   EMBL; X04676; CAA28381.1; -; Genomic_DNA.
DR   EMBL; X04677; CAA28382.1; -; Genomic_DNA.
DR   CCDS; CCDS34414.1; -. [P08107-1]
DR   CCDS; CCDS34415.1; -. [P08107-1]
DR   PIR; A29160; A29160.
DR   PIR; A45871; A45871.
DR   PIR; I59139; I59139.
DR   PIR; I79540; I79540.
DR   RefSeq; NP_005336.3; NM_005345.5. [P08107-1]
DR   RefSeq; NP_005337.2; NM_005346.4. [P08107-1]
DR   UniGene; Hs.274402; -.
DR   UniGene; Hs.702139; -.
DR   UniGene; Hs.719966; -.
DR   PDB; 1HJO; X-ray; 2.30 A; A=3-382.
DR   PDB; 1S3X; X-ray; 1.84 A; A=1-382.
DR   PDB; 1XQS; X-ray; 2.90 A; C/D=184-371.
DR   PDB; 2E88; X-ray; 1.80 A; A=1-388.
DR   PDB; 2E8A; X-ray; 1.77 A; A=1-388.
DR   PDB; 2LMG; NMR; -; A=537-610.
DR   PDB; 3A8Y; X-ray; 2.30 A; A/B=1-388.
DR   PDB; 3ATU; X-ray; 1.65 A; A=1-388.
DR   PDB; 3ATV; X-ray; 1.58 A; A=1-388.
DR   PDB; 3AY9; X-ray; 1.75 A; A=1-388.
DR   PDB; 3D2E; X-ray; 2.35 A; B/D=1-382.
DR   PDB; 3D2F; X-ray; 2.30 A; B/D=1-382.
DR   PDB; 3JXU; X-ray; 2.14 A; A=1-387.
DR   PDB; 3LOF; X-ray; 2.40 A; A/B/C/D/E/F=534-641.
DR   PDB; 4IO8; X-ray; 2.58 A; A=1-382.
DR   PDB; 4J8F; X-ray; 2.70 A; A=1-382.
DR   PDB; 4PO2; X-ray; 2.00 A; A/B=386-613.
DR   PDB; 4WV5; X-ray; 2.04 A; A/B=395-543.
DR   PDB; 4WV7; X-ray; 2.42 A; A/B=395-543.
DR   PDBsum; 1HJO; -.
DR   PDBsum; 1S3X; -.
DR   PDBsum; 1XQS; -.
DR   PDBsum; 2E88; -.
DR   PDBsum; 2E8A; -.
DR   PDBsum; 2LMG; -.
DR   PDBsum; 3A8Y; -.
DR   PDBsum; 3ATU; -.
DR   PDBsum; 3ATV; -.
DR   PDBsum; 3AY9; -.
DR   PDBsum; 3D2E; -.
DR   PDBsum; 3D2F; -.
DR   PDBsum; 3JXU; -.
DR   PDBsum; 3LOF; -.
DR   PDBsum; 4IO8; -.
DR   PDBsum; 4J8F; -.
DR   PDBsum; 4PO2; -.
DR   PDBsum; 4WV5; -.
DR   PDBsum; 4WV7; -.
DR   SMR; P08107; 1-613.
DR   BioGrid; 109535; 185.
DR   BioGrid; 109536; 60.
DR   DIP; DIP-211N; -.
DR   IntAct; P08107; 119.
DR   MINT; MINT-96699; -.
DR   STRING; 9606.ENSP00000364802; -.
DR   BindingDB; P08107; -.
DR   ChEMBL; CHEMBL5460; -.
DR   TCDB; 1.A.33.1.3; the cation channel-forming heat shock protein-70 (hsp70) family.
DR   PhosphoSite; P08107; -.
DR   DMDM; 147744565; -.
DR   DOSAC-COBS-2DPAGE; P08107; -.
DR   OGP; P08107; -.
DR   REPRODUCTION-2DPAGE; IPI00304925; -.
DR   SWISS-2DPAGE; P08107; -.
DR   UCD-2DPAGE; P08107; -.
DR   MaxQB; P08107; -.
DR   PaxDb; P08107; -.
DR   PRIDE; P08107; -.
DR   DNASU; 3303; -.
DR   Ensembl; ENST00000375650; ENSP00000364801; ENSG00000204388. [P08107-1]
DR   Ensembl; ENST00000375651; ENSP00000364802; ENSG00000204389. [P08107-1]
DR   Ensembl; ENST00000391548; ENSP00000375391; ENSG00000224501. [P08107-1]
DR   Ensembl; ENST00000391555; ENSP00000375399; ENSG00000212866. [P08107-1]
DR   Ensembl; ENST00000400040; ENSP00000382915; ENSG00000215328.
DR   Ensembl; ENST00000430065; ENSP00000404524; ENSG00000235941. [P08107-1]
DR   Ensembl; ENST00000433487; ENSP00000408907; ENSG00000234475. [P08107-1]
DR   Ensembl; ENST00000441618; ENSP00000406359; ENSG00000237724. [P08107-1]
DR   Ensembl; ENST00000445736; ENSP00000403530; ENSG00000231555. [P08107-1]
DR   Ensembl; ENST00000450744; ENSP00000393087; ENSG00000232804. [P08107-1]
DR   GeneID; 3303; -.
DR   GeneID; 3304; -.
DR   KEGG; hsa:3303; -.
DR   KEGG; hsa:3304; -.
DR   UCSC; uc003nxj.3; human. [P08107-1]
DR   CTD; 3303; -.
DR   CTD; 3304; -.
DR   GeneCards; GC06P031850; -.
DR   GeneCards; GC06P031853; -.
DR   GeneCards; GC06Pi31794; -.
DR   GeneCards; GC06Pi31806; -.
DR   GeneCards; GC06Pj31770; -.
DR   GeneCards; GC06Pj31782; -.
DR   GeneCards; GC06Pk31765; -.
DR   GeneCards; GC06Pk31777; -.
DR   GeneCards; GC06Pn31773; -.
DR   GeneCards; GC06Pn31785; -.
DR   H-InvDB; HIX0058169; -.
DR   H-InvDB; HIX0058187; -.
DR   H-InvDB; HIX0166160; -.
DR   HGNC; HGNC:5232; HSPA1A.
DR   HGNC; HGNC:5233; HSPA1B.
DR   HPA; CAB008640; -.
DR   HPA; CAB017451; -.
DR   HPA; CAB032815; -.
DR   HPA; HPA052504; -.
DR   MIM; 140550; gene.
DR   MIM; 603012; gene.
DR   neXtProt; NX_P08107; -.
DR   PharmGKB; PA29499; -.
DR   eggNOG; COG0443; -.
DR   GeneTree; ENSGT00750000117237; -.
DR   HOGENOM; HOG000228135; -.
DR   HOVERGEN; HBG051845; -.
DR   InParanoid; P08107; -.
DR   KO; K03283; -.
DR   OMA; MAKSTAI; -.
DR   OrthoDB; EOG7PCJGF; -.
DR   PhylomeDB; P08107; -.
DR   TreeFam; TF105042; -.
DR   Reactome; REACT_25325; AUF1 (hnRNP D0) destabilizes mRNA.
DR   Reactome; REACT_264075; Attenuation phase.
DR   Reactome; REACT_264164; HSF1-dependent transactivation.
DR   Reactome; REACT_264487; Regulation of HSF1-mediated heat shock response.
DR   Reactome; REACT_6198; Viral RNP Complexes in the Host Cell Nucleus.
DR   ChiTaRS; HSPA1A; human.
DR   ChiTaRS; HSPA1B; human.
DR   EvolutionaryTrace; P08107; -.
DR   GeneWiki; HSPA1A; -.
DR   NextBio; 13103; -.
DR   PRO; PR:P08107; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Proteomes; UP000005640; Unplaced.
DR   Bgee; P08107; -.
DR   CleanEx; HS_HSPA1A; -.
DR   ExpressionAtlas; P08107; baseline and differential.
DR   Genevestigator; P08107; -.
DR   GO; GO:0016235; C:aggresome; IDA:UniProtKB.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; TAS:UniProtKB.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0016234; C:inclusion body; IDA:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; TAS:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0016887; F:ATPase activity; IDA:BHF-UCL.
DR   GO; GO:0042623; F:ATPase activity, coupled; IDA:UniProtKB.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0001664; F:G-protein coupled receptor binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0031072; F:heat shock protein binding; IPI:UniProtKB.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0044183; F:protein binding involved in protein folding; IDA:BHF-UCL.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0051082; F:unfolded protein binding; IDA:UniProtKB.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0070370; P:cellular heat acclimation; IMP:UniProtKB.
DR   GO; GO:0034605; P:cellular response to heat; IDA:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0006402; P:mRNA catabolic process; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0060548; P:negative regulation of cell death; IMP:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:BHF-UCL.
DR   GO; GO:0090084; P:negative regulation of inclusion body assembly; IDA:UniProtKB.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0042026; P:protein refolding; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:0006986; P:response to unfolded protein; IDA:UniProtKB.
DR   Gene3D; 1.20.1270.10; -; 1.
DR   Gene3D; 2.60.34.10; -; 1.
DR   InterPro; IPR018181; Heat_shock_70_CS.
DR   InterPro; IPR029048; HSP70_C.
DR   InterPro; IPR029047; HSP70_peptide-bd.
DR   InterPro; IPR013126; Hsp_70_fam.
DR   Pfam; PF00012; HSP70; 1.
DR   PRINTS; PR00301; HEATSHOCK70.
DR   SUPFAM; SSF100920; SSF100920; 1.
DR   SUPFAM; SSF100934; SSF100934; 1.
DR   PROSITE; PS00297; HSP70_1; 1.
DR   PROSITE; PS00329; HSP70_2; 1.
DR   PROSITE; PS01036; HSP70_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Chaperone; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Host cell receptor for virus entry; Methylation; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Stress response.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:19413330}.
FT   CHAIN         2    641       Heat shock 70 kDa protein 1A/1B.
FT                                /FTId=PRO_0000078249.
FT   NP_BIND      12     15       ATP.
FT   NP_BIND     202    204       ATP.
FT   NP_BIND     268    275       ATP.
FT   NP_BIND     339    342       ATP.
FT   BINDING      71     71       ATP.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000269|PubMed:19413330}.
FT   MOD_RES     108    108       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES     246    246       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES     348    348       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES     561    561       N6,N6,N6-trimethyllysine; by METTL21A.
FT                                {ECO:0000269|PubMed:23349634,
FT                                ECO:0000269|PubMed:23921388}.
FT   MOD_RES     631    631       Phosphoserine.
FT                                {ECO:0000269|PubMed:20068231}.
FT   MOD_RES     633    633       Phosphoserine.
FT                                {ECO:0000269|PubMed:20068231}.
FT   MOD_RES     636    636       Phosphothreonine.
FT                                {ECO:0000269|PubMed:20068231}.
FT   VAR_SEQ      96    150       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044427.
FT   VARIANT      95     95       I -> V. {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_032152.
FT   VARIANT     110    110       E -> D (in dbSNP:rs562047).
FT                                {ECO:0000269|PubMed:14574404,
FT                                ECO:0000269|PubMed:14656967,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_029053.
FT   VARIANT     467    467       A -> V. {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_032153.
FT   VARIANT     499    499       N -> S (in dbSNP:rs483638).
FT                                {ECO:0000269|PubMed:14656967,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_029054.
FT   MUTAGEN      10     10       D->A: Reduces affinity for ADP.
FT                                {ECO:0000269|PubMed:21608060}.
FT   MUTAGEN     199    199       D->A: Reduces affinity for ADP.
FT                                {ECO:0000269|PubMed:21608060}.
FT   MUTAGEN     561    561       K->R: Complete loss of in vitro
FT                                methylation by METTL21A.
FT                                {ECO:0000269|PubMed:23349634,
FT                                ECO:0000269|PubMed:23921388}.
FT   CONFLICT      7      7       I -> V (in Ref. 2; AAA52697 and 10;
FT                                CAA28381). {ECO:0000305}.
FT   CONFLICT    355    355       N -> D (in Ref. 5; BAG65428).
FT                                {ECO:0000305}.
FT   CONFLICT    370    370       A -> G (in Ref. 2; AAA52697).
FT                                {ECO:0000305}.
FT   CONFLICT    469    469       Missing (in Ref. 2; AAA52697).
FT                                {ECO:0000305}.
FT   CONFLICT    497    497       K -> N (in Ref. 5; BAG65428).
FT                                {ECO:0000305}.
FT   STRAND        7     10       {ECO:0000244|PDB:3ATV}.
FT   STRAND       13     22       {ECO:0000244|PDB:3ATV}.
FT   STRAND       25     28       {ECO:0000244|PDB:3ATV}.
FT   STRAND       36     39       {ECO:0000244|PDB:3ATV}.
FT   STRAND       42     44       {ECO:0000244|PDB:3ATV}.
FT   STRAND       49     51       {ECO:0000244|PDB:3ATV}.
FT   HELIX        53     56       {ECO:0000244|PDB:3ATV}.
FT   TURN         57     61       {ECO:0000244|PDB:3ATV}.
FT   HELIX        63     65       {ECO:0000244|PDB:3ATV}.
FT   HELIX        70     73       {ECO:0000244|PDB:3ATV}.
FT   HELIX        81     87       {ECO:0000244|PDB:3ATV}.
FT   STRAND       91     97       {ECO:0000244|PDB:3ATV}.
FT   STRAND      100    107       {ECO:0000244|PDB:3ATV}.
FT   STRAND      110    114       {ECO:0000244|PDB:3ATV}.
FT   HELIX       116    135       {ECO:0000244|PDB:3ATV}.
FT   STRAND      141    146       {ECO:0000244|PDB:3ATV}.
FT   HELIX       152    164       {ECO:0000244|PDB:3ATV}.
FT   STRAND      168    174       {ECO:0000244|PDB:3ATV}.
FT   HELIX       175    182       {ECO:0000244|PDB:3ATV}.
FT   TURN        183    186       {ECO:0000244|PDB:3ATV}.
FT   STRAND      190    200       {ECO:0000244|PDB:3ATV}.
FT   STRAND      205    213       {ECO:0000244|PDB:3ATV}.
FT   STRAND      216    225       {ECO:0000244|PDB:3ATV}.
FT   HELIX       226    228       {ECO:0000244|PDB:2E88}.
FT   HELIX       230    249       {ECO:0000244|PDB:3ATV}.
FT   HELIX       253    255       {ECO:0000244|PDB:2E88}.
FT   HELIX       257    273       {ECO:0000244|PDB:3ATV}.
FT   TURN        274    276       {ECO:0000244|PDB:3ATV}.
FT   STRAND      277    288       {ECO:0000244|PDB:3ATV}.
FT   STRAND      291    298       {ECO:0000244|PDB:3ATV}.
FT   HELIX       299    305       {ECO:0000244|PDB:3ATV}.
FT   HELIX       307    311       {ECO:0000244|PDB:3ATV}.
FT   HELIX       314    323       {ECO:0000244|PDB:3ATV}.
FT   HELIX       328    330       {ECO:0000244|PDB:3ATV}.
FT   STRAND      333    338       {ECO:0000244|PDB:3ATV}.
FT   HELIX       339    342       {ECO:0000244|PDB:3ATV}.
FT   HELIX       344    353       {ECO:0000244|PDB:3ATV}.
FT   TURN        354    356       {ECO:0000244|PDB:3ATV}.
FT   TURN        365    367       {ECO:0000244|PDB:3ATV}.
FT   HELIX       368    381       {ECO:0000244|PDB:3ATV}.
FT   HELIX       390    393       {ECO:0000244|PDB:4PO2}.
FT   STRAND      394    396       {ECO:0000244|PDB:4PO2}.
FT   STRAND      401    405       {ECO:0000244|PDB:4PO2}.
FT   TURN        406    408       {ECO:0000244|PDB:4PO2}.
FT   STRAND      409    414       {ECO:0000244|PDB:4PO2}.
FT   STRAND      419    432       {ECO:0000244|PDB:4PO2}.
FT   STRAND      438    449       {ECO:0000244|PDB:4PO2}.
FT   HELIX       450    452       {ECO:0000244|PDB:4PO2}.
FT   STRAND      453    461       {ECO:0000244|PDB:4PO2}.
FT   STRAND      474    480       {ECO:0000244|PDB:4PO2}.
FT   STRAND      486    492       {ECO:0000244|PDB:4PO2}.
FT   TURN        493    495       {ECO:0000244|PDB:4PO2}.
FT   STRAND      498    503       {ECO:0000244|PDB:4PO2}.
FT   HELIX       506    508       {ECO:0000244|PDB:4PO2}.
FT   HELIX       512    524       {ECO:0000244|PDB:4PO2}.
FT   HELIX       526    554       {ECO:0000244|PDB:4PO2}.
FT   HELIX       556    558       {ECO:0000244|PDB:4PO2}.
FT   HELIX       564    583       {ECO:0000244|PDB:4PO2}.
FT   HELIX       589    608       {ECO:0000244|PDB:4PO2}.
FT   HELIX       609    611       {ECO:0000244|PDB:4PO2}.
**
**   #################    INTERNAL SECTION    ##################
**CL 6p21.3; 6p21.3;
**EV ECO:0000244; PDB:2E88; INT; 08-OCT-2014.
**EV ECO:0000244; PDB:3ATV; INT; 08-OCT-2014.
**EV ECO:0000244; PDB:4PO2; INT; 08-OCT-2014.
**EV ECO:0000269; PubMed:10216320; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:11274138; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:12853476; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:14574404; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:14656967; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:15383005; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:15963462; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:16537599; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:17233114; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:17289661; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:18620420; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:19413330; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:19608861; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:20053985; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:20068231; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:20072699; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:20179333; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:20223214; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:21081504; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:21608060; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:23349634; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:23921388; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:23973223; SHS; 21-JAN-2015.
**EV ECO:0000269; PubMed:24270810; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:24790089; BAP; 03-FEB-2015.
**EV ECO:0000269; Ref.6; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:14702039; XXX; 01-JAN-1900.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**IS P08107-3
**SO UPD; 20140; 17-APR-2007.
**SO UPD; 37856; 05-DEC-2008.
**SO UPD; 78907; 11-JUL-2013.
**SO UPD; 79913; 23-AUG-2013.
**ZB LYG, 07-NOV-2006; LYG, 06-DEC-2006; ALG/LYG, 25-JAN-2007; SIJ, 19-APR-2007;
**ZB SIJ, 09-MAY-2007; SYP, 25-JUN-2007; ALG/LYG, 30-JUL-2007; LYG, 20-NOV-2007;
**ZB MAM, 21-APR-2007; WMC, 27-MAR-2008; ALG/LYG, 19-OCT-2008; SIJ, 04-FEB-2011;
**ZB ALG/GAP, 11-NOV-2008; MAM, 15-DEC-2008; GAP, 21-JAN-2009; SYP, 04-FEB-2009;
**ZB CHH, 16-FEB-2009; GAP, 20-MAR-2009; ANN, 26-MAR-2009; ANN, 08-APR-2009;
**ZB ALG/EMB, 17-SEP-2009; ANS, 07-OCT-2009; MIM, 12-OCT-2009; ANN, 14-MAR-2011;
**ZB ALB/EMB, 16-OCT-2009; JAJ, 22-DEC-2009; SIJ, 22-APR-2010; ALG, 04-MAY-2011;
**ZB SYP, 09-MAR-2012; ALG, 03-OCT-2012; SHS, 11-DEC-2012; ANN, 06-JUN-2013;
**ZB SYP, 12-JUL-2013; CRC/LIB, 27-AUG-2013; UHI, 06-SEP-2013; ANN, 20-MAR-2014;
**ZB RAB, 20-OCT-2014; SHS, 30-JAN-2015; BAP, 27-FEB-2015;
SQ   SEQUENCE   641 AA;  70052 MW;  78F513118C96DE66 CRC64;
     MAKAAAIGID LGTTYSCVGV FQHGKVEIIA NDQGNRTTPS YVAFTDTERL IGDAAKNQVA
     LNPQNTVFDA KRLIGRKFGD PVVQSDMKHW PFQVINDGDK PKVQVSYKGE TKAFYPEEIS
     SMVLTKMKEI AEAYLGYPVT NAVITVPAYF NDSQRQATKD AGVIAGLNVL RIINEPTAAA
     IAYGLDRTGK GERNVLIFDL GGGTFDVSIL TIDDGIFEVK ATAGDTHLGG EDFDNRLVNH
     FVEEFKRKHK KDISQNKRAV RRLRTACERA KRTLSSSTQA SLEIDSLFEG IDFYTSITRA
     RFEELCSDLF RSTLEPVEKA LRDAKLDKAQ IHDLVLVGGS TRIPKVQKLL QDFFNGRDLN
     KSINPDEAVA YGAAVQAAIL MGDKSENVQD LLLLDVAPLS LGLETAGGVM TALIKRNSTI
     PTKQTQIFTT YSDNQPGVLI QVYEGERAMT KDNNLLGRFE LSGIPPAPRG VPQIEVTFDI
     DANGILNVTA TDKSTGKANK ITITNDKGRL SKEEIERMVQ EAEKYKAEDE VQRERVSAKN
     ALESYAFNMK SAVEDEGLKG KISEADKKKV LDKCQEVISW LDANTLAEKD EFEHKRKELE
     QVCNPIISGL YQGAGGPGPG GFGAQGPKGG SGSGPTIEEV D
//
ID   HS71A_MOUSE             Reviewed;         641 AA.
AC   Q61696; Q61697; Q7TQD8; Q9QWJ5;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   21-DEC-2004, sequence version 2.
DT   04-MAR-2015, entry version 121.
DE   RecName: Full=Heat shock 70 kDa protein 1A;
DE   AltName: Full=Heat shock 70 kDa protein 3;
DE            Short=HSP70.3;
DE   AltName: Full=Hsp68;
GN   Name=Hspa1a; Synonyms=Hsp70-3, Hsp70A1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Liver;
RX   PubMed=8076831; DOI=10.1016/0378-1119(94)90305-0;
RA   Perry M.D., Aujame L., Shtang S., Moran L.A.;
RT   "Structure and expression of an inducible HSP70-encoding gene from Mus
RT   musculus.";
RL   Gene 146:273-278(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=129;
RX   PubMed=14656967; DOI=10.1101/gr.1736803;
RA   Xie T., Rowen L., Aguado B., Ahearn M.E., Madan A., Qin S.,
RA   Campbell R.D., Hood L.;
RT   "Analysis of the gene-dense major histocompatibility complex class III
RT   region and its comparison to mouse.";
RL   Genome Res. 13:2621-2636(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 26-49 AND 103-112, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   STRAIN=C57BL/6; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (APR-2007) to UniProtKB.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 221-641.
RX   PubMed=2868009;
RA   Lowe D.G., Moran L.A.;
RT   "Molecular cloning and analysis of DNA complementary to three mouse Mr
RT   = 68,000 heat shock protein mRNAs.";
RL   J. Biol. Chem. 261:2102-2112(1986).
RN   [6]
RP   INTERACTION WITH DNAAF2.
RX   PubMed=19052621; DOI=10.1038/nature07471;
RA   Omran H., Kobayashi D., Olbrich H., Tsukahara T., Loges N.T.,
RA   Hagiwara H., Zhang Q., Leblond G., O'Toole E., Hara C., Mizuno H.,
RA   Kawano H., Fliegauf M., Yagi T., Koshida S., Miyawaki A., Zentgraf H.,
RA   Seithe H., Reinhardt R., Watanabe Y., Kamiya R., Mitchell D.R.,
RA   Takeda H.;
RT   "Ktu/PF13 is required for cytoplasmic pre-assembly of axonemal
RT   dyneins.";
RL   Nature 456:611-616(2008).
RN   [7]
RP   INTERACTION WITH FOXP3.
RX   PubMed=23973223; DOI=10.1016/j.immuni.2013.08.006;
RA   Chen Z., Barbi J., Bu S., Yang H.Y., Li Z., Gao Y., Jinasena D.,
RA   Fu J., Lin F., Chen C., Zhang J., Yu N., Li X., Shan Z., Nie J.,
RA   Gao Z., Tian H., Li Y., Yao Z., Zheng Y., Park B.V., Pan Z., Zhang J.,
RA   Dang E., Li Z., Wang H., Luo W., Li L., Semenza G.L., Zheng S.G.,
RA   Loser K., Tsun A., Greene M.I., Pardoll D.M., Pan F., Li B.;
RT   "The ubiquitin ligase Stub1 negatively modulates regulatory T cell
RT   suppressive activity by promoting degradation of the transcription
RT   factor Foxp3.";
RL   Immunity 39:272-285(2013).
CC   -!- FUNCTION: In cooperation with other chaperones, Hsp70s stabilize
CC       preexistent proteins against aggregation and mediate the folding
CC       of newly translated polypeptides in the cytosol as well as within
CC       organelles. These chaperones participate in all these processes
CC       through their ability to recognize nonnative conformations of
CC       other proteins. They bind extended peptide segments with a net
CC       hydrophobic character exposed by polypeptides during translation
CC       and membrane translocation, or following stress-induced damage.
CC       Essential for STUB1-mediated ubiquitination and degradation of
CC       FOXP3 in regulatory T-cells (Treg) during inflammation.
CC       {ECO:0000250|UniProtKB:P08107}.
CC   -!- SUBUNIT: Identified in a IGF2BP1-dependent mRNP granule complex
CC       containing untranslated mRNAs. Interacts with IRAK1BP1 and TSC2.
CC       Interacts with TERT; the interaction occurs in the absence of the
CC       RNA component, TERC, and dissociates once the TERT complex has
CC       formed. Interacts with DNAAF2 (PubMed:19052621). Interacts with
CC       TRIM5 (via B30.2/SPRY domain). Interacts with FOXP3
CC       (PubMed:23973223).Interacts with NOD2; the interaction enhances
CC       NOD2 stability (By similarity). {ECO:0000250|UniProtKB:P08107,
CC       ECO:0000269|PubMed:19052621, ECO:0000269|PubMed:23973223}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Note=Localized in
CC       cytoplasmic mRNP granules containing untranslated mRNAs.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the heat shock protein 70 family.
CC       {ECO:0000305}.
DR   EMBL; M76613; AAA57233.1; -; Genomic_DNA.
DR   EMBL; AF109906; AAC84169.1; -; Genomic_DNA.
DR   EMBL; BC054782; AAH54782.1; -; mRNA.
DR   EMBL; M12571; AAA57234.1; -; mRNA.
DR   EMBL; M12572; AAA57235.1; -; mRNA.
DR   CCDS; CCDS50080.1; -.
DR   PIR; A26283; A26283.
DR   RefSeq; NP_034609.2; NM_010479.2.
DR   UniGene; Mm.6388; -.
DR   ProteinModelPortal; Q61696; -.
DR   SMR; Q61696; 1-613.
DR   BioGrid; 228756; 1.
DR   IntAct; Q61696; 3.
DR   MINT; MINT-1866478; -.
DR   PhosphoSite; Q61696; -.
DR   REPRODUCTION-2DPAGE; Q61696; -.
DR   MaxQB; Q61696; -.
DR   PaxDb; Q61696; -.
DR   PRIDE; Q61696; -.
DR   Ensembl; ENSMUST00000087328; ENSMUSP00000084586; ENSMUSG00000091971.
DR   GeneID; 193740; -.
DR   KEGG; mmu:193740; -.
DR   UCSC; uc008cep.1; mouse.
DR   CTD; 3303; -.
DR   MGI; MGI:96244; Hspa1a.
DR   eggNOG; COG0443; -.
DR   GeneTree; ENSGT00750000117237; -.
DR   HOGENOM; HOG000228135; -.
DR   HOVERGEN; HBG051845; -.
DR   InParanoid; Q61696; -.
DR   KO; K03283; -.
DR   OMA; MAKSTAI; -.
DR   OrthoDB; EOG7PCJGF; -.
DR   PhylomeDB; Q61696; -.
DR   TreeFam; TF105042; -.
DR   Reactome; REACT_272921; Regulation of HSF1-mediated heat shock response.
DR   Reactome; REACT_278474; Attenuation phase.
DR   Reactome; REACT_278878; AUF1 (hnRNP D0) destabilizes mRNA.
DR   Reactome; REACT_288168; HSF1-dependent transactivation.
DR   NextBio; 371508; -.
DR   PRO; PR:Q61696; -.
DR   Proteomes; UP000000589; Chromosome 17.
DR   Bgee; Q61696; -.
DR   CleanEx; MM_HSPA1A; -.
DR   ExpressionAtlas; Q61696; baseline and differential.
DR   Genevestigator; Q61696; -.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0006402; P:mRNA catabolic process; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0006986; P:response to unfolded protein; ISS:UniProtKB.
DR   Gene3D; 1.20.1270.10; -; 1.
DR   Gene3D; 2.60.34.10; -; 1.
DR   InterPro; IPR018181; Heat_shock_70_CS.
DR   InterPro; IPR029048; HSP70_C.
DR   InterPro; IPR029047; HSP70_peptide-bd.
DR   InterPro; IPR013126; Hsp_70_fam.
DR   Pfam; PF00012; HSP70; 1.
DR   PRINTS; PR00301; HEATSHOCK70.
DR   SUPFAM; SSF100920; SSF100920; 1.
DR   SUPFAM; SSF100934; SSF100934; 1.
DR   PROSITE; PS00297; HSP70_1; 1.
DR   PROSITE; PS00329; HSP70_2; 1.
DR   PROSITE; PS01036; HSP70_3; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ATP-binding; Chaperone; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Methylation; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Stress response.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P08107}.
FT   CHAIN         2    641       Heat shock 70 kDa protein 1A.
FT                                /FTId=PRO_0000078250.
FT   NP_BIND      12     15       ATP. {ECO:0000250}.
FT   NP_BIND     202    204       ATP. {ECO:0000250}.
FT   NP_BIND     268    275       ATP. {ECO:0000250}.
FT   NP_BIND     339    342       ATP. {ECO:0000250}.
FT   BINDING      71     71       ATP. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     108    108       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     246    246       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     348    348       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     561    561       N6,N6,N6-trimethyllysine; by METTL21A.
FT                                {ECO:0000250}.
FT   MOD_RES     631    631       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     633    633       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     636    636       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   CONFLICT    221    225       ATAGD -> TDGRT (in Ref. 5; AAA57234).
FT                                {ECO:0000305}.
FT   CONFLICT    229    229       G -> E (in Ref. 5; AAA57234).
FT                                {ECO:0000305}.
FT   CONFLICT    233    233       F -> V (in Ref. 5; AAA57234).
FT                                {ECO:0000305}.
FT   CONFLICT    238    244       VSHFVEE -> EDLREQ (in Ref. 5; AAA57234).
FT                                {ECO:0000305}.
FT   CONFLICT    295    295       T -> R (in Ref. 5; AAA57234).
FT                                {ECO:0000305}.
FT   CONFLICT    332    332       H -> Q (in Ref. 5; AAA57234).
FT                                {ECO:0000305}.
FT   CONFLICT    342    342       R -> A (in Ref. 1; AAA57233).
FT                                {ECO:0000305}.
FT   CONFLICT    409    409       V -> G (in Ref. 5; AAA57235).
FT                                {ECO:0000305}.
FT   CONFLICT    413    416       LIKR -> RHQA (in Ref. 5; AAA57234/
FT                                AAA57235). {ECO:0000305}.
FT   CONFLICT    494    494       S -> T (in Ref. 3; AAH54782).
FT                                {ECO:0000305}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:P08107; BAP; 03-FEB-2015.
**EV ECO:0000269; PubMed:19052621; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:23973223; SHS; 21-JAN-2015.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**SO UPD; 20141; 17-APR-2007.
**ZB MAM, 09-MAY-2007; SYP, 04-FEB-2009; ANN, 26-MAR-2009; ANN, 08-APR-2009;
**ZB ANS, 07-OCT-2009; JAJ, 22-DEC-2009; ISC, 14-JUN-2011; SHS, 11-DEC-2012;
**ZB ANN, 06-JUN-2013; SHS, 30-JAN-2015; BAP, 27-FEB-2015;
SQ   SEQUENCE   641 AA;  70079 MW;  F49C33E602EAE334 CRC64;
     MAKNTAIGID LGTTYSCVGV FQHGKVEIIA NDQGNRTTPS YVAFTDTERL IGDAAKNQVA
     LNPQNTVFDA KRLIGRKFGD AVVQSDMKHW PFQVVNDGDK PKVQVNYKGE SRSFFPEEIS
     SMVLTKMKEI AEAYLGHPVT NAVITVPAYF NDSQRQATKD AGVIAGLNVL RIINEPTAAA
     IAYGLDRTGK GERNVLIFDL GGGTFDVSIL TIDDGIFEVK ATAGDTHLGG EDFDNRLVSH
     FVEEFKRKHK KDISQNKRAV RRLRTACERA KRTLSSSTQA SLEIDSLFEG IDFYTSITRA
     RFEELCSDLF RGTLEPVEKA LRDAKMDKAQ IHDLVLVGGS TRIPKVQKLL QDFFNGRDLN
     KSINPDEAVA YGAAVQAAIL MGDKSENVQD LLLLDVAPLS LGLETAGGVM TALIKRNSTI
     PTKQTQTFTT YSDNQPGVLI QVYEGERAMT RDNNLLGRFE LSGIPPAPRG VPQIEVTFDI
     DANGILNVTA TDKSTGKANK ITITNDKGRL SKEEIERMVQ EAERYKAEDE VQRDRVAAKN
     ALESYAFNMK SAVEDEGLKG KLSEADKKKV LDKCQEVISW LDSNTLADKE EFVHKREELE
     RVCSPIISGL YQGAGAPGAG GFGAQAPKGA SGSGPTIEEV D
//
ID   HS71A_PIG               Reviewed;         641 AA.
AC   P34930;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   04-MAR-2015, entry version 72.
DE   RecName: Full=Heat shock 70 kDa protein 1A;
DE   AltName: Full=Heat shock 70 kDa protein 1;
DE            Short=HSP70.1;
GN   Name=HSPA1A; Synonyms=HSPA1;
OS   Sus scrofa (Pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
OC   Sus.
OX   NCBI_TaxID=9823;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1339404; DOI=10.1007/BF00166836;
RA   Peelman L.J., de Weghe A.R., Coppieters W.R., van Zeveren A.J.,
RA   Bouquet Y.H.;
RT   "Complete nucleotide sequence of a porcine HSP70 gene.";
RL   Immunogenetics 35:286-289(1992).
CC   -!- FUNCTION: In cooperation with other chaperones, Hsp70s stabilize
CC       preexistent proteins against aggregation and mediate the folding
CC       of newly translated polypeptides in the cytosol as well as within
CC       organelles. These chaperones participate in all these processes
CC       through their ability to recognize nonnative conformations of
CC       other proteins. They bind extended peptide segments with a net
CC       hydrophobic character exposed by polypeptides during translation
CC       and membrane translocation, or following stress-induced damage.
CC       Essential for STUB1-mediated ubiquitination and degradation of
CC       FOXP3 in regulatory T-cells (Treg) during inflammation.
CC       {ECO:0000250|UniProtKB:P08107}.
CC   -!- SUBUNIT: Identified in a IGF2BP1-dependent mRNP granule complex
CC       containing untranslated mRNAs. Interacts with IRAK1BP1, DNAAF2 and
CC       TSC2. Interacts with TERT; the interaction occurs in the absence
CC       of the RNA component, TERC, and dissociates once the TERT complex
CC       has formed. Interacts with TRIM5 (via B30.2/SPRY domain).
CC       Interacts with FOXP3. Interacts with NOD2; the interaction
CC       enhances NOD2 stability (By similarity).
CC       {ECO:0000250|UniProtKB:P08107}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Note=Localized in
CC       cytoplasmic mRNP granules containing untranslated mRNAs.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the heat shock protein 70 family.
CC       {ECO:0000305}.
DR   EMBL; M69100; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   PIR; S35718; S35718.
DR   ProteinModelPortal; P34930; -.
DR   SMR; P34930; 1-621.
DR   IntAct; P34930; 2.
DR   MINT; MINT-7384270; -.
DR   PRIDE; P34930; -.
DR   HOVERGEN; HBG051845; -.
DR   InParanoid; P34930; -.
DR   PRO; PR:P34930; -.
DR   Proteomes; UP000008227; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.1270.10; -; 1.
DR   Gene3D; 2.60.34.10; -; 1.
DR   InterPro; IPR018181; Heat_shock_70_CS.
DR   InterPro; IPR029048; HSP70_C.
DR   InterPro; IPR029047; HSP70_peptide-bd.
DR   InterPro; IPR013126; Hsp_70_fam.
DR   Pfam; PF00012; HSP70; 1.
DR   PRINTS; PR00301; HEATSHOCK70.
DR   SUPFAM; SSF100920; SSF100920; 1.
DR   SUPFAM; SSF100934; SSF100934; 1.
DR   PROSITE; PS00297; HSP70_1; 1.
DR   PROSITE; PS00329; HSP70_2; 1.
DR   PROSITE; PS01036; HSP70_3; 1.
PE   3: Inferred from homology;
KW   Acetylation; ATP-binding; Chaperone; Complete proteome; Cytoplasm;
KW   Methylation; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Stress response.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P08107}.
FT   CHAIN         2    641       Heat shock 70 kDa protein 1A.
FT                                /FTId=PRO_0000078252.
FT   NP_BIND      12     15       ATP. {ECO:0000250}.
FT   NP_BIND     202    204       ATP. {ECO:0000250}.
FT   NP_BIND     268    275       ATP. {ECO:0000250}.
FT   NP_BIND     339    342       ATP. {ECO:0000250}.
FT   BINDING      71     71       ATP. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     108    108       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     246    246       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     348    348       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     561    561       N6,N6,N6-trimethyllysine; by METTL21A.
FT                                {ECO:0000250}.
FT   MOD_RES     631    631       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     633    633       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     636    636       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P08107}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:P08107; SHS; 21-JAN-2015.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**ZB SYP, 04-FEB-2009; ANN, 26-MAR-2009; ANN, 08-APR-2009; ANS, 07-OCT-2009;
**ZB JAJ, 22-DEC-2009; ISC, 14-JUN-2011; ELS, 11-APR-2012; SHS, 11-DEC-2012;
**ZB ANN, 06-JUN-2013; SHS, 30-JAN-2015; BAP, 27-FEB-2015;
SQ   SEQUENCE   641 AA;  70083 MW;  FE77BB20A03E0A33 CRC64;
     MAKSVAIGID LGTTYSCVGV FQHGKVEIIA NDQGNRTTPS SVAFTDTERL IGDAAKNQVA
     LNPQNTVFDA KRLIGRKFGD PVVQGDMKHW PFRVINDGDK PKVQVSYKGE TKGFYPEEIS
     SMVLTKMKEI AEGYLGHPVS NAVITVPAYF NDSQRQATKD AGVIAGLNVL RIINEPTAAA
     IAYGLDRTGK GERNVLIFDL GGGTFDVSIL TIDDGIFEVK ATAGDTHLGG EDFDNRLVNH
     FVEEFKRKHK KDYSQNKRAV RRLRTACERA KRTLSSSTQA SLEIDSLFEG IDFYTSITRA
     RFEELCSDLF RSTLEPVEKA LRDAKLDKAQ IHDLVLVGGS TRIPKVQKLL QDFFNGRDLN
     KSINPDEAVA YGAAVQAAIL MGDKSENVQD LLLLDVAPLS LGLETAGGVM TALIKRNSTI
     PTKQTQIFTT YSDNQPGVLI QVYEGERAMT RDNNLLGRFE LSGIPPAPRG VPQIEVTFDI
     DANGILNVTA TDKSTGKANK ITITNDKGRL SKEEIERMVQ EAEKYKAEDE IQRERVGAKN
     ALESYAFNMK SVVEDEGLKG KISEADKKKV LDKCQEVISW LDANTLAEKD EFEHKRKELE
     QVCNPIISGL YQGAGGPGPG GFGAPDLKGG SGSGPTIEEV D
//
ID   HSP71_RAT               Reviewed;         641 AA.
AC   Q07439; P42853; Q63256;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   23-NOV-2004, sequence version 2.
DT   04-MAR-2015, entry version 121.
DE   RecName: Full=Heat shock 70 kDa protein 1A/1B;
DE   AltName: Full=Heat shock 70 kDa protein 1/2;
DE            Short=HSP70-1/HSP70-2;
DE            Short=HSP70.1/HSP70.2;
GN   Name=Hspa1a; Synonyms=Hsp70-1, Hspa1;
GN   and
GN   Name=Hspa1b; Synonyms=Hsp70-2, Hspa2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=8271311; DOI=10.1002/jnr.490360310;
RA   Longo F.M., Wang S., Narasimhan P., Zhang J.S., Chen J., Massa S.M.,
RA   Sharp F.R.;
RT   "cDNA cloning and expression of stress-inducible rat hsp70 in normal
RT   and injured rat brain.";
RL   J. Neurosci. Res. 36:325-335(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=LEW.1W/GUN;
RX   PubMed=7927536; DOI=10.1007/BF01246673;
RA   Walter L., Rauh F., Guenther E.;
RT   "Comparative analysis of the three major histocompatibility complex-
RT   linked heat shock protein 70 (Hsp70) genes of the rat.";
RL   Immunogenetics 40:325-330(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=8086479; DOI=10.1016/0167-4781(94)90247-X;
RA   Lisowska K., Krawczyk Z., Widlak W., Wolniczek P., Wisniewski J.;
RT   "Cloning, nucleotide sequence and expression of rat heat inducible
RT   hsp70 gene.";
RL   Biochim. Biophys. Acta 1219:64-72(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Wistar; TISSUE=Spleen;
RX   PubMed=8141767;
RA   Mestril R., Chi S.H., Sayen M.R., Dillmann W.H.;
RT   "Isolation of a novel inducible rat heat shock protein (HSP70) gene
RT   and its expression during ischaemia/hypoxia and heat shock.";
RL   Biochem. J. 298:561-569(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15060004; DOI=10.1101/gr.1987704;
RA   Hurt P., Walter L., Sudbrak R., Klages S., Mueller I., Shiina T.,
RA   Inoko H., Lehrach H., Guenther E., Reinhardt R., Himmelbauer H.;
RT   "The genomic sequence and comparative analysis of the rat major
RT   histocompatibility complex.";
RL   Genome Res. 14:631-639(2004).
CC   -!- FUNCTION: In cooperation with other chaperones, Hsp70s stabilize
CC       preexistent proteins against aggregation and mediate the folding
CC       of newly translated polypeptides in the cytosol as well as within
CC       organelles. These chaperones participate in all these processes
CC       through their ability to recognize nonnative conformations of
CC       other proteins. They bind extended peptide segments with a net
CC       hydrophobic character exposed by polypeptides during translation
CC       and membrane translocation, or following stress-induced damage.
CC       Essential for STUB1-mediated ubiquitination and degradation of
CC       FOXP3 in regulatory T-cells (Treg) during inflammation.
CC       {ECO:0000250|UniProtKB:P08107}.
CC   -!- SUBUNIT: Component of the CatSper complex. Identified in a
CC       IGF2BP1-dependent mRNP granule complex containing untranslated
CC       mRNAs. Interacts with CHCHD3, DNAJC7, IRAK1BP1, PPP5C and TSC2.
CC       Interacts with TERT; the interaction occurs in the absence of the
CC       RNA component, TERC, and dissociates once the TERT complex has
CC       formed. Interacts with TRIM5 (via B30.2/SPRY domain). Interacts
CC       with PARK2. Interacts with FOXP3. Interacts with NOD2; the
CC       interaction enhances NOD2 stability (By similarity).
CC       {ECO:0000250|UniProtKB:P08107}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Note=Localized in
CC       cytoplasmic mRNP granules containing untranslated mRNAs.
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: HSPA1B is testis-specific.
CC   -!- INDUCTION: By heat shock.
CC   -!- SIMILARITY: Belongs to the heat shock protein 70 family.
CC       {ECO:0000305}.
DR   EMBL; L16764; AAA17441.1; -; mRNA.
DR   EMBL; X77208; CAA54423.1; -; Genomic_DNA.
DR   EMBL; X77207; CAA54422.1; -; Genomic_DNA.
DR   EMBL; X74271; CAA52328.1; -; Genomic_DNA.
DR   EMBL; X75357; CAA53140.1; -; Genomic_DNA.
DR   EMBL; BX883045; CAE83977.1; -; Genomic_DNA.
DR   EMBL; BX883045; CAE83978.1; -; Genomic_DNA.
DR   PIR; I54542; I54542.
DR   RefSeq; NP_114177.2; NM_031971.2.
DR   RefSeq; NP_997669.1; NM_212504.1.
DR   UniGene; Rn.1950; -.
DR   UniGene; Rn.228581; -.
DR   ProteinModelPortal; Q07439; -.
DR   SMR; Q07439; 1-619.
DR   BioGrid; 246633; 3.
DR   IntAct; Q07439; 1.
DR   MINT; MINT-240978; -.
DR   STRING; 10116.ENSRNOP00000050605; -.
DR   PhosphoSite; Q07439; -.
DR   PaxDb; Q07439; -.
DR   PRIDE; Q07439; -.
DR   Ensembl; ENSRNOT00000049667; ENSRNOP00000050605; ENSRNOG00000045654.
DR   Ensembl; ENSRNOT00000061950; ENSRNOP00000067749; ENSRNOG00000050647.
DR   GeneID; 24472; -.
DR   GeneID; 294254; -.
DR   KEGG; rno:24472; -.
DR   KEGG; rno:294254; -.
DR   CTD; 3303; -.
DR   CTD; 3304; -.
DR   RGD; 1593284; Hspa1a.
DR   RGD; 2840; Hspa1b.
DR   eggNOG; COG0443; -.
DR   GeneTree; ENSGT00750000117237; -.
DR   HOGENOM; HOG000228135; -.
DR   HOVERGEN; HBG051845; -.
DR   InParanoid; Q07439; -.
DR   KO; K03283; -.
DR   OMA; NANAEVE; -.
DR   OrthoDB; EOG7PCJGF; -.
DR   PhylomeDB; Q07439; -.
DR   Reactome; REACT_299983; Regulation of HSF1-mediated heat shock response.
DR   Reactome; REACT_319204; HSF1-dependent transactivation.
DR   Reactome; REACT_327685; Attenuation phase.
DR   Reactome; REACT_338477; AUF1 (hnRNP D0) destabilizes mRNA.
DR   NextBio; 603417; -.
DR   PRO; PR:Q07439; -.
DR   Proteomes; UP000002494; Chromosome 20.
DR   Genevestigator; Q07439; -.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:RGD.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:RGD.
DR   GO; GO:0016607; C:nuclear speck; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0051059; F:NF-kappaB binding; IPI:RGD.
DR   GO; GO:0002020; F:protease binding; IPI:RGD.
DR   GO; GO:0006952; P:defense response; IDA:RGD.
DR   GO; GO:0006402; P:mRNA catabolic process; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:RGD.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:RGD.
DR   GO; GO:0045906; P:negative regulation of vasoconstriction; IMP:RGD.
DR   GO; GO:0030182; P:neuron differentiation; IEP:RGD.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IMP:RGD.
DR   GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IDA:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0002931; P:response to ischemia; IEP:RGD.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEP:RGD.
DR   GO; GO:0009314; P:response to radiation; IEP:RGD.
DR   GO; GO:0006986; P:response to unfolded protein; ISS:UniProtKB.
DR   Gene3D; 1.20.1270.10; -; 1.
DR   Gene3D; 2.60.34.10; -; 1.
DR   InterPro; IPR018181; Heat_shock_70_CS.
DR   InterPro; IPR029048; HSP70_C.
DR   InterPro; IPR029047; HSP70_peptide-bd.
DR   InterPro; IPR013126; Hsp_70_fam.
DR   Pfam; PF00012; HSP70; 1.
DR   PRINTS; PR00301; HEATSHOCK70.
DR   SUPFAM; SSF100920; SSF100920; 1.
DR   SUPFAM; SSF100934; SSF100934; 1.
DR   PROSITE; PS00297; HSP70_1; 1.
DR   PROSITE; PS00329; HSP70_2; 1.
DR   PROSITE; PS01036; HSP70_3; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; ATP-binding; Chaperone; Complete proteome; Cytoplasm;
KW   Methylation; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Stress response.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P08107}.
FT   CHAIN         2    641       Heat shock 70 kDa protein 1A/1B.
FT                                /FTId=PRO_0000078254.
FT   NP_BIND      12     15       ATP. {ECO:0000250}.
FT   NP_BIND     202    204       ATP. {ECO:0000250}.
FT   NP_BIND     268    275       ATP. {ECO:0000250}.
FT   NP_BIND     339    342       ATP. {ECO:0000250}.
FT   BINDING      71     71       ATP. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     108    108       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     246    246       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     348    348       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     561    561       N6,N6,N6-trimethyllysine; by METTL21A.
FT                                {ECO:0000250}.
FT   MOD_RES     631    631       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     633    633       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   MOD_RES     636    636       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P08107}.
FT   CONFLICT     71     72       KR -> NG (in Ref. 3; CAA52328 and 4;
FT                                CAA53140). {ECO:0000305}.
FT   CONFLICT    110    110       E -> K (in Ref. 4; CAA53140).
FT                                {ECO:0000305}.
FT   CONFLICT    204    204       T -> R (in Ref. 4; CAA53140).
FT                                {ECO:0000305}.
FT   CONFLICT    227    227       H -> D (in Ref. 1; AAA17441).
FT                                {ECO:0000305}.
FT   CONFLICT    262    267       RLRTAC -> PLADGV (in Ref. 4; CAA53140).
FT                                {ECO:0000305}.
FT   CONFLICT    408    408       G -> A (in Ref. 3; CAA52328).
FT                                {ECO:0000305}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:P08107; SHS; 21-JAN-2015.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**ZB LYG, 07-NOV-2006; LYG, 06-DEC-2006; SYP, 25-JUN-2007; ALG/LYG, 30-JUL-2007;
**ZB LYG, 20-NOV-2007; WMC, 27-MAR-2008; ALG/LYG, 19-OCT-2008; SYP, 04-FEB-2009;
**ZB ANN, 26-MAR-2009; ANN, 08-APR-2009; ALG/EMB, 17-SEP-2009; ANS, 07-OCT-2009;
**ZB MIM, 12-OCT-2009; ALB/EMB, 16-OCT-2009; JAJ, 22-DEC-2009; ANN, 14-MAR-2011;
**ZB ISC, 14-JUN-2011; SYP, 09-MAR-2012; SHS, 11-DEC-2012; ANN, 06-JUN-2013;
**ZB CRC/LIB, 27-AUG-2013; ANN, 20-MAR-2014; SHS, 30-JAN-2015; BAP, 27-FEB-2015;
SQ   SEQUENCE   641 AA;  70185 MW;  2D745B1013F64E7B CRC64;
     MAKKTAIGID LGTTYSCVGV FQHGKVEIIA NDQGNRTTPS YVAFTDTERL IGDAAKNQVA
     LNPQNTVFDA KRLIGRKFGD PVVQSDMKHW PFQVVNDGDK PKVQVNYKGE NRSFYPEEIS
     SMVLTKMKEI AEAYLGHPVT NAVITVPAYF NDSQRQATKD AGVIAGLNVL RIINEPTAAA
     IAYGLDRTGK GERNVLIFDL GGGTFDVSIL TIDDGIFEVK ATAGDTHLGG EDFDNRLVSH
     FVEEFKRKHK KDISQNKRAV RRLRTACERA KRTLSSSTQA SLEIDSLFEG IDFYTSITRA
     RFEELCSDLF RGTLEPVEKA LRDAKLDKAQ IHDLVLVGGS TRIPKVQKLL QDFFNGRDLN
     KSINPDEAVA YGAAVQAAIL MGDKSENVQD LLLLDVAPLS LGLETAGGVM TALIKRNSTI
     PTKQTQTFTT YSDNQPGVLI QVYEGERAMT RDNNLLGRFE LSGIPPAPRG VPQIEVTFDI
     DANGILNVTA TDKSTGKANK ITITNDKGRL SKEEIERMVQ EAERYKAEDE VQRERVAAKN
     ALESYAFNMK SAVEDEGLKG KISEADKKKV LDKCQEVISW LDSNTLAEKE EFVHKREELE
     RVCNPIISGL YQGAGAPGAG GFGAQAPKGG SGSGPTIEEV D
//
ID   LAP2_HUMAN              Reviewed;        1412 AA.
AC   Q96RT1; A0AVR1; B4E3F1; B7ZLV9; E7EQW9; E9PCR8; Q1RMD0; Q86W38;
AC   Q9NR18; Q9NW48; Q9ULJ5;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   04-MAR-2015, entry version 140.
DE   RecName: Full=Protein LAP2;
DE   AltName: Full=Densin-180-like protein;
DE   AltName: Full=Erbb2-interacting protein;
DE            Short=Erbin;
GN   Name=ERBB2IP; Synonyms=ERBIN, KIAA1225, LAP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), INTERACTION WITH ERBB2, TISSUE
RP   SPECIFICITY, SUBCELLULAR LOCATION, AND FUNCTION.
RC   TISSUE=B-cell;
RX   PubMed=10878805; DOI=10.1038/35017038;
RA   Borg J.-P., Marchetto S., Le Bivic A., Ollendorff V.,
RA   Jaulin-Bastard F., Saito H., Fournier E., Adelaide J., Margolis B.,
RA   Birnbaum D.;
RT   "ERBIN: a basolateral PDZ protein that interacts with the mammalian
RT   ERBB2/HER2 receptor.";
RL   Nat. Cell Biol. 2:407-414(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5; 6 AND 7),
RP   INTERACTION WITH BPAG1; DST AND ITGB4, SUBCELLULAR LOCATION, AND
RP   VARIANT GLU-1207.
RX   PubMed=11375975; DOI=10.1074/jbc.M011005200;
RA   Favre B., Fontao L., Koster J., Shafaatian R., Jaunin F.,
RA   Saurat J.-H., Sonnenberg A., Borradori L.;
RT   "The hemidesmosomal protein bullous pemphigoid antigen 1 and the
RT   integrin beta 4 subunit bind to ERBIN. Molecular cloning of multiple
RT   alternative splice variants of ERBIN and analysis of their tissue
RT   expression.";
RL   J. Biol. Chem. 276:32427-32436(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10574462; DOI=10.1093/dnares/6.5.337;
RA   Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XV.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:337-345(1999).
RN   [4]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 601-1206 (ISOFORM 1).
RC   TISSUE=Teratocarcinoma, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 8 AND 9), AND
RP   VARIANTS LEU-274 AND VAL-313.
RC   TISSUE=Cerebellum, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH DELTA CATENIN AND ARVCF.
RX   PubMed=11821434; DOI=10.1074/jbc.M200818200;
RA   Laura R.P., Witt A.S., Held H.A., Gerstner R., Deshayes K.,
RA   Koehler M.F.T., Kosik K.S., Sidhu S.S., Lasky L.A.;
RT   "The Erbin PDZ domain binds with high affinity and specificity to the
RT   carboxyl termini of delta-catenin and ARVCF.";
RL   J. Biol. Chem. 277:12906-12914(2002).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-920, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [10]
RP   FUNCTION, INTERACTION WITH NOD2, SUBCELLULAR LOCATION, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16203728; DOI=10.1074/jbc.M508538200;
RA   McDonald C., Chen F.F., Ollendorff V., Ogura Y., Marchetto S.,
RA   Lecine P., Borg J.P., Nunez G.;
RT   "A role for Erbin in the regulation of Nod2-dependent NF-kappaB
RT   signaling.";
RL   J. Biol. Chem. 280:40301-40309(2005).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-972, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-440, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569; SER-857; THR-917
RP   AND SER-1286, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-872; THR-917; SER-931
RP   AND SER-1158, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-569; SER-602 AND
RP   SER-603, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-485 AND SER-852, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 1321-1412 IN COMPLEX WITH
RP   ERBB2 C-TERMINUS.
RX   PubMed=12444095; DOI=10.1074/jbc.C200571200;
RA   Birrane G., Chung J., Ladias J.A.;
RT   "Novel mode of ligand recognition by the Erbin PDZ domain.";
RL   J. Biol. Chem. 278:1399-1402(2003).
RN   [20]
RP   STRUCTURE BY NMR OF 1314-1412 IN COMPLEX WITH PHAGE-DERIVED PEPTIDE.
RX   PubMed=12446668; DOI=10.1074/jbc.M209751200;
RA   Skelton N.J., Koehler M.F.T., Zobel K., Wong W.L., Yeh S.,
RA   Pisabarro M.T., Yin J.P., Lasky L.A., Sidhu S.S.;
RT   "Origins of PDZ domain ligand specificity. Structure determination and
RT   mutagenesis of the Erbin PDZ domain.";
RL   J. Biol. Chem. 278:7645-7654(2003).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.0 ANGSTROMS) OF 1314-1412.
RX   PubMed=16737969; DOI=10.1074/jbc.M602901200;
RA   Appleton B.A., Zhang Y., Wu P., Yin J.P., Hunziker W., Skelton N.J.,
RA   Sidhu S.S., Wiesmann C.;
RT   "Comparative structural analysis of the erbin PDZ domain and the first
RT   PDZ domain of ZO-1. Insights into determinants of PDZ domain
RT   specificity.";
RL   J. Biol. Chem. 281:22312-22320(2006).
CC   -!- FUNCTION: Acts as an adapter for the receptor ERBB2, in epithelia.
CC       By binding the unphosphorylated 'Tyr-1248' of receptor ERBB2, it
CC       may contribute to stabilize this unphosphorylated state. Inhibits
CC       NOD2-dependent NF-kappa-B signaling and proinflammatory cytokine
CC       secretion (PubMed:16203728). {ECO:0000269|PubMed:10878805,
CC       ECO:0000269|PubMed:16203728}.
CC   -!- SUBUNIT: Interacts with ERBB2, BPAG1 and ITGB4 (PubMed:10878805,
CC       PubMed:11375975, PubMed:12444095). May favor the localization of
CC       ERBB2, by restricting its presence to the basolateral membrane of
CC       epithelial cells. Also found to interact with ARVCF and delta
CC       catenin (PubMed:11821434). Interacts (via C-terminus) with DST
CC       Isoform 3 (via N-terminus) (PubMed:11375975). Interacts with NOD2
CC       (via CARD domain) (PubMed:16203728). {ECO:0000269|PubMed:10878805,
CC       ECO:0000269|PubMed:11375975, ECO:0000269|PubMed:11821434,
CC       ECO:0000269|PubMed:12444095, ECO:0000269|PubMed:12446668,
CC       ECO:0000269|PubMed:16203728}.
CC   -!- INTERACTION:
CC       Q99569:PKP4; NbExp=3; IntAct=EBI-993903, EBI-726447;
CC   -!- SUBCELLULAR LOCATION: Cell junction, hemidesmosome
CC       {ECO:0000269|PubMed:10878805, ECO:0000269|PubMed:11375975}.
CC       Nucleus membrane {ECO:0000250}. Basolateral cell membrane
CC       {ECO:0000269|PubMed:16203728}. Note=Found in hemidesmosomes, which
CC       are cell-substrate adhesion complexes in stratified epithelia. In
CC       transfected cells, either diffusely distributed over the cytoplasm
CC       or concentrated at the basolateral membrane. Colocalizes with the
CC       adrenergic receptors, ADREN1A and ADREN1B, at the nuclear membrane
CC       of cardiac myocytes (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:16203728}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=9;
CC       Name=1;
CC         IsoId=Q96RT1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96RT1-2; Sequence=VSP_010802;
CC       Name=3;
CC         IsoId=Q96RT1-3; Sequence=VSP_010802, VSP_010804;
CC       Name=4;
CC         IsoId=Q96RT1-4; Sequence=VSP_010802, VSP_010807;
CC       Name=5;
CC         IsoId=Q96RT1-5; Sequence=VSP_010802, VSP_010803;
CC       Name=6;
CC         IsoId=Q96RT1-6; Sequence=VSP_010802, VSP_010806;
CC       Name=7;
CC         IsoId=Q96RT1-7; Sequence=VSP_010802, VSP_010803, VSP_010804,
CC                                  VSP_010805;
CC       Name=8;
CC         IsoId=Q96RT1-8; Sequence=VSP_044536;
CC         Note=No experimental confirmation available.;
CC       Name=9;
CC         IsoId=Q96RT1-9; Sequence=VSP_047389, VSP_010802;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, heart, kidney,
CC       muscle and stomach, followed by liver, spleen and intestine.
CC       {ECO:0000269|PubMed:10878805}.
CC   -!- SIMILARITY: Belongs to the LAP (LRR and PDZ) protein family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 17 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 PDZ (DHR) domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00143}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH50692.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=BAA91538.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
DR   EMBL; AF263744; AAF77048.1; -; mRNA.
DR   EMBL; AF276423; AAK69431.1; -; mRNA.
DR   EMBL; AB033051; BAA86539.2; -; mRNA.
DR   EMBL; AK001180; BAA91538.1; ALT_INIT; mRNA.
DR   EMBL; AK304693; BAG65463.1; -; mRNA.
DR   EMBL; AC010359; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025442; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC050692; AAH50692.1; ALT_SEQ; mRNA.
DR   EMBL; BC115012; AAI15013.1; -; mRNA.
DR   EMBL; BC126464; AAI26465.1; -; mRNA.
DR   EMBL; BC144075; AAI44076.1; -; mRNA.
DR   CCDS; CCDS34172.1; -. [Q96RT1-7]
DR   CCDS; CCDS3990.1; -. [Q96RT1-2]
DR   CCDS; CCDS58951.1; -. [Q96RT1-9]
DR   CCDS; CCDS58952.1; -. [Q96RT1-8]
DR   CCDS; CCDS58953.1; -. [Q96RT1-1]
DR   CCDS; CCDS58954.1; -. [Q96RT1-4]
DR   RefSeq; NP_001006600.1; NM_001006600.2. [Q96RT1-7]
DR   RefSeq; NP_001240626.1; NM_001253697.1. [Q96RT1-1]
DR   RefSeq; NP_001240627.1; NM_001253698.1. [Q96RT1-4]
DR   RefSeq; NP_001240628.1; NM_001253699.1. [Q96RT1-8]
DR   RefSeq; NP_001240630.1; NM_001253701.1. [Q96RT1-9]
DR   RefSeq; NP_061165.1; NM_018695.3. [Q96RT1-2]
DR   UniGene; Hs.591774; -.
DR   UniGene; Hs.597241; -.
DR   PDB; 1MFG; X-ray; 1.25 A; A=1321-1412.
DR   PDB; 1MFL; X-ray; 1.88 A; A=1321-1412.
DR   PDB; 1N7T; NMR; -; A=1314-1412.
DR   PDB; 2H3L; X-ray; 1.00 A; A/B=1314-1412.
DR   PDB; 2QBW; X-ray; 1.80 A; A=1330-1410.
DR   PDB; 3CH8; X-ray; 1.90 A; A=1330-1410.
DR   PDBsum; 1MFG; -.
DR   PDBsum; 1MFL; -.
DR   PDBsum; 1N7T; -.
DR   PDBsum; 2H3L; -.
DR   PDBsum; 2QBW; -.
DR   PDBsum; 3CH8; -.
DR   SMR; Q96RT1; 26-422, 1283-1412.
DR   BioGrid; 120997; 75.
DR   IntAct; Q96RT1; 14.
DR   MINT; MINT-199447; -.
DR   STRING; 9606.ENSP00000370330; -.
DR   PhosphoSite; Q96RT1; -.
DR   DMDM; 116242614; -.
DR   MaxQB; Q96RT1; -.
DR   PaxDb; Q96RT1; -.
DR   PRIDE; Q96RT1; -.
DR   Ensembl; ENST00000284037; ENSP00000284037; ENSG00000112851. [Q96RT1-1]
DR   Ensembl; ENST00000380935; ENSP00000370322; ENSG00000112851. [Q96RT1-7]
DR   Ensembl; ENST00000380938; ENSP00000370325; ENSG00000112851. [Q96RT1-4]
DR   Ensembl; ENST00000380943; ENSP00000370330; ENSG00000112851. [Q96RT1-2]
DR   Ensembl; ENST00000506030; ENSP00000426632; ENSG00000112851. [Q96RT1-8]
DR   Ensembl; ENST00000508515; ENSP00000422015; ENSG00000112851. [Q96RT1-7]
DR   Ensembl; ENST00000511297; ENSP00000422766; ENSG00000112851. [Q96RT1-9]
DR   GeneID; 55914; -.
DR   KEGG; hsa:55914; -.
DR   UCSC; uc003jui.2; human. [Q96RT1-2]
DR   UCSC; uc003juj.2; human. [Q96RT1-7]
DR   UCSC; uc003juk.2; human. [Q96RT1-1]
DR   UCSC; uc011cqy.2; human. [Q96RT1-4]
DR   CTD; 55914; -.
DR   GeneCards; GC05P065223; -.
DR   HGNC; HGNC:15842; ERBB2IP.
DR   HPA; HPA048606; -.
DR   HPA; HPA059863; -.
DR   MIM; 606944; gene.
DR   neXtProt; NX_Q96RT1; -.
DR   PharmGKB; PA27845; -.
DR   eggNOG; COG4886; -.
DR   GeneTree; ENSGT00780000121846; -.
DR   HOGENOM; HOG000060229; -.
DR   HOVERGEN; HBG052305; -.
DR   InParanoid; Q96RT1; -.
DR   KO; K12796; -.
DR   OMA; SDEEMKM; -.
DR   OrthoDB; EOG72C501; -.
DR   PhylomeDB; Q96RT1; -.
DR   TreeFam; TF351429; -.
DR   Reactome; REACT_115755; Signaling by ERBB2.
DR   SignaLink; Q96RT1; -.
DR   ChiTaRS; ERBB2IP; human.
DR   EvolutionaryTrace; Q96RT1; -.
DR   GeneWiki; Erbin_(protein); -.
DR   GenomeRNAi; 55914; -.
DR   NextBio; 61305; -.
DR   PRO; PR:Q96RT1; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; Q96RT1; -.
DR   CleanEx; HS_ERBB2IP; -.
DR   ExpressionAtlas; Q96RT1; baseline and differential.
DR   Genevestigator; Q96RT1; -.
DR   GO; GO:0009925; C:basal plasma membrane; NAS:UniProtKB.
DR   GO; GO:0005604; C:basement membrane; TAS:ProtInc.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030056; C:hemidesmosome; IDA:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005176; F:ErbB-2 class receptor binding; TAS:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; IPI:UniProtKB.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; NAS:UniProtKB.
DR   GO; GO:0045175; P:basal protein localization; NAS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; NAS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; NAS:UniProtKB.
DR   GO; GO:0016049; P:cell growth; NAS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0045197; P:establishment or maintenance of epithelial cell apical/basal polarity; NAS:UniProtKB.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; NAS:UniProtKB.
DR   GO; GO:0045104; P:intermediate filament cytoskeleton organization; NAS:UniProtKB.
DR   GO; GO:0006605; P:protein targeting; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 2.30.42.10; -; 1.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR025875; Leu-rich_rpt_4.
DR   InterPro; IPR001478; PDZ.
DR   Pfam; PF12799; LRR_4; 2.
DR   Pfam; PF13855; LRR_8; 2.
DR   Pfam; PF00595; PDZ; 1.
DR   SMART; SM00228; PDZ; 1.
DR   SUPFAM; SSF50156; SSF50156; 1.
DR   PROSITE; PS51450; LRR; 15.
DR   PROSITE; PS50106; PDZ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane;
KW   Complete proteome; Leucine-rich repeat; Membrane; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat.
FT   CHAIN         1   1412       Protein LAP2.
FT                                /FTId=PRO_0000188301.
FT   REPEAT       23     44       LRR 1.
FT   REPEAT       47     68       LRR 2.
FT   REPEAT       70     91       LRR 3.
FT   REPEAT       93    114       LRR 4.
FT   REPEAT      116    137       LRR 5.
FT   REPEAT      139    161       LRR 6.
FT   REPEAT      162    183       LRR 7.
FT   REPEAT      185    206       LRR 8.
FT   REPEAT      208    229       LRR 9.
FT   REPEAT      231    252       LRR 10.
FT   REPEAT      254    275       LRR 11.
FT   REPEAT      277    298       LRR 12.
FT   REPEAT      300    321       LRR 13.
FT   REPEAT      323    344       LRR 14.
FT   REPEAT      346    367       LRR 15.
FT   REPEAT      369    391       LRR 16.
FT   REPEAT      392    413       LRR 17.
FT   DOMAIN     1321   1410       PDZ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   COMPBIAS    930    934       Poly-Ser.
FT   MOD_RES     440    440       Phosphoserine.
FT                                {ECO:0000269|PubMed:17081983}.
FT   MOD_RES     485    485       Phosphothreonine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES     569    569       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES     602    602       Phosphoserine.
FT                                {ECO:0000269|PubMed:20068231}.
FT   MOD_RES     603    603       Phosphoserine.
FT                                {ECO:0000269|PubMed:20068231}.
FT   MOD_RES     715    715       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80TH2}.
FT   MOD_RES     852    852       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES     857    857       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES     872    872       Phosphoserine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   MOD_RES     917    917       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332}.
FT   MOD_RES     920    920       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:15144186}.
FT   MOD_RES     931    931       Phosphoserine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   MOD_RES     972    972       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:15592455}.
FT   MOD_RES    1104   1104       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q80TH2}.
FT   MOD_RES    1158   1158       Phosphoserine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   MOD_RES    1286   1286       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   VAR_SEQ     531    534       Missing (in isoform 9).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_047389.
FT   VAR_SEQ    1212   1252       Missing (in isoform 2, isoform 3, isoform
FT                                4, isoform 5, isoform 6, isoform 7 and
FT                                isoform 9). {ECO:0000303|PubMed:10574462,
FT                                ECO:0000303|PubMed:10878805,
FT                                ECO:0000303|PubMed:11375975,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_010802.
FT   VAR_SEQ    1212   1252       KHPQTSSSGDPCQDGIFISGQQNYSSATLSHKDVPPDSLMK
FT                                -> SMLSRSFNSNFTTVSSFHCGSSRDLHGSQGSLALSVAD
FT                                RRGSGGHIFR (in isoform 8).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_044536.
FT   VAR_SEQ    1253   1267       Missing (in isoform 5 and isoform 7).
FT                                {ECO:0000303|PubMed:11375975}.
FT                                /FTId=VSP_010803.
FT   VAR_SEQ    1268   1278       Missing (in isoform 3 and isoform 7).
FT                                {ECO:0000303|PubMed:11375975}.
FT                                /FTId=VSP_010804.
FT   VAR_SEQ    1279   1321       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:11375975}.
FT                                /FTId=VSP_010805.
FT   VAR_SEQ    1322   1352       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:11375975}.
FT                                /FTId=VSP_010806.
FT   VAR_SEQ    1353   1377       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:11375975,
FT                                ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_010807.
FT   VARIANT     274    274       S -> L (in dbSNP:rs3213837).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_019346.
FT   VARIANT     313    313       A -> V (in dbSNP:rs191137999).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_068905.
FT   VARIANT     746    746       K -> E (in dbSNP:rs16894812).
FT                                /FTId=VAR_028304.
FT   VARIANT     914    914       K -> R (in dbSNP:rs34521887).
FT                                /FTId=VAR_046673.
FT   VARIANT    1089   1089       G -> V (in dbSNP:rs35601230).
FT                                /FTId=VAR_046674.
FT   VARIANT    1112   1112       S -> L (in dbSNP:rs3805466).
FT                                /FTId=VAR_019347.
FT   VARIANT    1207   1207       K -> E. {ECO:0000269|PubMed:11375975}.
FT                                /FTId=VAR_019348.
FT   CONFLICT    271    271       T -> P (in Ref. 7; AAI15013).
FT                                {ECO:0000305}.
FT   CONFLICT    547    547       D -> G (in Ref. 7; AAI15013).
FT                                {ECO:0000305}.
FT   CONFLICT    805    805       E -> G (in Ref. 5; BAA91538).
FT                                {ECO:0000305}.
FT   CONFLICT    813    813       Y -> C (in Ref. 2; AAK69431).
FT                                {ECO:0000305}.
FT   CONFLICT    848    848       G -> C (in Ref. 5; BAG65463).
FT                                {ECO:0000305}.
FT   CONFLICT   1047   1047       R -> S (in Ref. 5; BAG65463).
FT                                {ECO:0000305}.
FT   CONFLICT   1205   1205       E -> G (in Ref. 7; AAI15013).
FT                                {ECO:0000305}.
FT   CONFLICT   1267   1267       Q -> P (in Ref. 7; AAI15013).
FT                                {ECO:0000305}.
FT   CONFLICT   1328   1328       K -> R (in Ref. 7; AAI15013).
FT                                {ECO:0000305}.
FT   STRAND     1318   1327       {ECO:0000244|PDB:2H3L}.
FT   STRAND     1329   1331       {ECO:0000244|PDB:2H3L}.
FT   STRAND     1333   1338       {ECO:0000244|PDB:2H3L}.
FT   TURN       1339   1342       {ECO:0000244|PDB:2H3L}.
FT   STRAND     1346   1348       {ECO:0000244|PDB:2H3L}.
FT   STRAND     1353   1359       {ECO:0000244|PDB:2H3L}.
FT   TURN       1364   1368       {ECO:0000244|PDB:2H3L}.
FT   STRAND     1374   1378       {ECO:0000244|PDB:2H3L}.
FT   HELIX      1388   1397       {ECO:0000244|PDB:2H3L}.
FT   STRAND     1400   1410       {ECO:0000244|PDB:2H3L}.
**
**   #################    INTERNAL SECTION    ##################
**CL 5q12.3;
**EV ECO:0000244; PDB:2H3L; INT; 08-OCT-2014.
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:Q80TH2; INT; 14-JAN-2015.
**EV ECO:0000255; PROSITE-ProRule:PRU00143; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:10878805; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:11375975; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:11821434; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:12444095; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:12446668; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:15144186; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:15489334; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:15592455; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:16203728; BAP; 19-FEB-2015.
**EV ECO:0000269; PubMed:17081983; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:18669648; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:19690332; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:20068231; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:24275569; INT; 14-JAN-2015.
**EV ECO:0000303; PubMed:10574462; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:10878805; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:11375975; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:14702039; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:15489334; XXX; 01-JAN-1900.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**IS Q96RT1-10
**SO UPD; 72348; 18-OCT-2012.
**ZA SIB, 17-JUN-2004;
**ZB LYG, 25-NOV-2005; BER, 29-SEP-2006; ALG/LYG, 09-NOV-2006; SIJ, 17-MAY-2010;
**ZB ALG/LYG, 01-FEB-2007; ALG/LYG, 29-APR-2007; LYG, 23-OCT-2007;
**ZB ALG/LYG, 18-MAR-2008; ALG/LYG, 18-APR-2008; UHI, 12-SEP-2008;
**ZB ALG/GAP, 01-APR-2009; ALG/GAP, 15-JUL-2009; ALG/EMB, 07-OCT-2009;
**ZB ALB/EMB, 16-OCT-2009; ALG/EMB, 03-NOV-2009; ALG/SIJ, 14-MAY-2010;
**ZB SIJ, 17-MAY-2010; ANS, 09-MAY-2011; JAJ, 29-JUN-2012; ANN, 23-OCT-2012;
**ZB LIB, 21-MAY-2013; BAP, 27-FEB-2015;
SQ   SEQUENCE   1412 AA;  158298 MW;  304DFC81578CF671 CRC64;
     MTTKRSLFVR LVPCRCLRGE EETVTTLDYS HCSLEQVPKE IFTFEKTLEE LYLDANQIEE
     LPKQLFNCQS LHKLSLPDND LTTLPASIAN LINLRELDVS KNGIQEFPEN IKNCKVLTIV
     EASVNPISKL PDGFSQLLNL TQLYLNDAFL EFLPANFGRL TKLQILELRE NQLKMLPKTM
     NRLTQLERLD LGSNEFTEVP EVLEQLSGLK EFWMDANRLT FIPGFIGSLK QLTYLDVSKN
     NIEMVEEGIS TCENLQDLLL SSNSLQQLPE TIGSLKNITT LKIDENQLMY LPDSIGGLIS
     VEELDCSFNE VEALPSSIGQ LTNLRTFAAD HNYLQQLPPE IGSWKNITVL FLHSNKLETL
     PEEMGDMQKL KVINLSDNRL KNLPFSFTKL QQLTAMWLSD NQSKPLIPLQ KETDSETQKM
     VLTNYMFPQQ PRTEDVMFIS DNESFNPSLW EEQRKQRAQV AFECDEDKDE REAPPREGNL
     KRYPTPYPDE LKNMVKTVQT IVHRLKDEET NEDSGRDLKP HEDQQDINKD VGVKTSESTT
     TVKSKVDERE KYMIGNSVQK ISEPEAEISP GSLPVTANMK ASENLKHIVN HDDVFEESEE
     LSSDEEMKMA EMRPPLIETS INQPKVVALS NNKKDDTKET DSLSDEVTHN SNQNNSNCSS
     PSRMSDSVSL NTDSSQDTSL CSPVKQTHID INSKIRQEDE NFNSLLQNGD ILNSSTEEKF
     KAHDKKDFNL PEYDLNVEER LVLIEKSVDS TATADDTHKL DHINMNLNKL ITNDTFQPEI
     MERSKTQDIV LGTSFLSINS KEETEHLENG NKYPNLESVN KVNGHSEETS QSPNRTEPHD
     SDCSVDLGIS KSTEDLSPQK SGPVGSVVKS HSITNMEIGG LKIYDILSDN GPQQPSTTVK
     ITSAVDGKNI VRSKSATLLY DQPLQVFTGS SSSSDLISGT KAIFKFDSNH NPEEPNIIRG
     PTSGPQSAPQ IYGPPQYNIQ YSSSAAVKDT LWHSKQNPQI DHASFPPQLL PRSESTENQS
     YAKHSANMNF SNHNNVRANT AYHLHQRLGP ARHGEMWAIS PNDRLIPAVT RSTIQRQSSV
     SSTASVNLGD PGSTRRAQIP EGDYLSYREF HSAGRTPPMM PGSQRPLSAR TYSIDGPNAS
     RPQSARPSIN EIPERTMSVS DFNYSRTSPS KRPNARVGSE HSLLDPPGKS KVPRDWREQV
     LRHIEAKKLE KKHPQTSSSG DPCQDGIFIS GQQNYSSATL SHKDVPPDSL MKMPLSNGQM
     GQPLRPQANY SQIHHPPQAS VARHPSREQL IDYLMLKVAH QPPYTQPHCS PRQGHELAKQ
     EIRVRVEKDP ELGFSISGGV GGRGNPFRPD DDGIFVTRVQ PEGPASKLLQ PGDKIIQANG
     YSFINIEHGQ AVSLLKTFQN TVELIIVREV SS
//
ID   LAP2_MOUSE              Reviewed;        1402 AA.
AC   Q80TH2; E9QND6; Q8BQ14; Q8CE41; Q8K171; Q99JU3; Q9JI47;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 3.
DT   04-MAR-2015, entry version 120.
DE   RecName: Full=Protein LAP2;
DE   AltName: Full=Densin-180-like protein;
DE   AltName: Full=Erbb2-interacting protein;
DE            Short=Erbin;
GN   Name=Erbb2ip; Synonyms=Erbin, Kiaa1225, Lap2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=12693553; DOI=10.1093/dnares/10.1.35;
RA   Okazaki N., Kikuno R., Ohara R., Inamoto S., Aizawa H., Yuasa S.,
RA   Nakajima D., Nagase T., Ohara O., Koga H.;
RT   "Prediction of the coding sequences of mouse homologues of KIAA gene:
RT   II. The complete nucleotide sequences of 400 mouse KIAA-homologous
RT   cDNAs identified by screening of terminal sequences of cDNA clones
RT   randomly sampled from size-fractionated libraries.";
RL   DNA Res. 10:35-48(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 308-1376 (ISOFORMS 2 AND 3).
RC   STRAIN=C57BL/6J; TISSUE=Skin, and Spinal ganglion;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 721-1402 (ISOFORM 2), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1160-1402 (ISOFORM 1).
RC   TISSUE=Colon, and Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 908-1402 (ISOFORM 3).
RX   PubMed=10878805; DOI=10.1038/35017038;
RA   Borg J.-P., Marchetto S., Le Bivic A., Ollendorff V.,
RA   Jaulin-Bastard F., Saito H., Fournier E., Adelaide J., Margolis B.,
RA   Birnbaum D.;
RT   "ERBIN: a basolateral PDZ protein that interacts with the mammalian
RT   ERBB2/HER2 receptor.";
RL   Nat. Cell Biol. 2:407-414(2000).
RN   [6]
RP   FUNCTION, INTERACTION WITH NOD2, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF PRO-315.
RX   PubMed=16203728; DOI=10.1074/jbc.M508538200;
RA   McDonald C., Chen F.F., Ollendorff V., Ogura Y., Marchetto S.,
RA   Lecine P., Borg J.P., Nunez G.;
RT   "A role for Erbin in the regulation of Nod2-dependent NF-kappaB
RT   signaling.";
RL   J. Biol. Chem. 280:40301-40309(2005).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1097, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Mast cell;
RX   PubMed=17947660; DOI=10.4049/jimmunol.179.9.5864;
RA   Cao L., Yu K., Banh C., Nguyen V., Ritz A., Raphael B.J., Kawakami Y.,
RA   Kawakami T., Salomon A.R.;
RT   "Quantitative time-resolved phosphoproteomic analysis of mast cell
RT   signaling.";
RL   J. Immunol. 179:5864-5876(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-599 AND SER-600, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18802028; DOI=10.1161/CIRCRESAHA.108.176024;
RA   Wright C.D., Chen Q., Baye N.L., Huang Y., Healy C.L., Kasinathan S.,
RA   O'Connell T.D.;
RT   "Nuclear alpha1-adrenergic receptors signal activated ERK localization
RT   to caveolae in adult cardiac myocytes.";
RL   Circ. Res. 103:992-1000(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-599; SER-600; SER-712
RP   AND SER-854, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic fibroblast;
RX   PubMed=19131326; DOI=10.1074/mcp.M800451-MCP200;
RA   Sweet S.M., Bailey C.M., Cunningham D.L., Heath J.K., Cooper H.J.;
RT   "Large scale localization of protein phosphorylation by use of
RT   electron capture dissociation mass spectrometry.";
RL   Mol. Cell. Proteomics 8:904-912(2009).
CC   -!- FUNCTION: Acts as an adapter for the receptor ERBB2, in epithelia.
CC       By binding the unphosphorylated ERBB2 'Tyr-1248' receptor, it may
CC       contribute to stabilize this unphosphorylated state (By
CC       similarity). Inhibits NOD2-dependent NF-kappa-B signaling and
CC       proinflammatory cytokine secretion (PubMed:16203728).
CC       {ECO:0000250, ECO:0000269|PubMed:16203728}.
CC   -!- SUBUNIT: Interacts with ERBB2, BPAG1 and ITGB4. May favor the
CC       localization of ERBB2, by restricting its presence to the
CC       basolateral membrane of epithelial cells. Also found to interact
CC       with ARVCF and delta catenin. Interacts (via C-terminus) with DST
CC       (via N-terminus) (By similarity). Interacts with NOD2 (via CARD
CC       domain) (PubMed:16203728). {ECO:0000250,
CC       ECO:0000269|PubMed:16203728}.
CC   -!- SUBCELLULAR LOCATION: Cell junction, hemidesmosome {ECO:0000250}.
CC       Nucleus membrane {ECO:0000269|PubMed:18802028}. Basolateral cell
CC       membrane {ECO:0000269|PubMed:16203728}. Note=Found in
CC       hemidesmosomes, which are cell-substrate adhesion complexes in
CC       stratified epithelia. In transfected cells, either diffusely
CC       distributed over the cytoplasm or concentrated at the basolateral
CC       membrane (By similarity). Colocalizes with the adrenergic
CC       receptors, ADREN1A and ADREN1B, at the nuclear membrane of cardiac
CC       myocytes. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=3;
CC         IsoId=Q80TH2-3; Sequence=Displayed;
CC       Name=1;
CC         IsoId=Q80TH2-1; Sequence=VSP_010809;
CC       Name=2;
CC         IsoId=Q80TH2-2; Sequence=VSP_010808;
CC   -!- PTM: Isoform 2 is phosphorylated on Ser-1231 and Ser-1234.
CC   -!- SIMILARITY: Belongs to the LAP (LRR and PDZ) protein family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 17 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 PDZ (DHR) domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00143}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC65755.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
DR   EMBL; AK122473; BAC65755.1; ALT_INIT; mRNA.
DR   EMBL; AC154310; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CT009728; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK029054; BAC26267.1; -; mRNA.
DR   EMBL; AK051733; BAC34742.1; -; mRNA.
DR   EMBL; BC005691; AAH05691.3; -; mRNA.
DR   EMBL; BC028256; AAH28256.1; -; mRNA.
DR   EMBL; AF263743; AAF77047.1; -; mRNA.
DR   CCDS; CCDS26744.1; -. [Q80TH2-2]
DR   RefSeq; NP_001005868.1; NM_001005868.2. [Q80TH2-2]
DR   RefSeq; NP_001276402.1; NM_001289473.1. [Q80TH2-3]
DR   RefSeq; NP_001276403.1; NM_001289474.1.
DR   RefSeq; NP_001276404.1; NM_001289475.1.
DR   UniGene; Mm.277354; -.
DR   ProteinModelPortal; Q80TH2; -.
DR   SMR; Q80TH2; 26-460, 1273-1402.
DR   BioGrid; 208523; 1.
DR   IntAct; Q80TH2; 1.
DR   MINT; MINT-138078; -.
DR   PhosphoSite; Q80TH2; -.
DR   MaxQB; Q80TH2; -.
DR   PaxDb; Q80TH2; -.
DR   PRIDE; Q80TH2; -.
DR   Ensembl; ENSMUST00000022222; ENSMUSP00000022222; ENSMUSG00000021709. [Q80TH2-1]
DR   Ensembl; ENSMUST00000053927; ENSMUSP00000057956; ENSMUSG00000021709. [Q80TH2-1]
DR   Ensembl; ENSMUST00000091269; ENSMUSP00000088813; ENSMUSG00000021709. [Q80TH2-3]
DR   Ensembl; ENSMUST00000191275; ENSMUSP00000140536; ENSMUSG00000021709. [Q80TH2-2]
DR   GeneID; 59079; -.
DR   KEGG; mmu:59079; -.
DR   UCSC; uc007rsk.2; mouse. [Q80TH2-3]
DR   UCSC; uc007rsm.1; mouse. [Q80TH2-1]
DR   CTD; 55914; -.
DR   MGI; MGI:1890169; Erbb2ip.
DR   eggNOG; COG4886; -.
DR   GeneTree; ENSGT00780000121846; -.
DR   HOVERGEN; HBG052305; -.
DR   InParanoid; Q80TH2; -.
DR   KO; K12796; -.
DR   OMA; SDEEMKM; -.
DR   OrthoDB; EOG72C501; -.
DR   TreeFam; TF351429; -.
DR   Reactome; REACT_348099; Signaling by ERBB2.
DR   NextBio; 314720; -.
DR   PRO; PR:Q80TH2; -.
DR   Proteomes; UP000000589; Chromosome 13.
DR   Bgee; Q80TH2; -.
DR   CleanEx; MM_ERBB2IP; -.
DR   ExpressionAtlas; Q80TH2; baseline and differential.
DR   Genevestigator; Q80TH2; -.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:MGI.
DR   GO; GO:0030054; C:cell junction; ISO:MGI.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0030056; C:hemidesmosome; ISO:MGI.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0005178; F:integrin binding; ISO:MGI.
DR   GO; GO:0006605; P:protein targeting; IDA:MGI.
DR   Gene3D; 2.30.42.10; -; 1.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR025875; Leu-rich_rpt_4.
DR   InterPro; IPR001478; PDZ.
DR   Pfam; PF12799; LRR_4; 2.
DR   Pfam; PF13855; LRR_8; 2.
DR   Pfam; PF00595; PDZ; 1.
DR   SMART; SM00228; PDZ; 1.
DR   SUPFAM; SSF50156; SSF50156; 1.
DR   PROSITE; PS51450; LRR; 13.
DR   PROSITE; PS50106; PDZ; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell junction; Cell membrane; Complete proteome;
KW   Leucine-rich repeat; Membrane; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat.
FT   CHAIN         1   1402       Protein LAP2.
FT                                /FTId=PRO_0000188302.
FT   REPEAT       23     44       LRR 1.
FT   REPEAT       47     68       LRR 2.
FT   REPEAT       70     91       LRR 3.
FT   REPEAT       93    114       LRR 4.
FT   REPEAT      116    137       LRR 5.
FT   REPEAT      139    161       LRR 6.
FT   REPEAT      162    183       LRR 7.
FT   REPEAT      185    206       LRR 8.
FT   REPEAT      208    229       LRR 9.
FT   REPEAT      231    252       LRR 10.
FT   REPEAT      254    275       LRR 11.
FT   REPEAT      277    298       LRR 12.
FT   REPEAT      300    321       LRR 13.
FT   REPEAT      323    344       LRR 14.
FT   REPEAT      346    367       LRR 15.
FT   REPEAT      369    391       LRR 16.
FT   REPEAT      392    413       LRR 17.
FT   DOMAIN     1311   1400       PDZ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   COMPBIAS    928    931       Poly-Ser.
FT   MOD_RES     440    440       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q96RT1}.
FT   MOD_RES     485    485       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q96RT1}.
FT   MOD_RES     599    599       Phosphoserine.
FT                                {ECO:0000269|PubMed:17242355,
FT                                ECO:0000269|PubMed:19144319}.
FT   MOD_RES     600    600       Phosphoserine.
FT                                {ECO:0000269|PubMed:17242355,
FT                                ECO:0000269|PubMed:19144319}.
FT   MOD_RES     712    712       Phosphoserine.
FT                                {ECO:0000269|PubMed:19144319}.
FT   MOD_RES     849    849       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q96RT1}.
FT   MOD_RES     854    854       Phosphoserine.
FT                                {ECO:0000269|PubMed:19144319}.
FT   MOD_RES     869    869       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q96RT1}.
FT   MOD_RES     914    914       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q96RT1}.
FT   MOD_RES     917    917       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q96RT1}.
FT   MOD_RES     928    928       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q96RT1}.
FT   MOD_RES     970    970       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q96RT1}.
FT   MOD_RES    1097   1097       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:17947660}.
FT   MOD_RES    1150   1150       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q96RT1}.
FT   MOD_RES    1276   1276       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q96RT1}.
FT   VAR_SEQ    1203   1203       K -> KSMLSRSFNSNLTAVSSSHYGSSRDLHGSQGSLALS
FT                                VADGRGSGGHIFR (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:16141072}.
FT                                /FTId=VSP_010808.
FT   VAR_SEQ    1243   1268       Missing (in isoform 1).
FT                                {ECO:0000303|PubMed:12693553,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_010809.
FT   MUTAGEN     315    315       P->L: Decreases interaction with NOD2.
FT                                {ECO:0000269|PubMed:16203728}.
FT   CONFLICT    255    255       L -> P (in Ref. 1; BAC65755).
FT                                {ECO:0000305}.
FT   CONFLICT    721    723       DKK -> HAS (in Ref. 4; AAH28256).
FT                                {ECO:0000305}.
FT   CONFLICT    908    910       VRS -> ASG (in Ref. 5; AAF77047).
FT                                {ECO:0000305}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:Q96RT1; INT; 14-JAN-2015.
**EV ECO:0000255; PROSITE-ProRule:PRU00143; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:16203728; BAP; 04-FEB-2015.
**EV ECO:0000269; PubMed:17242355; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:17947660; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:18802028; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:19144319; INT; 14-JAN-2015.
**EV ECO:0000303; PubMed:12693553; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:15489334; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:16141072; XXX; 01-JAN-1900.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**IS Q80TH2-4
**ZA SIB, 18-JUN-2004;
**ZB LYG, 25-NOV-2005; ALG/LYG, 09-NOV-2006; ALG/LYG, 01-FEB-2007;
**ZB ALG/LYG, 18-APR-2007; ALG/LYG, 29-APR-2007; LYG, 23-OCT-2007;
**ZB LYG, 17-DEC-2007; ALG/LYG, 18-APR-2008; ALG/GAP, 01-APR-2009;
**ZB ALG/GAP, 15-JUL-2009; NAG, 05-OCT-2009; ALG/EMB, 07-OCT-2009;
**ZB ALB/EMB, 16-OCT-2009; ALG/EMB, 03-NOV-2009; ALG/SIJ, 14-MAY-2010;
**ZB ANS, 09-MAY-2011; LIB, 09-JUN-2011; JAJ, 29-JUN-2012; BAP, 27-FEB-2015;
SQ   SEQUENCE   1402 AA;  157248 MW;  DBAFF4BD1BC48019 CRC64;
     MTTKRSLFVR LVPCRCLRGE EETVTTLDYS HCSLEQVPKE IFTFEKTLEE LYLDANQIEE
     LPKQLFNCQS LHKLSLPDND LTTLPASIAN LINLRELDVS KNGIQEFPEN IKNCKVLTIV
     EASVNPISKL PDGFSQLLNL TQLYLNDAFL EFLPANFGRL TKLQILELRE NQLKMLPKTM
     NRLTQLERLD LGSNEFTEVP EVLEQLSGLR EFWMDGNRLT FIPGFIGSLR QLTYLDVSKN
     NIEMVEEGIS TCENLQDFLL SSNSLQQLPE TIGSLKNVTT LKIDENQLMY LPDSIGGLRS
     IEELDCSFNE IEALPSSIGQ LTNMRTFAAD HNYLQQLPPE IGNWKNITVL FLHCNKLETL
     PEEMGDMQKL KVINLSDNRL KNLPFSFTKL QQLTAMWLSD NQSKPLIPLQ KETDTETQKM
     VLTNYMFPQQ PRTEDVMFIS DNESFNPALW EEQRKQRAQV AFECDEDKDE REAPPREGNL
     KRYPTPYPDE LKNMVKTVQT IVHRLKDEET NEESGRDLKQ HEDQQVVNKD KCVKTSESTT
     TKSKLDEREK YMNSVQKMSE PEAETNGGNL PVTASMKLSG NLKHIVNHDD VFEESEELSS
     DEEMKMAEMR PPLIESSINQ PKVVALSNNK KDDAKDADSL SDEVTHNSNQ NNSNCSSPSR
     MSDSVSLNTD SSQDTSLCSP VKQTPVDSNS KVRQEDENFN SLLQNGVNLN NSPEEKFKIN
     DKKDFKLPEY DLNIEEQLVL IEKDIDSKAT SDDSRQLDHI NMNINKLVTN NIFQPEVMER
     SKMQDIVLGT GFLSIHPKNE AEHIENGAKF PNLESINKVN GLCEDTAPSP GRVEPQKASS
     SADVGISKST EDLSPQRSGP TGAVVKSHSI TNMETGGLKI YDILGDDGPQ PPSAAVKIAS
     AVDGKNIVRS KSATLLYDQP LQVFTAASSS SELLSGTKAV FKFDSNHNPE EPDIIRAATV
     SGPQSTPHLY GPPQYNVQYS GSATVKDTLW HPKQNPQIDP VSFPPQRLPR SESAENHSYA
     KHSANMNFSN HNNVRANTGY HLQQRLAPAR HGEMWAISPN DRLVPAVTRT TIQRQSSVSS
     TASVNLGDPT RRTEGDYLSY RELHSMGRTP VMSGSQRPLS ARAYSIDGPN TSRPQSARPS
     INEIPERTMS VSDFNYSRTS PSKRPNTRVG SEHSLLDPPG KSKVPHDWRE QVLRHIEAKK
     LEKHPQTSSP GECCQDDRFM SEEQNHPSGA LSHRGLPDSL MKMPLSNGQM GQPLRPQAHY
     SQTHHPPQAS VARHPSREQL IDYLMLKVAH QPPYTHPHCS PRQGHELAKQ EIRVRVEKDP
     ELGFSISGGV GGRGNPFRPD DDGIFVTRVQ PEGPASKLLQ PGDKIIQANG YSFINIEHGQ
     AVSLLKTFHN AVDLIIVREV SS
//
ID   CARD9_HUMAN             Reviewed;         536 AA.
AC   Q9H257; Q5SXM5; Q5SXM6; Q9H854;
DT   31-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   04-MAR-2015, entry version 122.
DE   RecName: Full=Caspase recruitment domain-containing protein 9;
DE            Short=hCARD9;
GN   Name=CARD9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ASN-12, FUNCTION,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH BCL10.
RX   PubMed=11053425; DOI=10.1074/jbc.C000726200;
RA   Bertin J., Guo Y., Wang L., Srinivasula S.M., Jacobson M.D.,
RA   Poyet J.-L., Merriam S., Du M.-Q., Dyer M.J.S., Robison K.E.,
RA   DiStefano P.S., Alnemri E.S.;
RT   "CARD9 is a novel caspase recruitment domain-containing protein that
RT   interacts with Bcl10/CLAP and activates NF-kappa B.";
RL   J. Biol. Chem. 275:41082-41086(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   ASN-12.
RC   TISSUE=Retinoblastoma, and Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-460, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [7]
RP   INVOLVEMENT IN CANDF2.
RX   PubMed=19864672; DOI=10.1056/NEJMoa0810719;
RA   Glocker E.-O., Hennigs A., Nabavi M., Schaeffer A.A., Woellner C.,
RA   Salzer U., Pfeifer D., Veelken H., Warnatz K., Tahami F., Jamal S.,
RA   Manguiat A., Rezaei N., Amirzargar A.A., Plebani A.,
RA   Hannesschlaeger N., Gross O., Ruland J., Grimbacher B.;
RT   "A homozygous CARD9 mutation in a family with susceptibility to fungal
RT   infections.";
RL   N. Engl. J. Med. 361:1727-1735(2009).
RN   [8]
RP   VARIANTS CANDF2 SER-72 AND PRO-373.
RX   PubMed=23335372; DOI=10.1182/blood-2012-08-450551;
RA   Drewniak A., Gazendam R.P., Tool A.T., van Houdt M., Jansen M.H.,
RA   van Hamme J.L., van Leeuwen E.M., Roos D., Scalais E., de Beaufort C.,
RA   Janssen H., van den Berg T.K., Kuijpers T.W.;
RT   "Invasive fungal infection and impaired neutrophil killing in human
RT   CARD9 deficiency.";
RL   Blood 121:2385-2392(2013).
RN   [9]
RP   VARIANT CANDF2 CYS-101.
RX   PubMed=24131138; DOI=10.1056/NEJMoa1208487;
RA   Lanternier F., Pathan S., Vincent Q.B., Liu L., Cypowyj S., Prando C.,
RA   Migaud M., Taibi L., Ammar-Khodja A., Boudghene Stambouli O.,
RA   Guellil B., Jacobs F., Goffard J.C., Schepers K., del Marmol V.,
RA   Boussofara L., Denguezli M., Larif M., Bachelez H., Michel L.,
RA   Lefranc G., Hay R., Jouvion G., Chretien F., Fraitag S.,
RA   Bougnoux M.E., Boudia M., Abel L., Lortholary O., Casanova J.L.,
RA   Picard C., Grimbacher B., Puel A.;
RT   "Deep dermatophytosis and inherited CARD9 deficiency.";
RL   N. Engl. J. Med. 369:1704-1714(2013).
CC   -!- FUNCTION: Adapter protein that plays a key role in innate immune
CC       response to a number of intracellular pathogens, such as
CC       C.albicans and L.monocytogenes. Is at the crossroads of ITAM-
CC       tyrosine kinase and the Toll-like receptors (TLR) and NOD2
CC       signaling pathways. Probably controls various innate immune
CC       response pathways depending on the intracellular pathogen. In
CC       response to L.monocytogenes infection, acts by connecting NOD2
CC       recognition of peptidoglycan to downstream activation of MAP
CC       kinases (MAPK) without activating NF-kappa-B. Also involved in
CC       activation of myeloid cells via classical ITAM-associated
CC       receptors and TLR: required for TLR-mediated activation of MAPK,
CC       while it is not required for TLR-induced activation of NF-kappa-B
CC       (By similarity). Controls CLEC7A (dectin-1)-mediated myeloid cell
CC       activation induced by the yeast cell wall component zymosan,
CC       leading to cytokine production and innate anti-fungal immunity:
CC       acts by regulating BCL10-MALT1-mediated NF-kappa-B activation
CC       pathway. Activates NF-kappa-B via BCL10. In response to the hyphal
CC       form of C.albicans, mediates CLEC6A (dectin-2)-induced I-kappa-B
CC       kinase ubiquitination, leading to NF-kappa-B activation via
CC       interaction with BCL10. In response to fungal infection, may be
CC       required for the development and subsequent differentiation of
CC       interleukin 17-producing T helper (TH-17) cells. {ECO:0000250,
CC       ECO:0000269|PubMed:11053425}.
CC   -!- SUBUNIT: Interacts with NOD2 (via NACHT domain) (By similarity).
CC       Interacts with RIPK2 (By similarity). Interacts with VHL; without
CC       leading to protein degradation (By similarity). Self-associates.
CC       Interacts (via CARD domain) with BCL10 (via CARD domain)
CC       (PubMed:11053425). {ECO:0000250|UniProtKB:A2AIV8,
CC       ECO:0000250|UniProtKB:Q9EPY0, ECO:0000269|PubMed:11053425}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11053425}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9H257-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H257-2; Sequence=VSP_024392, VSP_024393;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q9H257-3; Sequence=VSP_024390, VSP_024391;
CC         Note=No experimental confirmation available. May be produced at
CC         very low levels due to a premature stop codon in the mRNA,
CC         leading to nonsense-mediated mRNA decay.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in spleen. Also detected in
CC       liver, placenta, lung, peripheral blood leukocytes and in brain.
CC   -!- PTM: Phosphorylated at Thr-531 and Thr-533 by CK2 following
CC       interaction with VHL, leading to inhibit the ability to activate
CC       NF-kappa-B. {ECO:0000250}.
CC   -!- DISEASE: Candidiasis, familial, 2 (CANDF2) [MIM:212050]: A primary
CC       immunodeficiency disorder with altered immune responses and
CC       impaired clearance of fungal infections, selective against
CC       Candida. It is characterized by persistent and/or recurrent
CC       infections of the skin, nails and mucous membranes caused by
CC       organisms of the genus Candida, mainly Candida albicans.
CC       {ECO:0000269|PubMed:19864672, ECO:0000269|PubMed:23335372,
CC       ECO:0000269|PubMed:24131138}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. Defects
CC       induce reduced numbers of CD4(+) Th17 lymphocytes as well as a
CC       lack of monocyte-derived cytokines in response to Candida strains.
CC       Neutrophils show a selective Candida albicans killing defect with
CC       abnormal ultrastructural phagolysosomes and outgrowth of hyphae
CC       (PubMed:23335372). {ECO:0000269|PubMed:23335372}.
CC   -!- SIMILARITY: Contains 1 CARD domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00046}.
DR   EMBL; AF311287; AAG28790.1; -; mRNA.
DR   EMBL; AK024001; BAB14766.1; -; mRNA.
DR   EMBL; AK292081; BAF84770.1; -; mRNA.
DR   EMBL; AL592301; CAI13931.1; -; Genomic_DNA.
DR   EMBL; AL592301; CAI13932.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW88220.1; -; Genomic_DNA.
DR   EMBL; BC008877; AAH08877.1; -; mRNA.
DR   CCDS; CCDS48057.1; -. [Q9H257-2]
DR   CCDS; CCDS6997.1; -. [Q9H257-1]
DR   RefSeq; NP_434700.2; NM_052813.4. [Q9H257-1]
DR   RefSeq; NP_434701.1; NM_052814.3. [Q9H257-2]
DR   UniGene; Hs.694071; -.
DR   ProteinModelPortal; Q9H257; -.
DR   SMR; Q9H257; 11-98.
DR   BioGrid; 122094; 71.
DR   IntAct; Q9H257; 6.
DR   STRING; 9606.ENSP00000360797; -.
DR   PhosphoSite; Q9H257; -.
DR   DMDM; 143811370; -.
DR   MaxQB; Q9H257; -.
DR   PaxDb; Q9H257; -.
DR   PRIDE; Q9H257; -.
DR   DNASU; 64170; -.
DR   Ensembl; ENST00000371732; ENSP00000360797; ENSG00000187796. [Q9H257-1]
DR   Ensembl; ENST00000371734; ENSP00000360799; ENSG00000187796. [Q9H257-2]
DR   Ensembl; ENST00000489932; ENSP00000451368; ENSG00000187796. [Q9H257-3]
DR   GeneID; 64170; -.
DR   KEGG; hsa:64170; -.
DR   UCSC; uc004chg.3; human. [Q9H257-1]
DR   UCSC; uc010nbj.2; human. [Q9H257-3]
DR   UCSC; uc022bpo.1; human. [Q9H257-2]
DR   CTD; 64170; -.
DR   GeneCards; GC09M139259; -.
DR   HGNC; HGNC:16391; CARD9.
DR   HPA; HPA059502; -.
DR   MIM; 212050; phenotype.
DR   MIM; 607212; gene.
DR   neXtProt; NX_Q9H257; -.
DR   Orphanet; 1334; Chronic mucocutaneous candidosis.
DR   Orphanet; 397587; Deep dermatophytosis.
DR   PharmGKB; PA26077; -.
DR   eggNOG; NOG243105; -.
DR   GeneTree; ENSGT00530000063108; -.
DR   HOGENOM; HOG000231538; -.
DR   HOVERGEN; HBG058091; -.
DR   InParanoid; Q9H257; -.
DR   KO; K12794; -.
DR   OMA; QLLMSEV; -.
DR   OrthoDB; EOG747PH5; -.
DR   PhylomeDB; Q9H257; -.
DR   TreeFam; TF351139; -.
DR   Reactome; REACT_75776; NOD1/2 Signaling Pathway.
DR   GeneWiki; CARD9; -.
DR   GenomeRNAi; 64170; -.
DR   NextBio; 66079; -.
DR   PRO; PR:Q9H257; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; Q9H257; -.
DR   CleanEx; HS_CARD9; -.
DR   ExpressionAtlas; Q9H257; baseline and differential.
DR   Genevestigator; Q9H257; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0050700; F:CARD domain binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0051607; P:defense response to virus; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0035872; P:nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0070423; P:nucleotide-binding oligomerization domain containing signaling pathway; TAS:Reactome.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEP:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IEA:Ensembl.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:MGI.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; IDA:MGI.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:InterPro.
DR   GO; GO:0045076; P:regulation of interleukin-2 biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045408; P:regulation of interleukin-6 biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042534; P:regulation of tumor necrosis factor biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0009620; P:response to fungus; IEA:Ensembl.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IEA:Ensembl.
DR   GO; GO:0032494; P:response to peptidoglycan; IEA:Ensembl.
DR   Gene3D; 1.10.533.10; -; 1.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   Pfam; PF00619; CARD; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   PROSITE; PS50209; CARD; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Coiled coil; Complete proteome; Cytoplasm;
KW   Disease mutation; Immunity; Innate immunity; Phosphoprotein;
KW   Polymorphism; Reference proteome.
FT   CHAIN         1    536       Caspase recruitment domain-containing
FT                                protein 9.
FT                                /FTId=PRO_0000144082.
FT   DOMAIN        6     98       CARD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   COILED      117    277       {ECO:0000255}.
FT   COILED      332    419       {ECO:0000255}.
FT   MOD_RES     460    460       Phosphoserine.
FT                                {ECO:0000269|PubMed:18088087}.
FT   MOD_RES     531    531       Phosphothreonine; by CK2. {ECO:0000250}.
FT   MOD_RES     533    533       Phosphothreonine; by CK2. {ECO:0000250}.
FT   VAR_SEQ     360    366       AIATREE -> STQMEGL (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_024390.
FT   VAR_SEQ     367    536       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_024391.
FT   VAR_SEQ     482    492       LSSGEPPEKER -> PAGLPGIGAVC (in isoform
FT                                2). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_024392.
FT   VAR_SEQ     493    536       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_024393.
FT   VARIANT      12     12       S -> N (in dbSNP:rs4077515).
FT                                {ECO:0000269|PubMed:11053425,
FT                                ECO:0000269|PubMed:14702039}.
FT                                /FTId=VAR_048607.
FT   VARIANT      72     72       G -> S (in CANDF2; loss of protein
FT                                expression).
FT                                {ECO:0000269|PubMed:23335372}.
FT                                /FTId=VAR_070828.
FT   VARIANT     101    101       R -> C (in CANDF2).
FT                                {ECO:0000269|PubMed:24131138}.
FT                                /FTId=VAR_070829.
FT   VARIANT     373    373       R -> P (in CANDF2; loss of protein
FT                                expression).
FT                                {ECO:0000269|PubMed:23335372}.
FT                                /FTId=VAR_070830.
**
**   #################    INTERNAL SECTION    ##################
**CL 9q34.2-q34.3;
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:A2AIV8; BAP; 09-FEB-2015.
**EV ECO:0000250; UniProtKB:Q9EPY0; BAP; 09-FEB-2015.
**EV ECO:0000255; -; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00046; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:11053425; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:14702039; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:18088087; INT; 14-JAN-2015.
**EV ECO:0000269; PubMed:19864672; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:23335372; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:24131138; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:14702039; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:15489334; XXX; 01-JAN-1900.
**IS Q9H257-4
**ZA UHI/SIB, 29-NOV-2001;
**ZB SEF, 06-JAN-2006; ISC, 21-MAR-2007; ALG/LYG, 18-MAR-2008; ARG, 29-APR-2010;
**ZB SHS, 30-MAR-2011; ALG, 20-JUL-2012; SYP, 06-MAR-2014; BAP, 27-FEB-2015;
SQ   SEQUENCE   536 AA;  62241 MW;  6EB18353112F2BAC CRC64;
     MSDYENDDEC WSVLEGFRVT LTSVIDPSRI TPYLRQCKVL NPDDEEQVLS DPNLVIRKRK
     VGVLLDILQR TGHKGYVAFL ESLELYYPQL YKKVTGKEPA RVFSMIIDAS GESGLTQLLM
     TEVMKLQKKV QDLTALLSSK DDFIKELRVK DSLLRKHQER VQRLKEECEA GSRELKRCKE
     ENYDLAMRLA HQSEEKGAAL MRNRDLQLEI DQLKHSLMKA EDDCKVERKH TLKLRHAMEQ
     RPSQELLWEL QQEKALLQAR VQELEASVQE GKLDRSSPYI QVLEEDWRQA LRDHQEQANT
     IFSLRKDLRQ GEARRLRCME EKEMFELQCL ALRKDSKMYK DRIEAILLQM EEVAIERDQA
     IATREELHAQ HARGLQEKDA LRKQVRELGE KADELQLQVF QCEAQLLAVE GRLRRQQLET
     LVLSSDLEDG SPRRSQELSL PQDLEDTQLS DKGCLAGGGS PKQPFAALHQ EQVLRNPHDA
     GLSSGEPPEK ERRRLKESFE NYRRKRALRK MQKGWRQGEE DRENTTGSDN TDTEGS
//
ID   CARD9_MOUSE             Reviewed;         536 AA.
AC   A2AIV8;
DT   16-APR-2014, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 1.
DT   04-MAR-2015, entry version 71.
DE   RecName: Full=Caspase recruitment domain-containing protein 9;
GN   Name=Card9;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.
RX   PubMed=16862125; DOI=10.1038/nature04926;
RA   Gross O., Gewies A., Finger K., Schafer M., Sparwasser T., Peschel C.,
RA   Forster I., Ruland J.;
RT   "Card9 controls a non-TLR signalling pathway for innate anti-fungal
RT   immunity.";
RL   Nature 442:651-656(2006).
RN   [4]
RP   FUNCTION, TISSUE SPECIFICITY, DISRUPTION PHENOTYPE, AND INTERACTION
RP   WITH NOD2 AND RIPK2.
RX   PubMed=17187069; DOI=10.1038/ni1426;
RA   Hsu Y.M., Zhang Y., You Y., Wang D., Li H., Duramad O., Qin X.F.,
RA   Dong C., Lin X.;
RT   "The adaptor protein CARD9 is required for innate immune responses to
RT   intracellular pathogens.";
RL   Nat. Immunol. 8:198-205(2007).
RN   [5]
RP   REVIEW.
RX   PubMed=17514206; DOI=10.1038/ni0607-554;
RA   Colonna M.;
RT   "All roads lead to CARD9.";
RL   Nat. Immunol. 8:554-555(2007).
RN   [6]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=17486093; DOI=10.1038/ni1466;
RA   Hara H., Ishihara C., Takeuchi A., Imanishi T., Xue L., Morris S.W.,
RA   Inui M., Takai T., Shibuya A., Saijo S., Iwakura Y., Ohno N.,
RA   Koseki H., Yoshida H., Penninger J.M., Saito T.;
RT   "The adaptor protein CARD9 is essential for the activation of myeloid
RT   cells through ITAM-associated and Toll-like receptors.";
RL   Nat. Immunol. 8:619-629(2007).
RN   [7]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=17450144; DOI=10.1038/ni1460;
RA   LeibundGut-Landmann S., Gross O., Robinson M.J., Osorio F.,
RA   Slack E.C., Tsoni S.V., Schweighoffer E., Tybulewicz V., Brown G.D.,
RA   Ruland J., Reis e Sousa C.;
RT   "Syk- and CARD9-dependent coupling of innate immunity to the induction
RT   of T helper cells that produce interleukin 17.";
RL   Nat. Immunol. 8:630-638(2007).
RN   [8]
RP   FUNCTION.
RX   PubMed=20538615; DOI=10.1074/jbc.M110.131300;
RA   Bi L., Gojestani S., Wu W., Hsu Y.M., Zhu J., Ariizumi K., Lin X.;
RT   "CARD9 mediates dectin-2-induced IkappaBalpha kinase ubiquitination
RT   leading to activation of NF-kappaB in response to stimulation by the
RT   hyphal form of Candida albicans.";
RL   J. Biol. Chem. 285:25969-25977(2010).
RN   [9]
RP   INTERACTION WITH NOD2.
RX   PubMed=24960071; DOI=10.1016/j.febslet.2014.06.035;
RA   Parkhouse R., Boyle J.P., Mayle S., Sawmynaden K., Rittinger K.,
RA   Monie T.P.;
RT   "Interaction between NOD2 and CARD9 involves the NOD2 NACHT and the
RT   linker region between the NOD2 CARDs and NACHT domain.";
RL   FEBS Lett. 588:2830-2836(2014).
CC   -!- FUNCTION: Adapter protein that plays a key role in innate immune
CC       response to a number of intracellular pathogens, such as
CC       C.albicans and L.monocytogenes. Is at the crossroads of ITAM-
CC       tyrosine kinase and the Toll-like receptors (TLR) and NOD2
CC       signaling pathways (PubMed:17514206). Probably controls various
CC       innate immune response pathways depending on the intracellular
CC       pathogen. Controls CLEC7A (dectin-1)-mediated myeloid cell
CC       activation induced by the yeast cell wall component zymosan,
CC       leading to cytokine production and innate anti-fungal immunity:
CC       acts by regulating BCL10-MALT1-mediated NF-kappa-B activation
CC       pathway. Activates NF-kappa-B via BCL10 (PubMed:16862125). In
CC       response to the hyphal form of C.albicans, mediates CLEC6A
CC       (dectin-2)-induced I-kappa-B kinase ubiquitination, leading to NF-
CC       kappa-B activation via interaction with BCL10 (PubMed:20538615).
CC       In response to L.monocytogenes infection, acts by connecting NOD2
CC       recognition of peptidoglycan to downstream activation of MAP
CC       kinases (MAPK) without activating NF-kappa-B (PubMed:17187069). In
CC       response to fungal infection, may be required for the development
CC       and subsequent differentiation of interleukin 17-producing T
CC       helper (TH-17) cells (PubMed:17450144). Also involved in
CC       activation of myeloid cells via classical ITAM-associated
CC       receptors and TLR: required for TLR-mediated activation of MAPK,
CC       while it is not required for TLR-induced activation of NF-kappa-B
CC       (PubMed:17486093). {ECO:0000269|PubMed:16862125,
CC       ECO:0000269|PubMed:17187069, ECO:0000269|PubMed:17450144,
CC       ECO:0000269|PubMed:17486093, ECO:0000269|PubMed:17514206,
CC       ECO:0000269|PubMed:20538615}.
CC   -!- SUBUNIT: Interacts with VHL; without leading to protein
CC       degradation (By similarity). Self-associates. Interacts (via CARD
CC       domain) with BCL10 (via CARD domain) (By similarity). Interacts
CC       with NOD2 (via NACHT domain)(PubMed:17187069, PubMed:24960071).
CC       Interacts with RIPK2 (PubMed:17187069).
CC       {ECO:0000250|UniProtKB:Q9EPY0, ECO:0000250|UniProtKB:Q9H257,
CC       ECO:0000269|PubMed:17187069, ECO:0000269|PubMed:24960071}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in myeloid cells. Not expressed in
CC       non-lymphoid organs. {ECO:0000269|PubMed:16862125,
CC       ECO:0000269|PubMed:17187069}.
CC   -!- PTM: Phosphorylated at Thr-531 and Thr-531 by CK2 following
CC       interaction with VHL, leading to inhibit the ability to activate
CC       NF-kappa-B. {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Mice were born at the normal Mendelian ratio
CC       without obvious anatomical defects but display impaired innate
CC       immunity (PubMed:16862125, PubMed:17187069). All mice die within 5
CC       days after infection by C.albicans whereas more than half of the
CC       control mice survive for more than 12 days. Impaired zymosan-
CC       induced cytokine production. No defects in adaptive immunity
CC       (PubMed:16862125). Following infection by L.monocytogenes, mice
CC       fail to clear infection and show altered cytokine production
CC       (PubMed:17187069). {ECO:0000269|PubMed:16862125,
CC       ECO:0000269|PubMed:17187069, ECO:0000269|PubMed:17450144,
CC       ECO:0000269|PubMed:17486093}.
CC   -!- SIMILARITY: Contains 1 CARD domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00046}.
DR   EMBL; AL732541; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC151023; AAI51024.1; -; mRNA.
DR   CCDS; CCDS38084.1; -.
DR   RefSeq; NP_001032836.1; NM_001037747.1.
DR   RefSeq; XP_006498199.1; XM_006498136.2.
DR   UniGene; Mm.330064; -.
DR   ProteinModelPortal; A2AIV8; -.
DR   SMR; A2AIV8; 11-98.
DR   IntAct; A2AIV8; 1.
DR   STRING; 10090.ENSMUSP00000097876; -.
DR   MaxQB; A2AIV8; -.
DR   PRIDE; A2AIV8; -.
DR   DNASU; 332579; -.
DR   Ensembl; ENSMUST00000028294; ENSMUSP00000028294; ENSMUSG00000026928.
DR   Ensembl; ENSMUST00000100303; ENSMUSP00000097876; ENSMUSG00000026928.
DR   GeneID; 332579; -.
DR   KEGG; mmu:332579; -.
DR   UCSC; uc008iut.1; mouse.
DR   CTD; 64170; -.
DR   MGI; MGI:2685628; Card9.
DR   eggNOG; NOG243105; -.
DR   GeneTree; ENSGT00530000063108; -.
DR   HOGENOM; HOG000231538; -.
DR   HOVERGEN; HBG058091; -.
DR   InParanoid; A2AIV8; -.
DR   KO; K12794; -.
DR   OMA; QLLMSEV; -.
DR   OrthoDB; EOG747PH5; -.
DR   PhylomeDB; A2AIV8; -.
DR   TreeFam; TF351139; -.
DR   Reactome; REACT_301153; NOD1/2 Signaling Pathway.
DR   NextBio; 399892; -.
DR   PRO; PR:A2AIV8; -.
DR   Proteomes; UP000000589; Chromosome 2.
DR   ExpressionAtlas; A2AIV8; baseline and differential.
DR   Genevestigator; A2AIV8; -.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0050700; F:CARD domain binding; ISO:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:MGI.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IMP:MGI.
DR   GO; GO:0051607; P:defense response to virus; IMP:MGI.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0045089; P:positive regulation of innate immune response; IMP:MGI.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IMP:MGI.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:MGI.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; IMP:MGI.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IMP:MGI.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:InterPro.
DR   GO; GO:0045076; P:regulation of interleukin-2 biosynthetic process; IMP:MGI.
DR   GO; GO:0045408; P:regulation of interleukin-6 biosynthetic process; IMP:MGI.
DR   GO; GO:0042534; P:regulation of tumor necrosis factor biosynthetic process; IMP:MGI.
DR   GO; GO:0042493; P:response to drug; IMP:MGI.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IMP:MGI.
DR   GO; GO:0009620; P:response to fungus; IMP:MGI.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IMP:MGI.
DR   GO; GO:0032494; P:response to peptidoglycan; IMP:MGI.
DR   Gene3D; 1.10.533.10; -; 1.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   Pfam; PF00619; CARD; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   PROSITE; PS50209; CARD; 1.
PE   1: Evidence at protein level;
KW   Coiled coil; Complete proteome; Cytoplasm; Immunity; Innate immunity;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN         1    536       Caspase recruitment domain-containing
FT                                protein 9.
FT                                /FTId=PRO_0000428725.
FT   DOMAIN        6     98       CARD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   COILED      117    272       {ECO:0000255}.
FT   COILED      303    415       {ECO:0000255}.
FT   MOD_RES     461    461       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9H257}.
FT   MOD_RES     531    531       Phosphothreonine; by CK2. {ECO:0000250}.
FT   MOD_RES     533    533       Phosphothreonine; by CK2. {ECO:0000250}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:Q9EPY0; BAP; 09-FEB-2015.
**EV ECO:0000250; UniProtKB:Q9H257; BAP; 09-FEB-2015.
**EV ECO:0000255; -; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00046; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:16862125; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:17187069; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:17450144; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:17486093; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:17514206; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:20538615; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:24960071; BAP; 09-FEB-2015.
**ZA SYP, 14-FEB-2014;
**ZB BAP, 27-FEB-2015;
SQ   SEQUENCE   536 AA;  62462 MW;  3A5403C7A04EA2C9 CRC64;
     MSDYENDDEC WSTLESFRVK LISVIDPSRI TPYLRQCKVL NPDDEEQVLS DPNLVIRKRK
     VGVLLDILQR TGHKGYVAFL ESLELYYPQL YRKVTGKEPA RVFSMIIDAS GESGLTQLLM
     TEVMKLQKKV QDLTALLSSK DDFIKELRVK DSLLRKHQER VQRLKEECEL SSAELKRCKD
     ENYELAMCLA HLSEEKGAAL MRNRDLQLEV DRLRHSLMKA EDDCKVERKH TLKLRHAMEQ
     RPSQELLWEL QQEKDLLQAR VQELQVSVQE GKLDRNSPYI QVLEEDWRQA LQEHQKQVST
     IFSLRKDLRQ AETLRARCTE EKEMFELQCL ALRKDAKMYK DRIEAILLQM EEVSIERDQA
     MASREELHAQ CTQSFQDKDK LRKLVRELGE KADELQLQLF QTESRLLAAE GRLKQQQLDM
     LILSSDLEDS SPRNSQELSL PQDLEEDAQL SDKGVLADRE SPEQPFMALN KEHLSLTHGM
     GPSSSEPPEK ERRRLKESFE NYRRKRALRK MQNSWRQGEG DRGNTTGSDN TDTEGS
//
ID   CARD9_RAT               Reviewed;         536 AA.
AC   Q9EPY0; F1LQK8;
DT   31-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   04-MAR-2015, entry version 84.
DE   RecName: Full=Caspase recruitment domain-containing protein 9;
DE            Short=rCARD9;
GN   Name=Card9;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley;
RX   PubMed=11053425; DOI=10.1074/jbc.C000726200;
RA   Bertin J., Guo Y., Wang L., Srinivasula S.M., Jacobson M.D.,
RA   Poyet J.-L., Merriam S., Du M.-Q., Dyer M.J.S., Robison K.E.,
RA   DiStefano P.S., Alnemri E.S.;
RT   "CARD9 is a novel caspase recruitment domain-containing protein that
RT   interacts with Bcl10/CLAP and activates NF-kappa B.";
RL   J. Biol. Chem. 275:41082-41086(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T.,
RA   Smith D., Lee H.-M., Gustafson E., Cahill P., Kana A.,
RA   Doucette-Stamm L., Weinstock K., Fechtel K., Weiss R.B., Dunn D.M.,
RA   Green E.D., Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K.,
RA   Zhu B., Marra M., Schein J., Bosdet I., Fjell C., Jones S.,
RA   Krzywinski M., Mathewson C., Siddiqui A., Wye N., McPherson J.,
RA   Zhao S., Fraser C.M., Shetty J., Shatsman S., Geer K., Chen Y.,
RA   Abramzon S., Nierman W.C., Havlak P.H., Chen R., Durbin K.J., Egan A.,
RA   Ren Y., Song X.-Z., Li B., Liu Y., Qin X., Cawley S., Cooney A.J.,
RA   D'Souza L.M., Martin K., Wu J.Q., Gonzalez-Garay M.L., Jackson A.R.,
RA   Kalafus K.J., McLeod M.P., Milosavljevic A., Virk D., Volkov A.,
RA   Wheeler D.A., Zhang Z., Bailey J.A., Eichler E.E., Tuzun E.,
RA   Birney E., Mongin E., Ureta-Vidal A., Woodwark C., Zdobnov E.,
RA   Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D.,
RA   Schmidt J., Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M.,
RA   Abril J.F., Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O.,
RA   Poliakov A., Huebner N., Ganten D., Goesele C., Hummel O.,
RA   Kreitler T., Lee Y.-A., Monti J., Schulz H., Zimdahl H.,
RA   Himmelbauer H., Lehrach H., Jacob H.J., Bromberg S.,
RA   Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E., Lazar J.,
RA   Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E.,
RA   Webber C., Brandt P., Nyakatura G., Adetobi M., Chiaromonte F.,
RA   Elnitski L., Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K.,
RA   Miller W., Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S.,
RA   Zhang Y., Lindpaintner K., Andrews T.D., Caccamo M., Clamp M.,
RA   Clarke L., Curwen V., Durbin R.M., Eyras E., Searle S.M., Cooper G.M.,
RA   Batzoglou S., Brudno M., Sidow A., Stone E.A., Payseur B.A.,
RA   Bourque G., Lopez-Otin C., Puente X.S., Chakrabarti K., Chatterji S.,
RA   Dewey C., Pachter L., Bray N., Yap V.B., Caspi A., Tesler G.,
RA   Pevzner P.A., Haussler D., Roskin K.M., Baertsch R., Clawson H.,
RA   Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J., Rosenbloom K.R.,
RA   Trumbower H., Weirauch M., Cooper D.N., Stenson P.D., Ma B., Brent M.,
RA   Arumugam M., Shteynberg D., Copley R.R., Taylor M.S., Riethman H.,
RA   Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S., Mockrin S.,
RA   Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into
RT   mammalian evolution.";
RL   Nature 428:493-521(2004).
RN   [3]
RP   PHOSPHORYLATION AT THR-531 AND THR-533, MUTAGENESIS OF THR-526;
RP   SER-528; THR-531 AND THR-533, FUNCTION, AND INTERACTION WITH VHL.
RX   PubMed=17936701; DOI=10.1016/j.molcel.2007.09.010;
RA   Yang H., Minamishima Y.A., Yan Q., Schlisio S., Ebert B.L., Zhang X.,
RA   Zhang L., Kim W.Y., Olumi A.F., Kaelin W.G. Jr.;
RT   "pVHL acts as an adaptor to promote the inhibitory phosphorylation of
RT   the NF-kappaB agonist Card9 by CK2.";
RL   Mol. Cell 28:15-27(2007).
CC   -!- FUNCTION: Adapter protein that plays a key role in innate immune
CC       response to a number of intracellular pathogens, such as
CC       C.albicans and L.monocytogenes. Is at the crossroads of ITAM-
CC       tyrosine kinase and the Toll-like receptors (TLR) and NOD2
CC       signaling pathways. Probably controls various innate immune
CC       response pathways depending on the intracellular pathogen. In
CC       response to L.monocytogenes infection, acts by connecting NOD2
CC       recognition of peptidoglycan to downstream activation of MAP
CC       kinases (MAPK) without activating NF-kappa-B. In response to
CC       fungal infection, may be required for the development and
CC       subsequent differentiation of interleukin 17-producing T helper
CC       (TH-17) cells. Also involved in activation of myeloid cells via
CC       classical ITAM-associated receptors and TLR: required for TLR-
CC       mediated activation of MAPK, while it is not required for TLR-
CC       induced activation of NF-kappa-B (By similarity). Controls CLEC7A
CC       (dectin-1)-mediated myeloid cell activation induced by the yeast
CC       cell wall component zymosan, leading to cytokine production and
CC       innate anti-fungal immunity: acts by regulating BCL10-MALT1-
CC       mediated NF-kappa-B activation pathway. Activates NF-kappa-B via
CC       BCL10. In response to the hyphal form of C.albicans, mediates
CC       CLEC6A (dectin-2)-induced I-kappa-B kinase ubiquitination, leading
CC       to NF-kappa-B activation via interaction with BCL10. {ECO:0000250,
CC       ECO:0000269|PubMed:17936701}.
CC   -!- SUBUNIT: Self-associates. Interacts (via CARD domain) with BCL10
CC       (via CARD domain). Interacts with NOD2 (via NACHT domain) (By
CC       similarity). Interacts with RIPK2 (By similarity). Interacts with
CC       VHL; without leading to protein degradation (PubMed:17936701).
CC       {ECO:0000250, ECO:0000250|UniProtKB:A2AIV8,
CC       ECO:0000269|PubMed:17936701}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- PTM: Phosphorylated at Thr-531 and Thr-533 by CK2 following
CC       interaction with VHL, leading to inhibit the ability to activate
CC       NF-kappa-B. {ECO:0000269|PubMed:17936701}.
CC   -!- SIMILARITY: Contains 1 CARD domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00046}.
DR   EMBL; AF311288; AAG28791.1; -; mRNA.
DR   EMBL; AABR06021907; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_071639.1; NM_022303.1.
DR   UniGene; Rn.64486; -.
DR   ProteinModelPortal; Q9EPY0; -.
DR   STRING; 10116.ENSRNOP00000062283; -.
DR   PhosphoSite; Q9EPY0; -.
DR   PaxDb; Q9EPY0; -.
DR   PRIDE; Q9EPY0; -.
DR   GeneID; 64171; -.
DR   KEGG; rno:64171; -.
DR   UCSC; RGD:708370; rat.
DR   CTD; 64170; -.
DR   RGD; 708370; Card9.
DR   eggNOG; NOG243105; -.
DR   HOGENOM; HOG000231538; -.
DR   HOVERGEN; HBG058091; -.
DR   InParanoid; Q9EPY0; -.
DR   KO; K12794; -.
DR   OrthoDB; EOG747PH5; -.
DR   NextBio; 35576475; -.
DR   PRO; PR:Q9EPY0; -.
DR   Proteomes; UP000002494; Unplaced.
DR   Genevestigator; Q9EPY0; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0019904; F:protein domain specific binding; IMP:RGD.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IMP:RGD.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:InterPro.
DR   Gene3D; 1.10.533.10; -; 1.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   Pfam; PF00619; CARD; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   PROSITE; PS50209; CARD; 1.
PE   1: Evidence at protein level;
KW   Coiled coil; Complete proteome; Cytoplasm; Immunity; Innate immunity;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN         1    536       Caspase recruitment domain-containing
FT                                protein 9.
FT                                /FTId=PRO_0000144083.
FT   DOMAIN        6     98       CARD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   COILED      117    277       {ECO:0000255}.
FT   COILED      303    420       {ECO:0000255}.
FT   MOD_RES     461    461       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9H257}.
FT   MOD_RES     531    531       Phosphothreonine; by CK2.
FT                                {ECO:0000269|PubMed:17936701}.
FT   MOD_RES     533    533       Phosphothreonine; by CK2.
FT                                {ECO:0000269|PubMed:17936701}.
FT   MUTAGEN     526    526       T->A: Abolished phosphorylation by CK2
FT                                and increased activation of NF-kappa-B;
FT                                when associated with A-528; A-531 and A-
FT                                533. {ECO:0000269|PubMed:17936701}.
FT   MUTAGEN     528    528       S->A: Abolished phosphorylation by CK2
FT                                and increased activation of NF-kappa-B;
FT                                when associated with A-526; A-531 and A-
FT                                533. {ECO:0000269|PubMed:17936701}.
FT   MUTAGEN     531    531       T->A: Abolished phosphorylation by CK2
FT                                and increased activation of NF-kappa-B;
FT                                when associated with A-526; A-528 and A-
FT                                533. {ECO:0000269|PubMed:17936701}.
FT   MUTAGEN     533    533       T->A: Abolished phosphorylation by CK2
FT                                and increased activation of NF-kappa-B;
FT                                when associated with A-526; A-528 and A-
FT                                531. {ECO:0000269|PubMed:17936701}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:A2AIV8; BAP; 09-FEB-2015.
**EV ECO:0000250; UniProtKB:Q9H257; INT; 14-JAN-2015.
**EV ECO:0000255; -; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00046; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:17936701; XXX; 01-JAN-1900.
**ZA UHI/SIB, 29-NOV-2001;
**ZB SEF, 06-JAN-2006; ALG/LYG, 18-MAR-2008; SYP, 06-MAR-2014; BAP, 27-FEB-2015;
SQ   SEQUENCE   536 AA;  62632 MW;  6F33089CB7E6BAC9 CRC64;
     MSDYENDDEC WSALESFRVK LISVIDPSRI TPYLRQCKVL NPDDEEQVLS DPNLVIRKRK
     VGVLLDILQR TGHKGYVAFL ESLELYYPQL YRKVTGKEPA RVFSMIIDAS GESGLTQLLM
     TEVMKLQKKV QDLTALLSSK DDFIKELRVK DSLLRKHQER VQRLKEECEL SSAELKRCKD
     ENYDLAMRLA HLSEEKGAAL MRNRDLQLEV DQLRHSLMKA EDDCKVERKH TLKLRHAMEQ
     RPSQELLWDL QQERDLLQAR VQELEVSVQE GKLHRNSPYI QVLEEDWRQA LQEHQEQAST
     IFSLRKDLRQ AEALRTRCME EKEMFELQCL ALRKDAKMYK DRIEAILQQM EEVSIERDQA
     MTSREELHAQ CAQSFQDKDK LRKQVRELDE KADELQLQLF QTESRLLAAE GRLKQQQLDM
     LILSSDLEDS SPRNSQELSL PQDLEEDAQL SDKGVLADRE SPEQPFVVLN KKHLSQTHDT
     VPSSSEPPEK ERRRLKESFE NYRRKRALRK MQNSWRQGEG DHGNTTGSDN TDTEGS
//
ID   V_SV5                   Reviewed;         222 AA.
AC   P11207;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   24-JUN-2015, entry version 80.
DE   RecName: Full=Non-structural protein V;
GN   Name=P/V;
OS   Simian virus 5 (strain W3) (SV5).
OC   Viruses; ssRNA viruses; ssRNA negative-strand viruses;
OC   Mononegavirales; Paramyxoviridae; Paramyxovirinae; Rubulavirus.
OX   NCBI_TaxID=11208;
OH   NCBI_TaxID=9615; Canis familiaris (Dog) (Canis lupus familiaris).
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND RNA EDITING.
RX   PubMed=3044614; DOI=10.1016/S0092-8674(88)91285-8;
RA   Thomas S.M., Lamb R.A., Paterson R.G.;
RT   "Two mRNAs that differ by two nontemplated nucleotides encode the
RT   amino coterminal proteins P and V of the paramyxovirus SV5.";
RL   Cell 54:891-902(1988).
RN   [2]
RP   INTERACTION WITH PROTEIN NP.
RX   PubMed=8862406; DOI=10.1006/viro.1996.0513;
RA   Randall R.E., Bermingham A.;
RT   "NP:P and NP:V interactions of the paramyxovirus simian virus 5
RT   examined using a novel protein:protein capture assay.";
RL   Virology 224:121-129(1996).
RN   [3]
RP   RNA-BINDING.
RX   PubMed=9400618; DOI=10.1006/viro.1997.8866;
RA   Lin G.Y., Paterson R.G., Lamb R.A.;
RT   "The RNA binding region of the paramyxovirus SV5 V and P proteins.";
RL   Virology 238:460-469(1997).
RN   [4]
RP   INTERACTION WITH HUMAN IFIH1/MDA5, AND INTERFERON EVASION.
RX   PubMed=15563593; DOI=10.1073/pnas.0407639101;
RA   Andrejeva J., Childs K.S., Young D.F., Carlos T.S., Stock N.,
RA   Goodbourn S., Randall R.E.;
RT   "The V proteins of paramyxoviruses bind the IFN-inducible RNA
RT   helicase, mda-5, and inhibit its activation of the IFN-beta
RT   promoter.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:17264-17269(2004).
RN   [5]
RP   UBIQUITINATION OF HUMAN STAT1 AND HUMAN STAT2.
RX   PubMed=15604442; DOI=10.1099/vir.0.80263-0;
RA   Precious B., Young D.F., Andrejeva L., Goodbourn S., Randall R.E.;
RT   "In vitro and in vivo specificity of ubiquitination and degradation of
RT   STAT1 and STAT2 by the V proteins of the paramyxoviruses simian virus
RT   5 and human parainfluenza virus type 2.";
RL   J. Gen. Virol. 86:151-158(2005).
RN   [6]
RP   FUNCTION.
RX   PubMed=15950997; DOI=10.1016/j.virol.2005.05.014;
RA   Lin Y., Horvath F., Aligo J.A., Wilson R., He B.;
RT   "The role of simian virus 5 V protein on viral RNA synthesis.";
RL   Virology 338:270-280(2005).
RN   [7]
RP   INTERACTION WITH HUMAN DDB1 AND HUMAN STAT2.
RX   PubMed=16227264; DOI=10.1128/JVI.79.21.13434-13441.2005;
RA   Precious B., Childs K., Fitzpatrick-Swallow V., Goodbourn S.,
RA   Randall R.E.;
RT   "Simian virus 5 V protein acts as an adaptor, linking DDB1 to STAT2,
RT   to facilitate the ubiquitination of STAT1.";
RL   J. Virol. 79:13434-13441(2005).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH HOST DHX58.
RX   PubMed=22301134; DOI=10.1128/JVI.06405-11;
RA   Childs K., Randall R., Goodbourn S.;
RT   "Paramyxovirus V proteins interact with the RNA Helicase LGP2 to
RT   inhibit RIG-I-dependent interferon induction.";
RL   J. Virol. 86:3411-3421(2012).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) OF 1-222, AND FUNCTION.
RX   PubMed=16413485; DOI=10.1016/j.cell.2005.10.033;
RA   Li T., Chen X., Garbutt K.C., Zhou P., Zheng N.;
RT   "Structure of DDB1 in complex with a paramyxovirus V protein: viral
RT   hijack of a propeller cluster in ubiquitin ligase.";
RL   Cell 124:105-117(2006).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) IN COMPLEX WITH HUMAN CUL4A;
RP   DDB1 AND ROC1, AND FUNCTION.
RX   PubMed=16964240; DOI=10.1038/nature05175;
RA   Angers S., Li T., Yi X., MacCoss M.J., Moon R.T., Zheng N.;
RT   "Molecular architecture and assembly of the DDB1-CUL4A ubiquitin
RT   ligase machinery.";
RL   Nature 443:590-593(2006).
CC   -!- FUNCTION: Plays an essential role in the inhibition of host immune
CC       response. Prevents the establishment of cellular antiviral state
CC       by blocking interferon-alpha/beta (IFN-alpha/beta) production and
CC       signaling pathway. Interacts with host IFIH1/MDA5 and DHX58/LGP2
CC       to inhibit the transduction pathway involved in the activation of
CC       IFN-beta promoter, thus protecting the virus against cell
CC       antiviral state. Efficiently blocks type I IFN signaling following
CC       infection by behaving as a substrate receptor for CUL4-DDB1 E3
CC       ligase complex and targeting host STAT1 for proteasomal
CC       degradation. {ECO:0000269|PubMed:15950997,
CC       ECO:0000269|PubMed:16413485, ECO:0000269|PubMed:16964240,
CC       ECO:0000269|PubMed:22301134}.
CC   -!- SUBUNIT: Interacts with host DDB1, STAT2 and IFIH1/MDA5.
CC       {ECO:0000269|PubMed:15563593, ECO:0000269|PubMed:16227264,
CC       ECO:0000269|PubMed:16964240, ECO:0000269|PubMed:22301134,
CC       ECO:0000269|PubMed:8862406}.
CC   -!- INTERACTION:
CC       Q16531:DDB1 (xeno); NbExp=3; IntAct=EBI-6148694, EBI-350322;
CC       Q96C10:DHX58 (xeno); NbExp=2; IntAct=EBI-6148694, EBI-744193;
CC       Q9BYX4:IFIH1 (xeno); NbExp=2; IntAct=EBI-6148694, EBI-6115771;
CC       P52630:STAT2 (xeno); NbExp=2; IntAct=EBI-6148694, EBI-1546963;
CC   -!- SUBCELLULAR LOCATION: Host cytoplasm {ECO:0000250}.
CC   -!- RNA EDITING: Modified_positions=164 {ECO:0000269|PubMed:3044614};
CC       Note=Partially edited. RNA editing at this position consists of an
CC       insertion of two guanine nucleotides. The sequence displayed here
CC       is the V protein, derived from the unedited RNA. The edited RNA
CC       gives rise to the P protein (AC P11208).;
CC   -!- SIMILARITY: Belongs to the paramyxoviruses V protein family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03142; AAA47882.1; -; mRNA.
DR   EMBL; AF052755; AAC95512.1; -; Genomic_RNA.
DR   PIR; A31594; MNNZSP.
DR   RefSeq; YP_138513.1; NC_006430.1.
DR   PDB; 2B5L; X-ray; 2.85 A; C/D=1-222.
DR   PDB; 2HYE; X-ray; 3.10 A; B=1-222.
DR   PDB; 2K48; NMR; -; A=95-108.
DR   PDB; 4I1S; X-ray; 2.29 A; B=168-219.
DR   PDBsum; 2B5L; -.
DR   PDBsum; 2HYE; -.
DR   PDBsum; 2K48; -.
DR   PDBsum; 4I1S; -.
DR   ProteinModelPortal; P11207; -.
DR   SMR; P11207; 10-222.
DR   DIP; DIP-48759N; -.
DR   IntAct; P11207; 6.
DR   MINT; MINT-6623137; -.
DR   GeneID; 3160800; -.
DR   KEGG; vg:3160800; -.
DR   EvolutionaryTrace; P11207; -.
DR   Proteomes; UP000007232; Genome.
DR   GO; GO:0030430; C:host cell cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0039554; P:suppression by virus of host MDA-5 activity; IDA:CACAO.
DR   GO; GO:0039563; P:suppression by virus of host STAT1 activity; IEA:UniProtKB-KW.
DR   GO; GO:0039502; P:suppression by virus of host type I interferon-mediated signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR024279; Paramyx_V_Zn-bd.
DR   InterPro; IPR025909; Soyouz_module.
DR   Pfam; PF14313; Soyouz_module; 1.
DR   Pfam; PF13008; zf-Paramyx-P; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Host cytoplasm;
KW   Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host MDA5 by virus;
KW   Inhibition of host RLR pathway by virus;
KW   Inhibition of host STAT1 by virus;
KW   Interferon antiviral system evasion; Metal-binding; RNA editing;
KW   RNA-binding; Ubl conjugation pathway; Viral immunoevasion; Zinc.
FT   CHAIN         1    222       Non-structural protein V.
FT                                /FTId=PRO_0000142830.
FT   METAL       171    171       Zinc 1.
FT   METAL       190    190       Zinc 1.
FT   METAL       194    194       Zinc 2.
FT   METAL       206    206       Zinc 2.
FT   METAL       208    208       Zinc 2.
FT   METAL       211    211       Zinc 2.
FT   METAL       215    215       Zinc 1.
FT   METAL       218    218       Zinc 1.
FT   HELIX        23     32       {ECO:0000244|PDB:2B5L}.
FT   STRAND       95     97       {ECO:0000244|PDB:2B5L}.
FT   TURN        101    104       {ECO:0000244|PDB:2B5L}.
FT   STRAND      109    116       {ECO:0000244|PDB:2B5L}.
FT   STRAND      119    121       {ECO:0000244|PDB:2B5L}.
FT   HELIX       127    138       {ECO:0000244|PDB:2B5L}.
FT   STRAND      143    146       {ECO:0000244|PDB:2B5L}.
FT   STRAND      164    167       {ECO:0000244|PDB:2B5L}.
FT   STRAND      170    180       {ECO:0000244|PDB:4I1S}.
FT   STRAND      183    192       {ECO:0000244|PDB:4I1S}.
FT   STRAND      202    204       {ECO:0000244|PDB:2B5L}.
FT   STRAND      207    209       {ECO:0000244|PDB:4I1S}.
FT   HELIX       216    218       {ECO:0000244|PDB:4I1S}.
SQ   SEQUENCE   222 AA;  23935 MW;  13D2F1627D15AFA3 CRC64;
     MDPTDLSFSP DEINKLIETG LNTVEYFTSQ QVTGTSSLGK NTIPPGVTGL LTNAAEAKIQ
     ESTNHQKGSV GGGAKPKKPR PKIAIVPADD KTVPGKPIPN PLLGLDSTPS TQTVLDLSGK
     TLPSGSYKGV KLAKFGKENL MTRFIEEPRE NPIATSSPID FKRGRDTGGF HRREYSIGWV
     GDEVKVTEWC NPSCSPITAA ARRFECTCHQ CPVTCSECER DT
//
